ࡱ> %' !"#$q` RbjbjqPqP::^&####<$<$<$P$&&&8T&P*,P$3<<<"<<<I>?@P$ohBQ<$R'>"I>RRB##<<}LbbbR#<<$<bRbbFȯ$6<$<|< E&PW>زVST3.jcYcc<$@Db1GMIy @@@BBhbj@@@3RRRRP$P$(xvP$P$(xP$P$P$###### Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.q\NeNS6RoN gPlQSShandong Xinhua Pharmaceutical Company Limiteda joint stock limited company established in the People s Republic of China with limited liability Stock Code: 0719 2009 ANNUAL RESULTS ANNOUNCEMENTThe board of directors (the  Board ) and directors (Directors) of Shandong Xinhua Pharmaceutical Company Limited (the Company) hereby announces the audited consolidated results of the Company and its subsidiaries (the Group) for the year ended 31 December 2009. The following financial information has been prepared in accordance with Hong Kong Generally Accepted Accounting Principles (HKGAAP) and the Peoples Republic of China (PRC) accounting standards. This results announcement (the Announcement) is summarised from the annual report (the Annual Report) and investors are advised to read the full text of the Annual Report to understand the full details. The Announcement is published in Chinese and English. If there are any discrepancies between the Chinese version and the English version, the Chinese version shall prevail. I. Financial summary(i) Prepared in accordance with HKGAAP (Audited)Consolidated Income StatementItem2009 RMB0002008 RMB000 2007RMB000Revenue2,295,101 2,077,753 1,865,568 Profit before taxation116,388 41,447 37,364 Income tax (expense) / credit (13,008)(5,677)400 Profit for the year103,380 35,770 37,764 Minority interests3,6935,706 5,946 Profit attributable to owners of the Company99,687 30,064 31,818 Consolidated Statement of Financial PositionItem2009 RMB0002008 RMB0002007 RMB000Total assets2,636,363 2,159,424 2,260,100 Total liabilities(955,542)(659,144)(526,061)Minority interests(36,318)(33,746)(50,793)Equity attributable to owners of the Company1,644,503 1,466,534 1,683,246 (ii) Prepared in accordance with PRC accounting standards (Audited)Item2009 RMB 2008RMBChange as compared to the last year (%)2007RMBBefore adjustedAfter adjustedOperating income2,321,927,213.252,096,963,709.9110.73 1,886,978,951.191,886,978,951.19Profit before taxation119,373,878.2146,040,186.22159.28 46,510,493.4846,510,493.48Profit attributable to the equity shareholders of parent company102,244,346.1933,965,477.41201.02 32,723,034.6032,723,034.60Profit attributable to the equity shareholders of parent company after extraordinary loss109,058,885.6743,449,423.86151.009,959,541.299,793,035.79Net cash flow from operating activities344,795,891.77103,479,359.78233.20 120,591,043.84120,591,043.84Net cash flow from operating activities per share0.750.23226.090.260.26Total assets 2,626,187,060.382,161,734,318.6921.49 2,270,714,981.142,263,193,375.71Total equity attributable to holders of parent company1,633,645,846.351,453,252,991.3612.41 1,665,960,952.041,665,960,952.04Earnings per share 0.220.07214.290.070.07Net assets per share attributable to holders of parent company 3.573.1812.263.643.64Return on equity of weighted average (%)6.832.03Increase 4.80 points2.402.40Return on equity of weighted average after extraordinary loss (%)7.282.59Increase 4.69 points0.730.72(iii) Reconciliation of accounts prepared in accordance with PRC accounting standards and HKGAAPProfit attributable to owners of the CompanyRMBNet assetsRMB20092008As at 31 December 2009As at 1 January 2009Prepared under HKGAAP99,687,000.0030,064,000.001,644,503,000.001,466,534,000.00Prepared under PRC accounting standards102,244,346.1933,965,477.411,633,645,846.351,453,252,991.36HKGAAP adjustments:Deferred taxation427,653.81692,000.00(1,914,846.35)(2,343,991.36)Depreciation charge due to revaluation in previous years(1,432,000.00)(409,000.00)(21,300,000.00)(19,868,000.00)Provision for education fund(1,421,000.00)786,000.00 12,772,000.00 14,193,000.00 Provision for welfare expenses0.00 (4,993,000.00)0.00 0.00 Surplus from revaluation for listing of H Shares0.00 0.00 21,300,000.00 21,300,000.00 Others(132,000.00)22,522.59 0.00 0.00 HKGAAP adjustments total(2,557,346.19)(3,901,477.41)10,857,153.65 13,281,008.64  II. DIVIDENDSThe Board has announced and proposed a final dividend for the year ended 31 December 2009 of RMB0.05 per share in the Company (the Share) (approximately HK$0.057 per Share, including income tax) on 307,312,830 A Shares and 150,000,000 H Shares in issue. The proposed dividend is subject to approval by the shareholders of the Company at the Companys annual general meeting for the year 2009.III. MAIN BUSINESS AND FINANCIAL SITUATIONThe Group is mainly engaged in the development, production and sale of bulk pharmaceuticals, preparations, chemical products and other products. The profit of the Group is mainly attributable to its principal operations.Analysis of financial situation and operating results in accordance with PRC accounting standardsTotal assets of the Group as at 31 December 2009 increased by 21.49% or approximately RMB464,453,000 to approximately RMB2,626,187,000, as compared with the figure at the beginning of the year of approximately RMB2,161,734,000. The increase in total assets was mainly due to the increase of fair value of financial assets available for sale, cash and operation profits.Cash of the Group as at 31 December 2009 increased by 68.77% or approximately RMB163,770,000 to approximately RMB401,894,000, as compared with the figure at the beginning of the year of approximately RMB238,124,000. The increase in cash was mainly due to facts that the net cash flow from operating activities of the Group increased approximately RMB241,317,000 as compared with last year and the bank loans increased.Total equity attributable to the shareholders of the Company as at 31 December 2009 increased by approximately 12.41% or RMB180,393,000 from approximately RMB1,453,253,000 at the beginning of the year to approximately RMB1,633,646,000. This increase was mainly attributable to the increase of fair value of financial assets available for sale and operation profits this year.The total liabilities of the Group as at 31 December 2009 were approximately RMB956,224,000, representing an increase of approximately 41.72% or RMB281,488,000, as compared to approximately RMB674,736,000 at the beginning of the year. The increase was mainly attributable to part of the loans obtained by the Group from the bank to ensure the supply of funds, which increased the loans, at the same time, the Company received some relocation compensation from government and was included in deferred income, resulting in a relatively large increase in the total liabilities.Operating profit of the Group for 2009 and profit attributable to the Companys shareholders for 2009 amounted to approximately RMB135,909,000 and approximately RMB102,244,000 respectively, representing a great increase compared with those of the previous year. The increase was mainly attributable to the strengthened management of the Group, the decrease in the costs of raw materials, further development of the Companys leading role in the field of bulk pharmaceuticals, stabilization of the market price of major bulk pharmaceuticals, at the same time, the Company tackled key technological problems and reduced the consumption of raw material and power, and there is an increase in the gross profit of the Companys products.The Groups net increase in cash and cash equivalents for the year 2009 was approximately RMB180,731,000. The changes in net amounts of cash and cash equivalents was mainly due to the more increase of net cash flow from operating activities, of which the net increase for 2009 was approximately RMB241,317,000. Analysis under HKGAAPAs at 31 December 2009, the current ratio and the quick ratio of the Group was 174.64% and 119.42% respectively, and the rate of accounts receivable turnover (rate of accounts receivable turnover = revenue/average trade and bill receivables100%) and the rate of stock turnover (rate of stock turnover = cost of sales/average inventories100%) were 878.39% and 570.26% respectively.The Groups demand for working capital did not show significant seasonal fluctuation through the year.The Groups main source of funds were loans from financial institutions. As at 31 December 2009, the total amount of outstanding bank loans was approximately RMB394,024,000. As at 31 December 2009, cash on hand and in bank of the Group amounted to approximately RMB401,894,000 (including bank acceptance drafts deposits of approximately RMB37,496,000). The Group has stringent internal control systems for cash and fund management to strengthen its financial management. The Group maintained a good level of liquidity and had strong debt repayment ability.The Company invested an additional RMB50,000,000 in cash in Xinhua Pharmaceutical (Shouguang) Company Limited in 2009.Apart from the above transactions, the Group did not have any significant investment, acquisitions or asset disposals during this reporting period.As at 31 December 2009, the number of staff employed by the Group was 5,298, and the total amount for salaries and wages for 2009 was approximately RMB153,582,000.As at 31 December 2009, there was no charge on the Groups assets. The debt-to-capital ratio of the Group was 23.96% (debt-to-capital ratio = total borrowings / equity attributable to owners of the Company 100%).The bank balance of the Company will mainly be used as working capital for production and research and development.The assets and liabilities of the Group were mainly recorded in Renminbi. For the year ended 31 December 2009, the revenue from the Groups exports was approximately US$133,685,000, which may suffer from the risks associated with the fluctuation of exchange rates. Therefore, the Group has taken the following measures to lower the risks from the fluctuation of exchange rates: (1) the Group has increased the price of its export products to decrease the risks from the fluctuation of exchange rates; (2) the Group has made arrangements with overseas customers when entering into significant export contracts that the risks associated with the fluctuation in exchange rates shall be borne by both parties if the fluctuation exceeds the range of exchange rate fluctuation agreed by both parties.IV. business reviewIn 2009, the Group's production and operation, especially international trade, were aggravated by the international financial crisis. In face of such complicated external environment, the Group actively looked at ways to devise targeted strategies and took pragmatic and effective measures. With concerted efforts of its staff, the net profit for the whole year of the Group increased significantly and hit record high.1. Emphasized on marketing, costs reduction and technological progress to increase profitability.The Group actively expanded its footprint to new markets, highlighted preparation marketing and expanded preparation market. Leveraging its dominant position in the pharmaceutical industry, the Group stabilized market prices of major bulk pharmaceuticals. Making the best of product differentiation and distinct competitive edges, it also established its presence in overseas markets. Although export revenue dropped by 4.6% as compared with that of 2008, exports regained momentum after contraction. The Group maintained double-digit growth in sales revenue in 2009.Strengthened procurement and supply management. The Group kept abreast of market dynamics and took advantage of its strong liquidity position and sound reputation to optimize supplier structure and build an optimum supply chain, thereby reducing procurement costs significantly. In 2009, the purchase cost of raw materials of the Group declined as compared with last year.By developing new markets actively, stabilizing prices of major products, reducing purchase costs and making technical advancement, the Groups profit increased significantly in 2009.2. Highlighted structural adjustment, enhanced the proportion of preparation practices and optimized projects to lay solid foundation for corporate developmentPreparation products sales achieved double-digit growth for three consecutive years through adjustments to product mix and increase in the proportion of sales of preparation products. The Group achieved a preparation sales amount of approximately RMB472,812,000, representing an increase of 16.95% over 2008. Preparation products sales accounted for 29.98% of sales of industrial products, representing an increase of 3.13 percentage points over the previous year. The adjustment to the product mix marked remarkable success.Optimized the structure of our industrial zones. The Company focused on the construction project of Xinhua Pharmaceutical (Shouguang) Company Limited, a wholly owned subsidiary of the Company, secured pharmaceutical intermediates supply, perfected the project assessment system, strengthened the chain management and strived to minimize construction costs, thereby improving the overall competitiveness of the Company.3. Focused on research and innovation, grasped reforms, speeded up exploitation to add new frontiers of growth for the CompanyIn order to spark enthusiasm and encourage initiative of our researchers, quicken our pace of linking scientific research results with industrialization and promote scientific research system reforms, three management regimes such as Incentive Measures for Technical Advancement were formulated and revised in 2009.During this year, the Companys eight research projects were included in the national science and technology plan, the Company obtained certifications of production for two products from the State Food and Drugs Administration of the PRC, and a number of new products passed on-site inspection or entered technical review stage. The Company was also recognized as the first group of high-tech enterprises in Shandong Province, and passed the annual review of the State Enterprise Technology Center.4. Focused on management innovation, pressed ahead with improvement of technology and quality, rationalized ownership, and enhanced corporate competitiveness.By deepening efforts in promoting the program Year of breakthroughs in technology and quality, the Company made breakthroughs in 17 projects of technical quality in 2009. The Company saved raw materials worth approximately RMB3,608,000.The Group expedited technological advancement with a focus on the application of Four new technologies for strengthening the management on energy saving and emission reduction, and achieved energy saving of approximately RMB 25,030,000 in 2009.With a 12.98% decrease in energy consumption of RMB10,000 from last year, the Group was credited as the pioneer enterprise for energy saving in the province and the city. It had also met all safety and environment protection indicators, fulfilled targets and passed inspection tests. Thus, it was credited as the pioneer enterprise for safety month activity by Shandong Province.Strengthened baseline management across the organization. The Company successfully passed the GMP authentication for injection, ointment, nine pharmaceutical products, three solid dosage lines and one healthy product. One product passed HACCP authentication and three products passed EDQM on-site inspection and re-inspection. Our wholly-owned subsidiaries, Zibo Xinhua Pharmacy Chain Company Limited and Shandong Xinhua Medical Trade Company Limited, successfully passed GSP license review inspection. Quality system, environment system and detection system passed reviews successfully.The Company actively adjusted the equity relationship in subsidiaries. During the year, the Company completed the registration procedure for converting three non-wholly owned subsidiaries into wholly-owned subsidiaries of the Company. The Company also completed the procedure for change of foreign shareholder of and adjustment to shareholding proportion in Shandong Xinhua Pharmaceutical (Europe) GmbH. In addition, The Company commenced the procedure to transfer our equity interests in two entities with our equity participation.V. ProspectsAs the global economy starts to pick up in 2010, the external environment will be more favorable for corporate development, and international trade will recover. The Chinese government carries forward new medical reforms, implements and expands medical insurance policies and expands medical insurance coverage. These measures are set to help pharmaceutical enterprises gather pace. The global economy, however, is still shrouded in the mist of uncertainties as the impact of the international financial crisis remained deep. With escalating prices of chemical raw materials and packaging materials and governments promotion of procurement by bidding, pressure on price decrease of finished products mounted. In addition to fluctuations in the exchange rate of Renminbi, profit growth of the Company will slow down.In 2010, the Group will adhere to its business philosophy of striving for organic growth, expanding market, restructuring business, and promoting development, with a focus on the following:1. Develop rational plans and develop products to lay the foundation for a quantum leapThe Company will reasonably participate in all industrial zones and improve its construction projects from a strategic viewpoint. Taking advantage of the relocation of its headquarters, the Company will optimize its structure to upgrade products. With adherence to high standards, it will attach much importance to pharmaceutical intermediates supply and recycling and focus on the planning of Shouguang Park construction projects.Define plans to chart its course and focus on key products. The Company will expand and strengthen its existing premium products of bulk drugs, open up markets of pharmaceutical raw materials with new growth and increase research efforts of a small variety of specialty pharmaceutical products by both imitation and innovation. The Company aims at achieving product sales of more than RMB100 million through one single preparation product and increase the share of preparation sales in industry sales. Explore new ways of external partnership, seize opportunities of negotiations for external cooperative projects and organize the outsourced processing of existing preparation products.2. Insist on technological innovation and focus on implementation to take structural adjustment a step forwardThe Company will continue its efforts in studies and research on the industry and, by striking a balance among long-term, mid-term and short-term targets, the Company will focus on forward-looking products and produce products of good efficacy, high added value and excellent profit, especially new drugs that are valuable for anti-hypertensive, anti-high blood lipids and anti-high blood sugar purposes, and complete sequence of development varieties to achieve breakthroughs. The Company will grasp the exploitation of new dosage forms of preparations.The Company will ensure investment for scientific research and technology, further reform and set up incentive and constraint systems in scientific research and encourage input and creativity of scientific and technical personnel. The Company will diligently apply for approvals for clinical trials and production of new products . It will also pay due attention to new products reserve and speed up the progress of bringing scientific research result into practice.3. Continue to expand market and strive to increase profitsThe Company will set up the annual market target of main raw material medicine, reinforce the traditional bulk pharmaceuticals market and actively explore new market, expand the proportion of direct users in international trade of material importance. The Company will seriously study the new policies of relevant preparation products, actively respond to new conditions, implement specific measures , implement strategy of product focus and actively develop a broad mix of preparation products.The Company will capture market and industry changes, and stabilize prices of main products. The Company will expand its market share of products that promise growth and turn the products into new economic growth points, and ensure the steady increase in the sales of key profitable products and increase in the market share of its major products.The Company will make use of its domestic and overseas multi-channels, further improve the parity tender management, open up new suppliers, increase the proportion of direct procurement, and pragmatically strengthen the management and control across the entire process of procurement.While ensuring smooth construction of Shouguang Park project to cater for internal needs, we will also pay due attention to sell products of Shouguang Park both in China and overseas, so as to cultivate new growth points for the Company. 4. Enhance management to ensure the healthy operation of enterpriseThe Company will strictly implement the "three first" principle, that is quality first, safety first, environmental protection first, adhere to one-voteveto system and put energy-saving and emission reduction high on agenda. The Company will improve the internal wasted water online measurement system by online energy management system. The Company will formulate practical measures to carry out the progress of more than 30 research topics that have been included in the annual technical quality of research plan, work hard for the technology quality research, certification audit and on-site management, regard the on-site management as a breakthrough in upgrading technological and quality level, combining it with technology quality management, certification audit and etc, improve on-site assessment.The Company will focus on cost analysis and budget control, carry out the comprehensive budget management and avoid operational risk. The Company will comprehensively promote lean production and further improve the ERP system.In 2009, the Groups staff had the same mind, put effort together, overcame numerous difficulties and achieved various targets set for the year with remarkable success, with net profit posting an all-time high. Looking into 2010, the Board believes, by addressing challenges and seizing opportunities and with the concerted efforts and hard work of all the staff , we are confident in delivering satisfactory returns to shareholders.VI. Important IssuesStaff and RemunerationThe Groups staff remuneration was determined in accordance with State policies, the Companys profit in the corresponding period and the average income of local residents.As at 31 December 2009, the number of staff employed by the Group was 5,298, and the total amount of their salaries and wages for the year 2009 was approximately RMB153,582,000.Purchase, Sale or Redemption of the Companys Listed SecuritiesDuring the year ended 31 December 2009, the Company did not redeem the Companys listed securities. Neither the Company nor its subsidiaries, purchased, sold or redeemed any of the Companys listed securities.Connected TransactionsSignificant connected transactions carried out in the normal course of the Groups business are summarised as follows:Item2009 RMB0002008 RMB000With immediate holding companyShandong Xinhua Pharmaceutical Group Company Limited (SXPGC) and its subsidiaries Sale of water, electricity, steam and raw materials10,25812,870  Purchase of raw materials 84,802132,098 Payment of annual trademark licence fee1,1001,100  Purchase of property, plant and equipment-9,846  Rental income134361  Design fees income5024  Rental expenses500500  Purchase subsidiarys equity interest636- Transfer land use rights income-924With associates Purchase of raw materials 6,12712,875  Design fees income1112 With minority shareholders Sale of bulk pharmaceuticals and chemical raw materials144,926162,161 Purchase of chemical raw materials514-- Purchase of Shouguang Company equity interest-13,972 In the opinion of the Directors (including the Independent Non-Executive Directors), the above transactions were carried out in the ordinary and usual course of the Groups business and on normal commercial terms. The aggregate amount of the above transactions for each of the years 2008 and 2009 did not exceed the annual cap approved in the general meeting of the Company.AuditorsThe accounts of the Company and the Group for this year prepared in accordance with HKGAAP and PRC accounting standards have been audited by SHINEWING (HK) CPA Limited and ShineWing, Certified Public Accountant, PRC respectively.The Company intends to re-appoint SHINEWING (HK) CPA Limited and ShineWing as international auditors and PRC auditors of the Company respectively for the year 2010 at the annual general meeting for the year 2009 to be held in 2010.Code on Corporate Governance PracticesThe Directors (including the independent non-executive Directors) are of the opinion that for the year ended 31 December 2009, the Company has complied with all requirements set out in the Code on Corporate Governance Practices including provisions contained in Appendix 14 to the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.The Company has always strived to comply with the best practices of the Code on Corporate Governance Practices. Material Litigation and ArbitrationThe Group was not involved in any material litigation or arbitration and no material litigation or arbitration is pending or threatened or was made against the Group during the reporting period.Sale of AssetsDuring the reporting period, there were no material acquisitions and sales of assets, nor any material mergers.Amendments to the ArticlesA special resolution in respect of the amendments to Article 147 of the Articles of Association was passed at the 2008 Annual General Meeting of the Company held on 8 June 2009.Audit CommitteeThe audit committee has, together with the management, reviewed the accounting principles, practices and methods adopted by the Group and has reviewed the auditing, internal control and financial reporting of the Group. The audit committee has convened 4 meetings to review the audited financial statements for 2008, the unaudited 1st quarterly financial statements for 2009, the unaudited interim statements for 2009 and the unaudited 3rd quarterly financial statements for 2009.The audit committee convened a meeting on 8 April 2010 to review the 2009 audited accounts and annual results announcement.VII. FINANCIAL REPORTSThe financial reports of the Company and the Group for the financial year ended 31 December 2009 have been audited by SHINEWING (HK) CPA Limited (certified public accountants in Hong Kong) and ShineWing (certified public accountants in the PRC) in accordance with HKGAAP and PRC accounting standards respectively. In their respective auditors reports there was no qualified opinion.1. financial statement and notes Prepared Under PRC Accounting StandardsConsolidated and the Parent Companys Income Statement for the year 2009 (AUDITED) Unit: RMBItemConsolidatedParent company20092008200920081.Total operating income2,321,927,213.25 2,096,963,709.91 1,559,301,197.63 1,501,371,154.25  Includes: Operating income2,321,927,213.25 2,096,963,709.91 1,559,301,197.63 1,501,371,154.25 2.Total operating costs2,201,519,540.59 2,043,732,734.51 1,450,095,517.18 1,456,666,012.19  Includes: Operating cost1,877,427,603.27 1,804,214,578.65 1,239,789,642.29 1,312,006,980.07  Taxes and surcharges13,546,175.14 9,656,432.59 11,427,740.21 8,452,551.39  Selling expenses122,921,177.72 99,500,079.47 39,435,284.46 26,893,227.17  Administrative expenses159,579,455.09 117,404,414.35 133,230,876.27 98,312,577.56  Financial expenses26,777,339.32 8,464,601.59 26,300,296.79 7,497,096.10  Assets Impairment loss1,267,790.05 4,492,627.86 (88,322.84)3,503,579.90  Add: Gain or loss from changes in fair value7,591,083.73 (23,487,816.58)7,379,442.43 (23,276,175.28) Investment gain or loss7,910,733.39 6,649,200.78 9,911,920.58 6,756,827.30  Includes: Investment gain or loss from related ventures and joint ventures4,911,640.58 2,118,782.49 4,911,640.58 2,118,782.49 3. Operating profit135,909,489.78 36,392,359.60 126,497,043.46 28,185,794.08  Add: Non-operating income6,808,717.69 20,194,290.81 6,178,390.64 15,483,918.53  Less: Non-operating cost23,344,329.26 10,546,464.19 22,323,342.80 9,967,306.40  Includes: Loss from the disposal of non-current assets19,605,908.29 7,012,331.52 19,413,164.47 6,979,566.18 4. Profit before taxation119,373,878.21 46,040,186.22 110,352,091.30 33,702,406.21  Less: Income tax expense13,436,120.20 6,368,585.79 11,459,004.77 3,187,385.56 5. Profit after taxation105,937,758.01 39,671,600.43 98,893,086.53 30,515,020.65  Includes: Profit attributable to the equity shareholders of the parent company102,244,346.19 33,965,477.41  -  -  Minority interest3,693,411.82 5,706,123.02  -  - 6. Earnings per share0000 1) Basic earnings per share0.22 0.07 0.22 0.07  2) Diluted earnings per share0.22 0.07 0.22 0.07 7.Other comprehensive income91,210,640.55 (232,658,362.30)91,033,629.80 (232,159,560.75)8. Total comprehensive income197,148,398.56 (192,986,761.87)189,926,716.33 (201,644,540.10) Includes: Total comprehensive income attributable to the equity shareholders of the parent company193,403,969.35 (198,629,506.80) -  -  Total comprehensive income attributable to minority interest3,744,429.21 5,642,744.93  -  -  Financial Notes:xe "s, 1. compared with the latest annual reportA th"1. During this reporting period, there was no change in accounting policies, accounting estimates or corrections of accounting errors of the Company.xe "nfluences, 2. in the range of consolidation as co"2. During this reporting period, there was no change in the scope of consolidated financial statements of the Company.2. financial statements AND NOTES PREPARED UNDER HKGAAPCONSOLIDATED INCOME STATEMENTNOTESYear endedYear ended31/12/200931/12/2008RMB000RMB000RestatedRevenue32,295,1012,077,753Cost of sales(1,849,738)(1,776,658)Gross profit445,363301,095Investment income4,9287,639Other income7,43717,829Other gains and losses(16,700)(21,330)Distribution and selling expenses(133,713)(118,507)Administrative expenses(162,845)(125,978)Other expenses(13,616)(3,229)Share of profits of associates4,9121,884Finance costs4(19,378)(17,956)Profit before tax116,38841,447Income tax expense5(13,008)(5,677)Profit for the year6103,38035,770Profit for the year attributable to :Owners of the Company99,68730,064Minority interests3,6935,706103,38035,770Earnings per share basic and diluted8RMB0.218RMB0.066 CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME Year endedYear ended31/12/200931/12/2008RMB000RMB000RestatedProfit for the year103,38035,770Other comprehensive income: Exchange differences arising on translation(46)(377) Fair value gain(loss) on available-for-sale financial assets 107,398(273,428)Income tax relating to components of other comprehensive income(16,140)41,044Other comprehensive income for the year, net of tax91,212(232,761)Total comprehensive income for the year194,592(196,991)Total comprehensive income attributable to:Owners of the Company190,848(202,634)Minority interests3,7445,643194,592(196,991)CONSOLIDATED STATEMENT OF FINANCIAL POSITIONNOTES31/12/200931/12/2008RMB000RMB000Non-current assetsTechnical know-how117792Property, plant and equipment963,747959,882Construction in progress134,35688,206Prepaid lease payments on land use rights193,915105,061Investment properties36,694-Interests in associates14,36025,632Available-for-sale investments201,59694,767Deferred tax assets3,0441,0311,547,8291,275,371Current assetsInventories344,220304,515Trade and other receivables9314,353289,995Prepaid lease payments on land use rights4,0704,146Amount due from immediate holding company8,46543,091Amounts due from associates-1,482Tax recoverable1422,700Pledged bank deposits37,49654,457Bank balances and cash364,398183,6671,073,144884,053 Assets classified as held for sale15,390-1,088,534884,053Current liabilitiesTrade and other payables10491,698361,818Amount due to an associate4981,805Tax payable7,069462Derivative financial instruments-7,591Borrowings124,024284,474623,289656,150Net current assets465,245227,903Total assets less current liabilities2,013,0741,503,274Capital and reservesShare capital457,313457,313Reserves1,164,324995,502Proposed final dividend22,86613,719Equity attributable to owners of the Company1,644,5031,466,534Minority interests36,31833,746Total equity1,680,8211,500,280Non-current liabilityDeferred tax liabilities11,5972,994Borrowings270,000-Deferred income50,656-332,2532,9942,013,0741,503,274NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS UNDER HKGAAP1. BASIS OF PREPARATIONThe audited consolidated financial statements are prepared in accordance with Hong Kong Financial Reporting Standards (HKFRSs), Hong Kong Accounting Standards (HKASs) issued by Hong Kong Institute of Certified Public Accountants (HKICPA) and the disclosure requirements of Appendix 16 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.2. APPLICATION OF NEW AND REVISED HKFRSsIn the current year, the Group has applied the following new and revised Standards, Amendments to Standards and Interpretations (INT) (new and revised HKFRSs) issued by the HKICPA.HKAS 1 (Revised 2007)Revised Presentation of Financial StatementsHKAS 23 (Revised 2007)Borrowing CostsHKAS 32 & 1 (Amendments)Puttable Financial Instruments and Obligation Arising on LiquidationHKFRS 1 & 27 (Amendments)Cost of an Investment in a Subsidiary, Jointly Controlled Entity or AssociateHKFRS 2 (Amendment)Vesting Conditions and CancellationsHKFRS 7 (Amendment)Improving Disclosures about Financial InstrumentsHKFRS 8 Operating SegmentsHK(IFRIC)- INT 9 & HKAS 39 (Amendments)Embedded DerivativesHK(IFRIC)- INT 13 Customer Loyalty ProgrammesHK(IFRIC)- INT 15 Agreements for the Construction of Real EstateHK(IFRIC)- INT 16 Hedges of a Net Investment in a Foreign OperationHK(IFRIC)- INT 18 Transfers of Assets from CustomersHKFRSs (Amendments)Improvements to HKFRSs issued in 2008, except for the amendment to HKFRS 5 that is effective for annual periods beginning or after 1 July 2009HKFRSs (Amendments)Improvements to HKFRSs issued in 2009 in relation to the amendment to paragraph 80 of HKAS 39Except as described below, the adoption of the new and revised HKFRSs had no material effect on the consolidated financial statements of the Group for the current or prior accounting periods. New and revised HKFRSs affecting presentation and disclosure onlyHKAS 1 (Revised 2007) Presentation of Financial StatementsHKAS 1 (Revised 2007) has introduced terminology changes (including revised titles for the financial statements) and changes in the format and content of the financial statements.HKFRS 8 Operating SegmentsHKFRS 8 is a disclosure standard that has resulted in a redesignation of the Groups reportable segments (see Note 3).Improving Disclosures about Financial Instruments(Amendments to HKFRS 7 Financial Instruments: Disclosures) The amendments to HKFRS 7 expand the disclosures required in relation to fair value measurements in respect of financial instruments which are measured at fair value. The amendments also expand and amend the disclosures required in relation to liquidity risk. The Group has not provided comparative information for the expanded disclosures in accordance with the transitional provision set out in the amendments.New and revised HKFRSs affecting the reported results and/or financial positionHK AS 23 (Revised 2007)Borrowing Costs In previous years, the Group expensed all borrowing costs that were directly attributable to the acquisition or production of a qualifying asset when they were incurred. The adoption of HKAS 23 (Revised 2007) removes the option previously available to expense all borrowing costs when incurred. The adoption of HKAS 23 (Revised 2007) has resulted in the Group changing its accounting policy to capitalise all such borrowing costs as part of the cost of the qualifying asset. The Group has applied the revised accounting policy to borrowing costs relating to qualifying assets for which the commencement date for capitalisation is on or after 1 January 2009 in accordance with the transitional provisions in HKAS 23 (Revised 2007). As the revised accounting policy has been applied prospectively from 1 January 2009, this change in accounting policy has not resulted in restatement of amounts reported in respect of prior accounting periods.In the current year, no borrowing costs was capitalised as part of the cost of construction in progress. The Group has not early applied the following new and revised Standards, Amendments or INTs that have been issued but are not yet effective.HKFRSs (Amendments)Amendments to HKFRS 5 as part of Improvements to HKFRSs 20081HKFRSs (Amendments)Improvements to HKFRSs 20092HKAS 24 (Revised)Related Party Disclosures6 HKAS 27 (Revised) Consolidated and Separate Financial Statements1HKAS 32 (Amendment)Classification of Rights Issues4HKAS 39 (Amendment)Eligible Hedged Items1HKFRS 1 (Revised)HKFRS for First-time Adopters1HKFRS 1 (Amendment)Additional Exemptions for First-time Adopters3HKFRS 1 (Amendment)Limited Exemption from Comparative HKFRS 7 Disclosures for First-time Adopters6HKFRS 2 (Amendment)Group Cash-settled Share-based Payment Transactions3HKFRS 3 (Revised)Business Combinations1HKFRS 9 Financial Instruments7HK(IFRIC)INT14 (Amendment)Prepayments of a Minimum Funding Requirement6HK(IFRIC) INT 17Distribution of Non-cash Assets to Owners1HK(IFRIC) INT 19Extinguishing Financial Liabilities with Equity Instruments51 Effective for annual periods beginning on or after 1 July 2009.2 Effective for annual periods beginning on or after 1 July 2009 and 1 January 2010 as appropriate.3 Effective for annual periods beginning on or after 1 January 2010.4 Effective for annual periods beginning on or after 1 February 2010.5 Effective for annual periods beginning on or after 1 July 2010.6 Effective for annual periods beginning on or after 1 January 2011.7 Effective for annual periods beginning on or after 1 January 2013.The application of HKFRS 3 (Revised) may affect the accounting for business combinations for which the acquisition date is on or after the beginning of the first annual reporting period beginning on or after 1 July 2009. HKAS 27 (Revised) will affect the accounting treatment for changes in a parents ownership interest in a subsidiary. HKFRS 9 Financial Instruments introduces new requirements for the classification and measurement of financial assets and will be effective from 1 January 2013, with earlier application permitted. The Standard requires all recognised financial assets that are within scope of HKAS 39 Financial Instruments: Recognisation and Measurement to be measured at either amortised cost or fair value. Specially, debt investments that (i) are held within a business model whose objective is to collect the contractual cash flows and (ii) have contractual cash flows that are solely payments of principal and interest on the principal outstanding are generally measured at amortised cost. All other debt investments and equity investments are measured at fair value. The application of HKFRS 9 might affect the classification and measurement of the Groups financial assets. In addition, as part of Improvements to HKFRSs (2009), HKAS 17 Leases has been amended in relation to the classification of leasehold land. The amendments will be effective from 1 January 2010, with earlier application permitted. Before the amendments to HKAS 17, lessees were required to classify leasehold land as operating leases and presented as prepaid lease payments in the consolidated statement of financial position. The amendments have removed such a requirement. Instead, the amendments require the classification of leasehold land to be based on the general principles set out in HKAS 17, that are based on the extent to which risks and rewards incidental to ownership of a leased asset lie with the lessor or the lessee. The application of the amendments to HKAS 17 might affect the classification and measurement of the Groups leasehold land.The directors of the Company anticipate that the application of the other new and revised Standards, Amendments or INTs will have no material impact on the consolidated financial statements. 3. SEGMENTAL INFORMATIONThe Group has adopted HKFRS 8 Operating Segments with effect from 1 January 2009. HKFRS 8 is a disclosure standard that requires operating segments to be identified on the basis of internal reports about components of the Group that are regularly reviewed by the chief operating decision maker for the purpose of allocating resources to segments and assessing their performance. In contrast, the predecessor Standard (HKAS 14, Segment Reporting) required an entity to identify two sets of segments (business and geographical) using a risks and returns approach. In the past, the Groups primary reporting format was business segments. The application of HKFRS 8 has resulted in a redesignation of the Groups reportable segments as compared with the primary reportable segments determined in accordance with HKAS 14.Specifically, in prior years, segment information reported externally was analysised on the basis of the types of the revenues (i.e. sales of goods and other operating income). However, information reported to the chief operating decision maker in more specifically focused on the types of goods supplied. The principal types of goods supplied are bulk pharmaceuticals, preparations and chemical and other products. The Groups operating and reportable segments under HKFRS 8 are therefore as follows:Bulk pharmaceuticals:Development, production and sales of bulk pharmaceuticalsPreparations:Development, production and sales of preparations (e.g. tablets and injections)Chemical and other products:Production and sales of chemical and other products Commerce circulations:Trading of pharmaceutical products (including retail and wholesale)Information regarding the above segments is reported below. Amounts reported for the prior year have been restated to conform to the requirements of HKFRS 8.Segment revenues and resultsThe following is an analysis of the Groups revenue and results by reportable segment.For the year ended 31 December 2009Bulk pharmaceuticalsPreparationsChemical and other products Commerce circulationsEliminationsTotalRMB000RMB000RMB000RMB000RMB000RMB000REVENUE External sales1,219,263472,8123,968599,058-2,295,101Inter-segment sales3,447359,115124,49671,390(558,448)-Total 1,222,710831,927128,464670,448(558,448)2,295,101Segment profit 108,02825,05912,483 3,235148,805Investment and other income12,365Other gains and losses(16,700)Other expenses(13,616)Finance costs(19,378)Share of profits of associates4,912Profit before tax 116,388For the year ended 31 December 2008Bulk pharmaceuticalsPreparationsChemical and other products Commerce circulationsEliminationsTotalRMB000RMB000RMB000RMB000RMB000RMB000REVENUE External sales1,241,720404,29018,849412,894-2,077,753Inter-segment sales42,713325,20427,2974,666(399,880)-Total 1,284,433729,49446,146417,560(399,880)2,077,753Segment profit (loss)36,34416,055(3,424)7,63556,610Investment and other income 25,468Other gains and losses(21,330)Other expenses(3,229)Finance costs(17,956)Share of profits of associates1,884 Profit before tax 41,447The accounting policies of the reportable segments are the same as the Groups accounting policies. Segment profit represents the profit earned by each segment without allocation of investment and other income, other gains and losses, other expenses, financial costs and share of profits of associates. This is the measure reported to the chief operating decision maker for the purposes of resource allocation and performance assessment. Inter-segment sales are charged at prevailing market rates.Segment assets and liabilitiesThe following is an analysis of the Groups assets and liabilities by reportable segment.At 31 December 2009Bulk pharmaceuticalsPreparationsChemical and other products Commerce circulationsTotalRMB000RMB000RMB000RMB000RMB000Segment assets1,214,283396,322240,187112,4511,963,243Unallocated corporate assets673,120Consolidated assets2,636,363Segment liabilities302,206129,15671,83039,660542,852Unallocated corporate liabilities 412,690Consolidated liabilities955,542At 31 December 2008Bulk pharmaceuticalsPreparationsChemical and other products Commerce circulationsTotalRMB000RMB000RMB000RMB000RMB000Segment assets1,220,195387,71091,81197,4541,797,170Unallocated corporate assets362,254Consolidated assets2,159,424Segment liabilities248,08880,8184,37130,346363,623Unallocated corporate liabilities295,521Consolidated liabilities659,144For the purposes of monitoring segment performances and allocating resources among segments:all assets are allocated to reportable segments other than deferred tax assets, interests in associates, assets classified as held for sale, available-for-sale investments, investment properties, tax recoverable, pledged bank deposits and bank balances and cash. Assets used jointly by reportable segments are allocated on the basis of revenues earned by individual reportable segments; andall liabilities are allocated to reportable segments other than deferred tax liabilities, borrowings, derivative financial instruments and tax payable. Liabilities for which reportable segments are jointly liable are allocated on the basis of revenues earned by individual reportable segments. Other segment informationFor the year ended 31 December 2009Amounts included in the measure of segment profit or loss or segment assets:Bulk pharmaceuticalsPreparationsChemical and other products Commerce circulationsTotalRMB000RMB000RMB000RMB000RMB000Addition to non-current assets (Note) 148,43855,442109,558200313,638Depreciation and amortisation83,71829,9366,106906120,666Loss on disposal of property, plant and equipment11,4094,21021215,633(Reversal) recognition of impairment losses on trade receivables (501)(14) (5)309(211)Impairment losses on other receivables32286-126534Write-down of inventories234351-359944Amounts regularly provided to the chief operating decision maker but not included in the measure of segment profit or loss or segment assets:Bulk pharmaceuticalsPreparationsChemical and other products Commerce circulationsTotalRMB000RMB000RMB000RMB000RMB000Interests in associates-14,360--14,360Interest income1,265478148381,929Finance costs(13,765)(5,350)(2)(261)(19,378)Income tax expense(6,212)(2,930)(2,370)(1,496)(13,008)For the year ended 31 December 2008Amounts included in the measure of segment profit or loss or segment assets:Bulk pharmaceuticalsPreparationsChemical and other products Commerce circulationsTotalRMB000RMB000RMB000RMB000RMB000Addition to non-current assets (Note) 178,69155,16342,134949276,937Depreciation and amortisation89,53827,1792,249923119,889Loss on disposal of property, plant and equipment4,3221,3541115,688Impairment losses on trade receivables 1,9851,31467324,037Impairment losses on other receivables131--15146Write-down of inventories527471,175-1,749Amounts regularly provided to the chief operating decision maker but not included in the measure of segment profit or loss or segment assets:Bulk pharmaceuticalsPreparationsChemical and other products Commerce circulationsTotalRMB000RMB000RMB000RMB000RMB000Interests in associates9,84412,2523,536-25,632Interest income1,8631,056 1385603,617Finance costs(12,922)(4,923)(2)(109)(17,956)Income tax expense(1,815)(1,627)-(2,235)(5,677)Note: Non-current assets excluded financial instruments, deferred tax assets and interests in associates.Geographical informationThe Groups customers are located on the PRC, Europe, Americas and others. Revenues from external customersYear endedYear ended31/12/200931/12/2008RMB000RMB000PRC1,448,5591,241,673Europe252,710249,656Americas421,997400,072Others171,835186,3522,295,1012,077,753Over 99% of the Groups non-current assets are located in the PRC and therefore the analysis of non-current assets by geographical location of the assets is not presented.Information about major customersThe Group's customer base includes a wide range of different customers. The Group had no single customer amount to 10% or more of the Group's revenue and therefore no significant concentration of source of income from a particular customer.4. FINANCE COSTSYear endedYear ended31/12/200931/12/2008RMB000RMB000Interest on:- Bank loans wholly repayable within 5 years16,40317,956 Government loans not wholly repayable within 5 years549-16,95217,956Net foreign exchange loss on bank loans  70-Discount charges on bank acceptance notes2,356-19,37817,9565. INCOME TAX EXPENSEYear endedYear ended31/12/200931/12/2008RMB000RMB000PRC enterprise income tax - current25,2349,133 - (Over) under provision in prior years(2,676)69022,5589,823 Deferred tax (9,550)(4,146)13,0085,677Under the Law of the PRC on Enterprise Income Tax (the EIT Law) and Implementation Regulation of the EIT Law, the tax rate of the PRC companies is 25% from 1 January 2008 onwards. Pursuant to the relevant laws and regulations in the PRC, the Company was accredited as a high-tech enterprise. The accreditation is valid for three years. The Company is entitled to the preferential tax rate of 15% for a three-year period commencing from 2008.Pursuant to the relevant laws and regulations in the PRC, two subsidiaries operating in the PRC are entitled to exemption from the PRC income tax in the first two years from the first profit-making year, followed by a 50% reduction of the PRC income tax for the next three years. 6. PROFIT FOR THE YEARProfit for the year has been arrived at after charging (crediting):Year endedYear ended31/12/200931/12/2008RMB000RMB000Depreciation for property, plant and equipment115,527115,739Depreciation for investment properties394-Amortisation of prepaid lease payments on land use rights4,0703,020Amortisation of technical know-how6751,130Total depreciation and amortisation120,666119,889Auditors remuneration1,4241,165Research and development costs recognised as an expense19,71419,470Operating lease rentals on land and buildings1,0161,006(Reversal) recognition of impairment losses on financial assetstrade receivables(211)2,598other receivables5341463232,744Write-down of inventories (included in cost of sales)9441,749Staff costs (excluding directors and supervisors emoluments)242,124184,694Cost of inventories recognised as an expense1,849,7381,776,6587. DIVIDENDSYear endedYear ended31/12/200931/12/2008RMB000RMB000Dividends paid and recognised as distribution during the year- 2008 final dividend: RMB0.03 per share (2008 : 2007 final dividend RMB0.03 per share) 13,71913,719The final dividend of RMB0.05 (2008: RMB0.03) per share (approximately HK$0.057 (2008: HK$0.034) per share, including income tax of A shares) on 307,312,830 A shares and 150,000,000 H shares has been proposed by the directors of the Company and is subject to approval by shareholders at the Annual General Meeting and has been included as a dividend reserve in the consolidated financial statements.8. EARNINGS PER SHAREThe calculation of basic earnings per share is based on the Groups profit attributable to the owners of the Company of RMB 99,687,000 (2008: RMB30,064,000) and based on the weighted average of 457,312,830 (2008: 457,312,830) shares in issue during the year.Basic earnings per share and diluted earnings per share for two years ended 31 December 2009 are the same as there were no dilutive events existed during both years.9. TRADE AND OTHER RECEIVABLES31/12/200931/12/2008RMB000RMB000Trade and bills receivables280,080261,590Less : Allowance for doubtful debts of trade receivables(7,603)(11,498)272,477250,092Other receivables, deposits and prepayments49,71447,339Less : Allowance for doubtful debts of other receivables(7,838)(7,436)41,87639,903Total trade and other receivables314,353289,995The Groups revenue from export sales is on letter of credit or documents against payment. The credit period is agreed upon in the sales contract. Except for some particular customers where payment in advance is normally required, the Group allows an average credit period of 30 days to its local trade customers and 90 days for local hospital customers. Majority of the trade receivables that are neither past due nor impaired have no default payment history.The following is an aged analysis of the trade receivables net of allowance for doubtful debts of trade receivables presented based on the invoice date at the reporting date.31/12/200931/12/2008RMB000RMB000Within one year270,571246,965More than one year but less than two years1,5032,264More than two years but less than three years403588Over three years-275272,477250,092Included in the Group's trade receivable balance are debtors with aggregate carrying amount of RMB 3,951,000 (2008: RMB 4,186,000) which are past due as at the reporting date for which the Group has not provided for impairment loss. Ageing of trade receivables which are past due but not impaired:31/12/200931/12/2008RMB000RMB000Within one year2,5461,814More than one year but less than two years1,1361,705More than two years but less than three years269392More than three years-275Total3,9514,186Receivables that were past due but not impaired relate to a number of independent customers that have a good track record with the Group. Based on past experience, management believes that no impairment allowance is necessary in respect of these balances as there has not been a significant change in credit quality and the balances are still considered fully recoverable. The Group does not hold any collateral over these balances.Movements in the allowance for doubtful debts of trade receivables20092008RMB000RMB0001 January11,49814,185Impairment losses (reversed) recognised(211)2,598Amounts recovered during the year764-Amounts written off as uncollectible(4,448)(5,285)31 December7,60311,498Movements in the allowance for doubtful debts of other receivables20092008RMB000RMB0001 January7,4367,566Impairment losses recognised534146Amounts written off as uncollectible(132)(276)31 December7,8387,436 10. TRADE AND OTHER PAYABLESThe following is an aged analysis of accounts payable presented based on the invoice date at the end of the reporting period. 31/12/200931/12/2008RMB000RMB000Within one year269,164242,426More than one year but less than two years4,9872,151More than two years but less than three years747966Over three years5,4365,085 280,334250,628Other payables and accrued charges211,364111,190491,698361,818The average credit period on purchases of goods is 45 days. The Group has financial risk management policies in place to ensure that all payables are settled within the credit timeframe.11. RELATED PARTY TRANSACTIONSExcept as disclosed in elsewhere in the consolidated financial statements, the other significant related party transactions, which were carried out in the normal course of the Groups business are as follows:Year endedYear ended31/12/200931/12/2008RMB000RMB000SXPGC:- Payment of annual trademark licence fee (1)1,1001,100- Rental expense500500- Consideration for acquisition of additional interests in subsidiaries (2)636-Fellow subsidiaries :- Sale of water, electricity, steam and waste materials10,25812,870- Purchase of raw materials84,802132,098- Rental income134361- Design fee income5024- Purchase of property, plant and equipment, and land use rights-9,846 - Income from transfer of land use rights-924Associates :- Purchase of raw materials6,12712,875- Design fee income1112Minority shareholders :- Sale of bulk pharmaceuticals and chemical raw materials144,926162,161- Purchase of chemical raw materials514-- Acquisition of additional interests in Xinhua Shouguang-13,972Notes :On 7 December 1996, the Group was granted the exclusive right to use the trademark Xinhua (Trademark) by SXPGC for its existing and future products in and outside the PRC at an initial annual fee of RMB600,000 increasing at the rate of an extra RMB100,000 per year until the annual fee reaches the cap amount of RMB1,100,000, which shall stay as such until the agreement is terminated. The terms of the agreement shall continue to have effect during the validity period of the Trademark, being 28 February 2013, subject to further renewal of the registration of the Trademark. During the year ended 31 December 2009, the annual fee paid by the Group amounting RMB1,100,000 (2008: RMB1,100,000).During the year ended 31 December 2009, the Company acquired additional interests of subsidiaries from SXPGC at consideration of RMB636,000.The Group operates in an economic environment predominated by enterprises directly or indirectly owned or controlled by the PRC government through its numerous authorities, affiliates or other organisations (collectively State-owned Enterprises). During the year ended 31 December 2009, the Group had transactions with State-owned Enterprises including, but not limited to, sales of pharmaceutical products and purchases of raw materials. The directors of the Company consider that transactions with other State-owned Enterprises are activities in the ordinary course of business, and that dealings of the Group have not been significantly controlled or owned by the PRC government. The Group has also established pricing policies for products and such pricing policies do not depend on whether or not the customers are State-owned Enterprises. Having due regard to the substance of the relationships, the directors of the Company are of the opinion that none of these transactions is a material related party transaction that requires separate disclosure.By Order of the BoardShandong Xinhua Pharmaceutical Company LimitedGuo QinChairman9 April 2010, Zibo, PRCAs at the date of this announcement, the board of directors comprises: q s t  x z > @ B D d f h n p r ܶfS8fS4hm5B*CJOJPJQJ\aJnHo(phtH%hm5B*CJOJQJ\aJph1hm5B*CJOJPJQJ\aJnHphtH"hmCJOJPJQJaJnHtHhmCJOJQJaJhmCJOJQJaJhm5CJOJQJaJhm5CJOJQJaJo(,jhm5CJOJQJUmHnHo(uhm5CJOJQJo(+h4ihm6KHOJPJQJaJnHtHq r s u v  x B h z{)*?@qr^T^`^ $dT^a$ $UDb]a$$a$  mwx㺟kkkRRR1h(phmB*CJOJPJQJaJnHphtH1h(phtB*CJOJPJQJaJnHphtH4h(phtB*CJOJPJQJaJnHo(phtH4h(phmB*CJOJPJQJaJnHo(phtH%h(phmB*CJOJQJaJph+hmB*CJOJPJQJaJnHphtHhmB*CJOJQJaJphhmB*OJQJphYxz{()*@DNqrҷҨҍzkU7UU:h(ph>H5B*CJOJPJQJ\aJnHo(phtH+h(phm5B*CJOJQJ\aJphh(phmCJOJQJaJ%h(phmB*CJOJQJaJph4h(ph>HB*CJOJPJQJaJnHo(phtHh(phmCJOJQJaJ4h(ph=NhB*CJOJPJQJaJnHo(phtH%h(phmB*CJOJQJaJph4h(phB*CJOJPJQJaJnHo(phtHdzo^SA-&h(phm6CJPJ]aJnHtH#h(phmCJPJaJnHo(tHh(phmCJaJ h(phm56CJ\]aJ&h(phm5CJPJ\aJnHtH)h(phm5CJPJ\aJnHo(tHh(phm5CJ\aJh(phmCJKHaJ&h(phm5CJPJ]aJnHtH7h(phm5B*CJOJPJQJ\aJnHphtH7h(phm5B*CJOJPJQJ\aJnHphtHmbW $$1$Ifa$ $$1$Ifa$xkd$$Ifl,\3 EW! p9!644 la$1$IfWDd` $$1$Ifa$  '()034;<ESYfgpڗ{{h{ha h(phm$h(phmCJKHPJaJnHtHh(phCJaJ h(phCJPJaJnHtH h(phmCJPJaJnHtHh(phm5CJKHaJ#h(phH+CJPJaJnHo(tH#h(phmCJPJaJnHo(tHh(phmCJaJh(phmCJKHaJh(phm6CJ]aJ" {p $$1$Ifa$xkd$$Ifl,\3 EW! p9!644 la $$1$Ifa$<EMR{ppp $$1$Ifa$ $$1$Ifa$xkd$$Ifl,\3 EW! p9!644 laRSgpx{ppp $$1$Ifa$ $$1$Ifa$xkd$$Ifl,\3 EW! p9!644 la{ppp $$1$Ifa$ $$1$Ifa$xkd*$$Ifl,\3 EW! p9!644 laqfff $$1$Ifa$t$ $Ifa$xkd$$Ifl,\3 EW! p9!644 la ƪlV8:h(phs5B*CJOJPJQJ\aJnHo(phtH+h(phm5B*CJOJQJ\aJph+h(ph]4fCJOJPJQJaJnHo(tH%hmCJOJPJQJaJnHo(tH(h(phmCJOJPJQJaJnHtH7h(phm5B*CJOJPJQJ\aJnHphtHh(phmCJKHaJh(phm5CJKHaJh(phmaJ h(phmh(phH+PJnHo(tH !"ooooJJ%<TPL HD@< ^TQ ^xkdB$$Ifl,\3 EW! p9!644 la  !"&'*+,-4589ī~iXAX6$#h(phmCJPJaJnHo(tHh(phmCJaJ,h(phm56CJPJ\]aJnHtH h(phm56CJ\]aJ)h(phm5CJPJ\aJnHo(tHh(phm5CJ\aJh(phmCJaJ&h(phm5CJPJ]aJnHtH1h(phmB*CJOJPJQJaJnHphtH:h(phm5B*CJOJPJQJ\aJnHo(phtH:h(ph*O5B*CJOJPJQJ\aJnHo(phtH"'-5;CJRS`kmeZ $$1$Ifa$$1$Ifxkd$$Ifl,\S "b :::"644 la];$1$IfWD`; $$1$Ifa$ 9:;BCFGIJQS_`jkuvźДź~jVCVCź~jVCV$h(phmCJKHOJQJ^JaJ'h(phmCJKHOJQJ^JaJo('h(phm5CJKHOJQJ^JaJ*h(phm5CJKHOJQJ^JaJo(&h(phm6CJPJ]aJnHtH#h(phmCJPJaJnHo(tHh(phmCJaJh(phmCJaJh(phm6CJ]aJ&h(phm5CJPJ\aJnHtHh(phm5CJ\aJkv{s$1$IfxkdF$$Ifl,\S "b :::"644 la] $$1$Ifa$$%/0127|cM+h(phm5B*CJOJQJ\aJph1h(phmB*CJOJPJQJaJnHphtH#h(ph:CJPJaJnHo(tHh(ph:CJaJ'h(phmCJKHOJQJ^JaJo('h(phm5CJKHOJQJ^JaJ*h(phm5CJKHOJQJ^JaJo(h(phmCJaJh(phmCJaJ$h(phmCJKHOJQJ^JaJ~sss $$1$Ifa$$1$Ifxkd$$Ifl,\S "b :::"644 la]%0~sss $$1$Ifa$$1$IfxkdB$$Ifl,\S "b :::"644 la]012vw|a_:/ $$1$Ifa$%<TPL HD@< ^%<TPL HD@< ^xkd$$Ifl,\S "b :::"644 la]7Avw|̳ybQD0"Dh(phm6CJ]aJ'h(phmCJKHPJaJnHo(tHh(phmCJKHaJ h(phm56CJ\]aJ,h(phm56CJPJ\]aJnHtH-h(phm5CJKHPJ\aJnHo(tHh(phm5CJKH\aJ$h(phmCJKHPJaJnHtH1h(phmB*CJOJPJQJaJnHphtH+h(phm5B*CJOJQJ\aJph:h(ph>H5B*CJOJPJQJ\aJnHo(phtH |gkd>$$Ifl4grV FB$J6&44 laf4 $$1$Ifa$  CD[j tẕ̾zgZzgZzgZMh(ph~XCJKHaJh(ph~XCJKHaJ$h(ph~XCJKHOJQJ^JaJ'h(ph~X5CJKHOJQJ^JaJ$h(ph~XCJKHPJaJnHtHh(phm5CJKH\aJh(phmCJKHaJh(phm6CJ]aJ'h(phmCJKHPJaJnHo(tHh(phmCJKHaJ$h(phmCJKHPJaJnHtH KC5$$1$Ifa$gd)$1$Ifkd$$Ifl4,ֈV FBu$36&44 laf4 $$Ifa$ $$1$Ifa$ !2CD[jxTL$1$Ifkd$$IflֈV FBu$36&44 la$$1$Ifa$gd)xTL$1$Ifkdo$$IflֈV FBu$36&44 la$$1$Ifa$gd) zTL$1$Ifkd$ $$IflֈV FBu$36&44 la$$1$Ifa$gd)z%&X]stQRdgl ȻȻȻȻȻȻȻv'h(ph~XCJKHPJaJnHo(tH h(ph~XCJKHaJnHtHh(ph~XCJKHaJ$h(ph~XCJKHPJaJnHtHh(ph~XCJKHaJ$h(ph~XCJKHOJQJ^JaJ'h(ph~X5CJKHOJQJ^JaJh(ph~X5CJOJQJaJ%%TL$1$Ifkd $$IflvֈV FBu$36&44 la$$1$Ifa$gd)%&X]binsbZLLLLL$$1$Ifa$gd)$1$Ifkd $$IflvֈV FBu$36&44 lastbZLLLLL$$1$Ifa$gd)$1$IfkdC $$IflvֈV FBu$36&44 la(/@QbZLLLLL$$1$Ifa$gd)$1$Ifkd $$IflֈV FBu$36&44 laQRglqx}bZLLLLL$$1$Ifa$gd)$1$Ifkd $$IflֈV FBu$36&44 labZLLLLL$$1$Ifa$gd)$1$Ifkdb$$IflֈV FBu$36&44 la &+bZLL=L$$1$4$Ifa$gd~X$$1$Ifa$gd)$1$Ifkd$$IflֈV FBu$36&44 la%&01Anorswx|˲k^J4*h(ph~X5CJKHOJQJ^JaJo('h(ph~X5CJKHOJQJ^JaJh(ph~XCJKHaJ'h(ph~XCJKHPJaJnHo(tH$h(ph~XCJKHPJaJnHtHh(ph~XCJKHaJ$h(ph~XCJKHOJQJ^JaJ0h(ph~XCJKHOJPJQJ^JaJnHtH3h(phn=_CJKHOJPJQJ^JaJnHo(tH3h(ph~XCJKHOJPJQJ^JaJnHo(tH+01sx}TL=$$1$4$Ifa$gdn=_$1$Ifkd$$IflֈV FBu$36&44 la$$1$Ifa$gd)|}ѷ~kXB,+h(phm5B*CJOJQJ\aJph+h(phB\CJOJPJQJaJnHo(tH%hB\CJOJPJQJaJnHo(tH%hmCJOJPJQJaJnHo(tH1h(phmB*CJOJPJQJaJnHphtHh(ph~XCJKHaJ$h(ph~XCJKHOJQJ^JaJ3h(ph~XCJKHOJPJQJ^JaJnHo(tH3h(phn=_CJKHOJPJQJ^JaJnHo(tH'h(ph~XCJKHOJQJ^JaJo(T/-%<TPL HD@< ^kd$$IflֈV FBu$36&44 la$$1$Ifa$gd)37BF $$Ifa$"6TPL HD@<%^T^` #7EFHLMQRWZ[chiopqx}~;<OPQbc*+dh(phmCJKHaJ#h(phCJPJQJnHo(tH#h(phmCJPJQJnHo(tHh(phaoCJPJnHo(tHh(phmCJPJnHo(tHh(phmCJPJnHtHh(phmCJ,h(phmB*OJPJQJnHo(phtH0FGHMRi~ $$Ifa$`kd6$$If4FLt%u<d&    4 ahf4~xrgggg $$1$Ifa$$Ifkd$$If4rLt%ud&4 ahf4 *;{ujjjj $$1$Ifa$$Ifkdn$$IfrLt%ud&4 ah;<PQcn{u=u2 $$1$Ifa$7kd$$IfL%d&d&4 ah$Ifkd$$IfrLt%ud&4 ahnypj$Ifkd $$IfrLt%ud&4 ah $$1$Ifa$ +:FUd{ujjjj $$1$Ifa$$Ifkd$$IfrLt%ud&4 ahde{ujjjj $$1$Ifa$$IfkdG$$IfrLt%ud&4 ahdeos  ./GH˾˾˾˾taFa4h(phdG;B*CJOJPJQJaJnHo(phtH%h(phmB*CJOJQJaJphh(phmCJOJQJaJh(phmCJOJQJaJ1h(phmB*CJOJPJQJaJnHphtH%h(phmB*OJQJnHphtHh(phmCJKHaJh(phmCJPJnHo(tHh(phmCJQJo(#h(phmCJPJQJnHo(tH h(phm{ujjjj $$1$Ifa$$Ifkd$$IfrLt%ud&4 ah "(.{ujjjj $$1$Ifa$$Ifkd$$IfrLt%ud&4 ah./HWfu{ujjjj $$1$Ifa$$Ifkd$$$IfrLt%ud&4 ah23^{WUSQKQS^#9TPL HD@<%^kd$$IfrLt%ud&4 ah  3EJOP/02_;=JS]aks&wҹҹҹҪҹoҹҹ+h(phEN2CJOJPJQJaJnHo(tHh(phEN2CJOJQJaJ+h(pho*CJOJPJQJaJnHo(tHh(phmCJOJQJaJ1h(phmB*CJOJPJQJaJnHphtH%h(phmB*CJOJQJaJph4h(phmB*CJOJPJQJaJnHo(phtH+^_<=  !!/#0#o%p%M(N())))+ ^`gd-}^gd:**TPL HD@<^gd:*$^`a$gdEN2^wz|~    : ; < > I K L N d g h k ӸӸӸӸoooooooo4h(ph'B*CJOJPJQJaJnHo(phtH%h(ph:*B*CJOJQJaJph4h(ph:*B*CJOJPJQJaJnHo(phtH4h(phmB*CJOJPJQJaJnHo(phtH%h(phmB*CJOJQJaJph1h(phmB*CJOJPJQJaJnHphtH$ !!!"!.!H!I!|!ҿvcN34h(phmB*CJOJPJQJaJnHo(phtH(h(ph$B*CJOJQJaJo(ph%h(ph$B*CJOJQJaJph%hHeh$B*CJOJQJaJph4hHeh$B*CJOJPJQJaJnHo(phtH4hHeh(pB*CJOJPJQJaJnHo(phtH%hHeh:*B*CJOJQJaJph%h(ph:*B*CJOJQJaJph4h(phoY\B*CJOJPJQJaJnHo(phtH |!!!!!!!!!!!! "ʯʜnUnU:n4h(ph&B*CJOJPJQJaJnHo(phtH1h(phmB*CJOJPJQJaJnHphtH%h(phmB*CJOJQJaJph4h(ph:*B*CJOJPJQJaJnHo(phtH%h(ph:*B*CJOJQJaJph4h(ph0QB*CJOJPJQJaJnHo(phtH4h(phN B*CJOJPJQJaJnHo(phtH4h(ph}kB*CJOJPJQJaJnHo(phtH " " ""&"(")"+"3"6"7":"W"Z"["^"""""""""""###-#h#i###################C$O$T$ҹҹҹ҃4h(ph B*CJOJPJQJaJnHo(phtH4h(ph0B*CJOJPJQJaJnHo(phtH1h(phmB*CJOJPJQJaJnHphtH%h(phmB*CJOJQJaJph4h(phmB*CJOJPJQJaJnHo(phtH3T$U$]$$$$$$$$% %%*%2%5%\%a%o%p%%%%%%%渣ӸӸӣӣuZuAZA1hHehmB*CJOJPJQJaJnHphtH4hHehmB*CJOJPJQJaJnHo(phtH%hHehmB*CJOJQJaJph4h(ph B*CJOJPJQJaJnHo(phtH(h(phmB*CJOJQJaJo(ph4h(phmB*CJOJPJQJaJnHo(phtH%h(phmB*CJOJQJaJph1h(phmB*CJOJPJQJaJnHphtH%%%%%%&&&& &<&=&B&Z&_&c&o&u&&&&&&&''@(A(J(K(M(N(^(ѸѸѸmm4hHeh9LB*CJOJPJQJaJnHo(phtH(hHehmB*CJOJQJaJo(ph4hHeh0B*CJOJPJQJaJnHo(phtH1hHehmB*CJOJPJQJaJnHphtH4hHehmB*CJOJPJQJaJnHo(phtH%hHehmB*CJOJQJaJph!^(`(((((((((((((()))))>)@)I)ҷҷҷ҃hUh҃:ҷҷ:4hHeh7<B*CJOJPJQJaJnHo(phtH%hHehCZB*CJOJQJaJph4hHehX<B*CJOJPJQJaJnHo(phtH1hHehmB*CJOJPJQJaJnHphtH4hHehCBB*CJOJPJQJaJnHo(phtH4hHehmB*CJOJPJQJaJnHo(phtH%hHehmB*CJOJQJaJph4hHehBB*CJOJPJQJaJnHo(phtHI)J)Q)S)a)b)x){)|)))))))))))))))))))d*k****̽mmmmmmmRmRm4hHehT%B*CJOJPJQJaJnHo(phtH%hHehmB*CJOJQJaJph+hHehmCJOJPJQJaJnHo(tH"hHehm5CJOJQJ\aJ(hHehmCJOJPJQJaJnHtHhHehmCJOJQJaJ1hHehmB*CJOJPJQJaJnHphtH4hHehmB*CJOJPJQJaJnHo(phtH***++ + ++E+s+++',*,+,.,2,3,4,I,J,e,r,,,,,,,,,,,-----ҷҷҞҷҷҷҷҷ҃ҷҷҞҷҷҞn)hHehmB*CJOJPJQJaJph4hHeh(B*CJOJPJQJaJnHo(phtH1hHehmB*CJOJPJQJaJnHphtH4hHehmB*CJOJPJQJaJnHo(phtH%hHehmB*CJOJQJaJph4hHehC*B*CJOJPJQJaJnHo(phtH%++++,,---.....g/h///A0B00033335555^gd ,^------ ....'.+.-......../ / / //C/D/[/]/^/a/}/~////////// 0ʱʱʱʃʱʞnʞʞʞʞʞʞnʃʞʞ(hHehmB*CJOJQJaJo(ph4hHeh;FB*CJOJPJQJaJnHo(phtH%hHehmB*CJOJQJaJph1hHehmB*CJOJPJQJaJnHphtH4hHehmB*CJOJPJQJaJnHo(phtH4hHehF$)B*CJOJPJQJaJnHo(phtH* 00#0(080900000#1$1:1B1I1J1a1c1d1g111q2y22233333忦pp]NhHehmCJOJQJaJ%hHeh7DB*CJOJQJaJph4hHeh3,B*CJOJPJQJaJnHo(phtH4hHehmB*CJOJPJQJaJnHo(phtH1hHehmB*CJOJPJQJaJnHphtH%hHehmB*CJOJQJaJph%hHehL9!B*CJOJQJaJph4hHehL9!B*CJOJPJQJaJnHo(phtH333!4"454M4l44444?5R55555555555(6l6w6x6{666666r77ѾѾѾѾѣѾoѾѾoѾѾѾѾѾo4hHeh ,B*CJOJPJQJaJnHo(phtH1hHeh{B*CJOJPJQJaJnHphtH4hHeh{B*CJOJPJQJaJnHo(phtH%hHeh ,B*CJOJQJaJph(hHeh ,B*CJOJQJaJo(ph1hHehmB*CJOJPJQJaJnHphtH#7777778&8)83858W8h8o88899,:-:X:[:f:o:q:~:::::::::::::::;;;;;F;L;_;`;l;o;;;;;;˶˶ˣ˶˶˶˶%hHeh ,B*CJOJQJaJph(hHeh ,B*CJOJQJaJo(ph4hHeh ,B*CJOJPJQJaJnHo(phtH1hHeh ,B*CJOJPJQJaJnHphtH65(8)899W:X:::==>>+?,?j@k@^B_BBBCCdFeFHHJJ^^gd ,;;;;.<A<B<W<`<<======= >>>>0>>>>>>>>>>>????H?????@@C@D@~@@@@@@A%A[AnAеТТТТТТТТТТТТТТТТТТТТТТТЇТ4hHehhB*CJOJPJQJaJnHo(phtH%hHeh ,B*CJOJQJaJph4hHeh ,B*CJOJPJQJaJnHo(phtH(hHeh ,B*CJOJQJaJo(ph4hHehT"B*CJOJPJQJaJnHo(phtH5nAvAwA}AAAAAAAAAAAAAB!B\B_BbBwBBBBBB-C.C]C^CCCCC@DADVDXDDDeEkEEEEEEEEEEF6Fؽ4hHehuB*CJOJPJQJaJnHo(phtH4hHeh B*CJOJPJQJaJnHo(phtH4hHeh ,B*CJOJPJQJaJnHo(phtH%hHeh ,B*CJOJQJaJph(hHeh ,B*CJOJQJaJo(ph56F7FLFMFzFFFFFFGGAHHH\H~HHHHHHHHI?IIIJIPIaImInIrIsIIIIIIIIIIJDJSJ^JmJvJJJJJJ׼׼׼׼׼׼׼4hHeh?#B*CJOJPJQJaJnHo(phtH1hHeh ,B*CJOJPJQJaJnHphtH4hHeh ,B*CJOJPJQJaJnHo(phtH(hHeh ,B*CJOJQJaJo(ph%hHeh ,B*CJOJQJaJph4JJJJJJK KPKRKUKiKwKKKKKB*CJOJQJaJo(ph%hHeh>B*CJOJQJaJphhHehmCJOJQJaJ4hHehmB*CJOJPJQJaJnHo(phtH1JJJVLWL N NNN#O$OPPRRSSSS"V#VWW3X4X$Z%Z[[^gd>P P;P=P`P{PPPPPPPPPPP;QEQVQeQxQQQQ,R-R:R;RdReRlRmRRRRRRRSSB*CJOJPJQJaJnHphtH4hHeh>B*CJOJPJQJaJnHo(phtH4hHehBB*CJOJPJQJaJnHo(phtH%hHeh>B*CJOJQJaJph4hHeh@B*CJOJPJQJaJnHo(phtH(hHeh>B*CJOJQJaJo(ph)ASISMShSoSSSSSTTTU?UgUlUUUUUUU V4V:VKVVVVVVVVVV/W0W8W9WRW\W]W`WdW˶oo1hHeh>B*CJOJPJQJaJnHphtH4hHeh>B*CJOJPJQJaJnHo(phtH%hHeh>B*CJOJQJaJph(hHeh>B*CJOJQJaJo(ph4hHeh`TB*CJOJPJQJaJnHo(phtH1hHeh`TB*CJOJPJQJaJnHphtH+dWlWoWqWWW"X*X2XEXKXLXPXhXXXXXXXXXXXYYYBYQYeYnYyYYYYYYYYYYYYYYZZ5Z6ZYZZZ_ZZZ[[[H[I[[[[[[A\˶˶˶ˣˣ˶ˣˣˣˣ%hHeh>B*CJOJQJaJph(hHeh>B*CJOJQJaJo(ph4hHeh>B*CJOJPJQJaJnHo(phtH1hHeh>B*CJOJPJQJaJnHphtH@A\N\u\\\\\\\\]]]]]]]!]<]^]o]]]]]]]]]^^Y^e^{^^^^^^^^^^^^^ؽؽؽؽؽؽؽؽؽt4hHehOB*CJOJPJQJaJnHo(phtH(hHehOB*CJOJQJaJo(ph1hHeh>B*CJOJPJQJaJnHphtH4hHeh>B*CJOJPJQJaJnHo(phtH%hHeh>B*CJOJQJaJph(hHeh>B*CJOJQJaJo(ph-[\\]]]]+_,_aaaacccccctdud'e(eheie^ ^`gd>$a$gd>gd>^gd>^_ _____"_#_(_G_]________ `%`7`A`````````ao(4hHehhkB*CJOJPJQJaJnHo(phtH4hHeho B*CJOJPJQJaJnHo(phtH(hHeho B*CJOJQJaJo(ph(hHeh>B*CJOJQJaJo(ph%hHeh>B*CJOJQJaJph.aaa)bKbLbUb]bebibubbbbbbccc?cFcGcJcPcQcdcfcncqcrc~cccccccccյ{b1hHehmB*CJOJPJQJaJnHphtH%hHehmB*CJOJQJaJph.hHehm5CJOJPJQJ\aJnHtHhHehmCJOJQJaJ#hHehdCJOJPJQJaJo(hHeh3JPJnHo(tHhHeh>o( hHeh>hHeh?PJnHtHhHeh?PJnHo(tH&cddddddeeee%e'e(eieeeeeeeeѸ접v[B[1hHehvbB*CJOJPJQJaJnHphtH4hHehvbB*CJOJPJQJaJnHo(phtH4hHehx8B*CJOJPJQJaJnHo(phtHhHehmCJOJQJaJ.hHehm5CJOJPJQJ\aJnHtH1hHehmB*CJOJPJQJaJnHphtH4hHehmB*CJOJPJQJaJnHo(phtH%hHehmB*CJOJQJaJpheeeeffff ff;f>>>$$1$Ifa$gdwN $1$IfgdTkdI!$$Ifl4Tr +# &&&&#644 lagp2&w'wDwVwhwzwwYD6666$$1$Ifa$gdwNL$1$IfWD^L`gdTkd`"$$IflTr +#& &&&&#644 lagp2&w'wDwwwwww xQxRxmxxxxxx y_y`y{yyyyyyz z8ztzuzzzzzz{R{S{g{{{{{{|S|T|]|^||||| }!}=}w}x}}}}}}@~~~hHeh=CJKHaJhHeh=CJKH\aJhHeh=CJKHaJ$hHeh=CJKHPJaJnHtHhHeh=CJKHFwwwwwwwYN@@@@$$1$Ifa$gdwN $1$IfgdTkdo#$$IflTr +#& &&&&#644 lagp2ww xx-x?xQxYN@@@@$$1$Ifa$gdwN $1$IfgdTkd~$$$IflTr +#& &&&&#644 lagp2QxRxmx|xxxxYN@@@@$$1$Ifa$gdwN $1$IfgdTkd%$$IflTr +#& &&&&#644 lagp2xxxxxxxYN@@@@$$1$Ifa$gdwN $1$IfgdTkd&$$IflTr +#& &&&&#644 lagp2xxy y0y@yYN=//$$1$Ifa$gdwN $1$IfWD` gdT $1$IfgdTkd'$$IflTr +#& &&&&#644 lagp2@yPy_y`y{yyyK6 $1$IfWDp^ `gdTkd($$IflTr +#& &&&&#644 lagp2$$1$Ifa$gdwNyyyyyyyyK@ $1$IfgdTkd)$$IflTr +#& &&&&#644 lagp2$$1$Ifa$gdwNyz z8zFzVzdzK6 $1$IfWDp^ `gdTkd*$$IflTr +#& &&&&#644 lagp2$$1$Ifa$gdwNdztzuzzzzzzK@ $1$IfgdTkd+$$IflXr +#& &&&&#644 lagp2$$1$Ifa$gdwNzz{({6{D{R{YD6666$$1$Ifa$gdwN $1$IfWDp^ `gdTkd,$$IflTr +#& &&&&#644 lagp2R{S{g{w{{{{YN@@@@$$1$Ifa$gdwN $1$IfgdTkd.$$Iflr +# &&&&#644 lagp2{{{{{{{YD6666$$1$Ifa$gdwND$1$IfWD^`DgdTkd/$$IflTr +#& &&&&#644 lagp2{{|'|6|E|S|YD6666$$1$Ifa$gdwN $1$IfWDp^ `gdTkd#0$$IflTr +#& &&&&#644 lagp2S|T||||||YD6666$$1$Ifa$gdwN $1$IfWD^` gdTkd21$$IflXr +#& &&&&#644 lagp2||||}} }YN@@@@$$1$Ifa$gdwN $1$IfgdTkdA2$$IflXr +#& &&&&#644 lagp2 }!}=}L}Z}i}w}YN@@@@$$1$Ifa$gdwN $1$IfgdTkdP3$$IflTr +#& &&&&#644 lagp2w}x}}}}}}YN@@@@$$1$Ifa$gdwN $1$IfgdTkd_4$$IflXr +#& &&&&#644 lagp2}}@~`~~~~~YD6666$$1$Ifa$gdwN$1$IfWD ^`gdTkdn5$$IflXr +#& &&&&#644 lagp2~~,HvYN@@@@$$1$Ifa$gdwN $1$IfgdTkd}6$$IflTr +#& &&&&#644 lagp2YN@@@@$$1$Ifa$gdwN $1$IfgdTkd7$$IflTr +#& &&&&#644 lagp2()Iabހ !ՁցہøøøwwlwwlwwlX'hHehgCJKHPJaJnHo(tHhHeh[ CJKHhHeh[ CJKHaJhHeh[ CJKHaJo($hHeh[ CJKHPJaJnHtH$hHeh=CJKHPJaJnHtHhHeh=CJKHhHeh=CJKHaJhHeh=CJKHQJaJo(hHeh=CJKH\aJ"hHeh=CJKHQJ\aJo(""(YD6666$$1$Ifa$gdwN $1$IfWD^` gdTkd8$$IflTr +#& &&&&#644 lagp2()IOU[aYD6666$$1$Ifa$gdwN $1$IfWD^` gdTkd9$$IflTr +#& &&&&#644 lagp2abP;---$$1$Ifa$gdwN $1$IfWD^` gdTkd:$$IflTr +#& &&&&  #644 lagp2ހB- $1$IfWD^` gdTkd;$$IflTr +#& &&&&  #644 lagp2$$1$Ifa$gdwN !B- $1$IfWD^` gdTkd<$$IflXr +#& &&&&  #644 lagp2$$1$Ifa$gdwNՁցB- $1$IfWD^` gdTkd>$$IflXr +#& &&&&  #644 lagp2$$1$Ifa$gdwNہ%bcdfpqtŷq^G.1hHehm5CJOJPJQJ\]aJnHtH-hHehm5CJOJQJ\]aJnHtH%hHehm5CJOJQJ\]aJ/hHehm56OJPJQJ\]nHo(tH+hHehmCJOJPJQJaJnHo(tHhHeh[ CJKHhHeh[ CJKHaJhHeh[ CJKHaJo('hHeh[ CJKHPJaJnHo(tH'hHehgCJKHPJaJnHo(tH$hHehgCJKHPJaJnHtH &4KbcdB8 T^kd?$$IflXr +#& &&&&  #644 lagp2$$1$Ifa$gdwNdfwxFG/0NOPVr%$!d$Ifa$gdTZd$If^Z`gdTdgdRv%<TPL HD@<e C^"7TPL HD@<e C^ $da$gd/e T^tuvwxyׂ5DFλzzp`P@0hHeh/eCJPJnHo(tHhHehu"CJPJnHo(tHhHehOCJPJnHo(tHhHeh*WCJPJnHo(tHhHeh*WCJo(hHeh/eCJo(hHeh/eCJhHeh/eCJjhHeh/eCJU(hHehm56CJOJQJ\]aJ%hHehm5CJOJQJ\]aJ-hHehm5CJOJQJ\]aJnHtH4hHeh)G5CJOJPJQJ\]aJnHo(tHFGH~ă.óØjK=hHehqk5;B*CJOJPJQJ\aJnHo(phtH.hHehm5;B*CJOJQJ\aJph+hHehm5B*CJOJQJ\aJph4hHehmB*CJOJPJQJaJnHo(phtHhHehu"CJPJnHo(tHhHeh/eCJPJnHo(tHhHeh/eCJhHeh/eCJjhHeh/eCJUhHeh/eCJo(./0=DMNOPVlnoıiUJ:"J:.hHehRv>*CJOJPJQJaJnHo(tHhHehRv>*CJOJQJaJhHehRvCJaJ&hHehRv5CJPJaJnHo(tH3hHehm5B*CJOJPJQJnHo(phtH'hHehRv5B*CJOJQJo(ph3hHehRv5B*CJOJPJQJnHo(phtH$hHehRv5B*CJOJQJph:hHehRv5B*CJOJPJQJ\aJnHo(phtH:hHehm5B*CJOJPJQJ\aJnHo(phtH ValmnozeQ=%$!d$Ifa$gdTZd$If^Z`gdTpkd@$$Ifl\r#+vvv$4 a%$!d$Ifa$gdT%$!d$4$Ifa$gdTouxyzȄ̄̈́ބ߄͛xxxfxͯͯͯ# *hHehRvCJPJaJnHtH hHehRvCJPJaJnHtH#hHeh2.CJPJaJnHo(tH&hHehRv5CJPJaJnHo(tH#hHehRvCJPJaJnHo(tH *hHehRvCJaJhHehRvCJaJhHehRv>*CJOJQJaJ.hHehRv>*CJOJPJQJaJnHo(tH zzfWHH$d$Ifa$gdT$d$Ifa$gdTZd$If^Z`gdTpkd@$$Ifl\r#+vvv$4 a%$!d$Ifa$gdTzk\\$d$Ifa$gdT$d$Ifa$gdTZd$If^Z`gdTpkdA$$Ifl\r#+vvv$4 azk\\$d$Ifa$gdT$d$Ifa$gdTZd$If^Z`gdTpkdA$$Ifl\r#+vvv$4 aɄzk\\$d$Ifa$gdT$d$Ifa$gdTZd$If^Z`gdTpkdB$$Ifl\r#+vvv$4 aɄʄ˄̄̈́΄zk\\$d$Ifa$gdT$d$Ifa$gdTZd$If^Z`gdTpkdB$$Ifl\r#+vvv$4 a΄τ݄ބzkSS$d$&dIfPa$gdT$d$Ifa$gdTZd$If^Z`gdTpkd C$$Ifl\r#+vvv$4 a  +245689:;>BCESTUXY[\_cdf…ÅąЦЦЦЦĦЦЦЦ# *hHehRvCJPJaJnHtH#hHehRvCJPJaJnHo(tHhHehRv5CJaJ *hHehRvCJaJ hHehRvCJPJaJnHtHhHehRvCJaJ& *hHehRvCJPJaJnHo(tH:zk\\$d$Ifa$gdT$d$Ifa$gdTZd$If^Z`gdTpkdC$$Ifl\r#+vvv$4 a zk\\$d$Ifa$gdT$d$Ifa$gdTZd$If^Z`gdTpkdD$$Ifl\r#+vvv$4 azk\\$d$Ifa$gdT$d$Ifa$gdTZd$If^Z`gdTpkdD$$Ifl\r#+vvv$4 a 239?zk\\$d$Ifa$gdT$d$Ifa$gdTZd$If^Z`gdTpkdE$$Ifl\r#+vvv$4 a?@ABCDzk\\$d$Ifa$gdT$d$Ifa$gdTZd$If^Z`gdTpkdE$$Ifl\r#+vvv$4 aDERSY`zk\\$d$Ifa$gdT$d$Ifa$gdTZd$If^Z`gdTpkdF$$Ifl\r#+vvv$4 a`abcdezk\\$d$Ifa$gdT$d$Ifa$gdTZd$If^Z`gdTpkd~F$$Ifl\r#+vvv$4 aef}~zk\I$d$Ifa$gdT$d$Ifa$gdT$d$Ifa$gdTZd$If^Z`gdTpkdF$$Ifl\r#+vvv$4 azk\\$d$Ifa$gdT$d$Ifa$gdTZd$If^Z`gdTpkdzG$$Ifl\r#+vvv$4 aÅͅzk\\$d$Ifa$gdT$d$Ifa$gdTZd$If^Z`gdTpkdG$$Ifl\r#+vvv$4 aą˅Ѕх !"%*+6>KLMNORSX\]mnoprsvwxyƲƲ䦔Ʋ#hHeh2.CJPJaJnHo(tH# *hHehRvCJPJaJnHtH *hHehRvCJaJ& *hHehRvCJPJaJnHo(tH#hHehRvCJPJaJnHo(tH *hHehRvCJaJhHehRvCJaJ hHehRvCJPJaJnHtH3ͅ΅υЅх҅zk\\$d$Ifa$gdT$d$Ifa$gdTZd$If^Z`gdTpkdvH$$Ifl\r#+vvv$4 a҅Ӆzk\\$d$Ifa$gdT$d$Ifa$gdTZd$If^Z`gdTpkdH$$Ifl\r#+vvv$4 azk\\$d$Ifa$gdT$d$Ifa$gdTZd$If^Z`gdTpkdrI$$Ifl\r#+vvv$4 a'zk\\$d$Ifa$gdT$d$Ifa$gdTZd$If^Z`gdTpkdI$$Ifl\r#+vvv$4 a'()*+,zk\\$d$Ifa$gdT$d$Ifa$gdTZd$If^Z`gdTpkdnJ$$Ifl\r#+vvv$4 a,-LMSYzk\\$d$Ifa$gdT$d$Ifa$gdTZd$If^Z`gdTpkdJ$$Ifl\r#+vvv$4 aYZ[\]^zk\\$d$Ifa$gdT$d$Ifa$gdTZd$If^Z`gdTpkdjK$$Ifl\r#+vvv$4 a^_moxzkSS$d$&dIfPa$gdT$d$Ifa$gdTZd$If^Z`gdTpkdK$$Ifl\r#+vvv$4 azk\\$d$Ifa$gdT$d$Ifa$gdTZd$If^Z`gdTpkdfL$$Ifl\r#+vvv$4 a†ÆĆņƆ̆͆Ԇ؆نۆ,-.05GMNT˹蹓˹˹܁˹m蹥&hHehRv5CJPJaJnHo(tH#hHehg'CJPJaJnHo(tH#hHeh2.CJPJaJnHo(tH& *hHehRvCJPJaJnHo(tH#hHehRvCJPJaJnHo(tH hHehRvCJPJaJnHtHhHehRv5CJaJhHehRvCJaJ *hHehRvCJaJ*zk\\$d$Ifa$gdT$d$Ifa$gdTZd$If^Z`gdTpkdL$$Ifl\r#+vvv$4 azk\\$d$Ifa$gdT$d$Ifa$gdTZd$If^Z`gdTpkdbM$$Ifl\r#+vvv$4 a†Ć͆ՆzkSS$d$&dIfPa$gdT$d$Ifa$gdTZd$If^Z`gdTpkdM$$Ifl\r#+vvv$4 aՆֆ׆؆نچzk\\$d$Ifa$gdT$d$Ifa$gdTZd$If^Z`gdTpkd^N$$Ifl\r#+vvv$4 aچۆzkSS$d$&dIfPa$gdT$d$Ifa$gdTZd$If^Z`gdTpkdN$$Ifl\r#+vvv$4 azk\\$d$Ifa$gdT$d$Ifa$gdTZd$If^Z`gdTpkdZO$$Ifl\r#+vvv$4 a,-./zk\\$d$Ifa$gdT$d$Ifa$gdTZd$If^Z`gdTpkdO$$Ifl\r#+vvv$4 a/0FGNU|m^^$d$Ifa$gdT$d$Ifa$gdTd$IfVDG^gdRvpkdVP$$Ifl\r#+vvv$4 aUVijpv|mUU$d$&dIfPa$gdT$d$Ifa$gdTd$IfVDG^gdRvpkdP$$Ifl\r#+vvv$4 aTV^jkopuyz~Ƈɇʇ҇߇kahHehx5CJ)hHehRv5CJPJ\aJnHo(tH#hHeh{v4CJPJaJnHo(tH&hHehRv5CJPJaJnHo(tHhHehRv5CJaJ *hHehRvCJaJ& *hHehRvCJPJaJnHo(tH hHehRvCJPJaJnHtH#hHehRvCJPJaJnHo(tHhHehRvCJaJvwxyz{zk\\$d$Ifa$gdT$d$Ifa$gdTZd$If^Z`gdTpkdRQ$$Ifl\r#+vvv$4 a{|}~zkSS$d$&dIfPa$gdT$d$Ifa$gdTZd$If^Z`gdTpkdQ$$Ifl\r#+vvv$4 azk\\$d$Ifa$gdT$d$Ifa$gdTZd$If^Z`gdTpkdNR$$Ifl\r#+vvv$4 azk\\$d$Ifa$gdT$d$Ifa$gdTZd$If^Z`gdTpkdR$$Ifl\r#+vvv$4 aʇ߇zkSS#$d$&dIfPa$gdT$d$Ifa$gdTZd$If^Z`gdTpkdJS$$Ifl\r#+vvv$4 a߇ ufL%$!d$4$Ifa$gdToK$d$Ifa$gdT d$IfgdTgdxdgdRvpkdS$$Ifl\r#+vvv$4 a+.47?BDGWYZdfgilmnoν~~o]M]MoMhHehxCJOJQJaJo(#hHehx>*CJPJaJnHtHhHehxCJOJQJaJhHehx>*CJOJQJaJ"hHehx>*CJOJQJaJo(hHehxCJaJ#hHehxCJPJaJnHo(tH hHehxCJPJaJnHtHhHehxPJnHo(tH"hHehRv5CJPJnHo(tH"hHehx5CJPJnHo(tH +,-.9DthY$d$Ifa$gdT d$IfgdTpkdFT$$If\r+BY#$4 a%$!d$4$Ifa$gdToKDEFGOWs^^%$!d$4$Ifa$gdT$d$Ifa$gdT d$IfgdTpkdT$$If\r+BY#$4 aWXYZ[ds^^%$!d$4$Ifa$gdT$d$Ifa$gdT d$IfgdTpkdRU$$If\r+BY#$4 adefghis^^%$!d$4$Ifa$gdT$d$Ifa$gdT d$IfgdTpkdU$$If\r+BY#$4 aijklmnxiTT%$!d$4$Ifa$gdT$d$Ifa$gdT$d$IfWD^`$gdTpkd^V$$If\r+BY#$4 anozkMM%$!d$&d4$IfPa$gdT$d$Ifa$gdTZd$If^Z`gdTpkdV$$If\r+BY#$4 ao~4569>?IJůş~ş~l~ԯ~lԟůlԯ~#hHehxCJPJaJnHo(tHhHehxCJaJo((hHehxCJOJPJQJaJnHtHhHehxCJOJQJaJo(+hHehxCJOJPJQJaJnHo(tHhHehxCJOJQJaJhHehxCJaJ&hHehx5CJPJaJnHo(tHhHehx5CJaJ*zkVV%$!d$4$Ifa$gdT$d$Ifa$gdTZd$If^Z`gdTpkdjW$$If\r+BY#$4 azkVV%$!d$4$Ifa$gdT$d$Ifa$gdTZd$If^Z`gdTpkdW$$If\r+BY#$4 azkVV%$!d$4$Ifa$gdT$d$Ifa$gdTZd$If^Z`gdTpkdvX$$If\r+BY#$4 a456>?IxiTTTT%$!d$4$Ifa$gdT$d$Ifa$gdT4d$IfWDt^4`gdTpkdX$$If\r+BY#$4 aIJvgD"%$!d$&d4$IfPa$gdToK$d$Ifa$gdTJ:d$IfVD7WD^J`:gdxpkdY$$If\r+BY#$4 aJ6Zd$If^Z`gdTukdZ$$If\r+BY#$4 agU"%$!d$&d4$IfPa$gdToK%$!d$&dIfPa$gdT׉؉jVZd$If^Z`gdTpkdZ$$If\r+BY#$4 a%$!d$4$Ifa$gdT$d$Ifa$gdTƉʉ׉؉,/012^_`abcdz{}ȴ֞֒ȴրt֒֒֒hHehx5CJaJ"hHehx5CJOJQJaJo(hHehxCJaJo(+hHehxCJOJPJQJaJnHo(tH&hHehx5CJPJaJnHo(tHhHehx5CJaJo(hHehxCJaJhHehxCJOJQJaJo(hHehxCJOJQJaJ-؉ىT@Zd$If^Z`gdTpkd[$$If\r+BY#$4 a%$!d$&dIfPa$gdT%$!d$&d4$IfPa$gdTjVZd$If^Z`gdTpkd[$$If\r+BY#$4 a%$!d$4$Ifa$gdT$d$Ifa$gdT",-./0p\M8%$!d$4$Ifa$gdT$d$Ifa$gdTZd$If^Z`gdTpkd*\$$If\r+BY#$4 a%$!d$&d4$IfPa$gdT012^_yh07kd6]$$Ifr#$$4 a%!d$IfgdTpkd\$$If\r+BY#$4 a%$!d$4$Ifa$gdT_`abcdz{VDnd$IfWD2`ngdTpkd]$$If\r+BY#$4 a%$!d$4$Ifa$gdT$d$Ifa$gdTZd$If^Z`gdT{ygX:%$!d$&d4$IfPa$gdT$d$Ifa$gdTnd$IfWD2`ngdTpkd^$$If\r+BY#$4 a%$!d$4$Ifa$gdTp\M88%$!d$4$Ifa$gdT$d$Ifa$gdTZd$If^Z`gdTpkd^$$If\r+BY#$4 a%$!d$&d4$IfPa$gdTȊzkMM%$!d$&d4$IfPa$gdT$d$Ifa$gdTZd$If^Z`gdTpkd_$$If\r+BY#$4 aNJȊɊʊ׊жoQ;0hHeh"CJaJ+hHehmCJOJPJQJaJnHo(tH:hHehRv5B*CJOJPJQJ\aJnHo(phtH3hHeh%y5B*CJOJPJQJnHo(phtH3hHeh"5B*CJOJPJQJnHo(phtH$hHeh"5B*CJOJQJph3hHehg5B*CJOJPJQJnHo(phtHhHehxCJaJ+hHehxCJOJPJQJaJnHo(tHhHehxCJOJQJaJ ȊɊʊiigS?%$!d0$Ifa$gdTZd0$If^Z`gdT%<TPL HD@<e C^pkd_$$If\r+BY#$4 a.AWXY\]`13568@׶q&hHeh"hCJPJaJnHtH#hHeh"CJPJaJnHo(tH hHeh"CJPJaJnHtHhHeh"5CJ\aJhHeh"CJaJ+hHeh">*CJOJPJQJaJnHtH.hHeh">*CJOJPJQJaJnHo(tHhHeh">*CJOJQJaJ,  r^O:$xd0$IfUD2]xa$gd"$d0$Ifa$gdTZd0$If^Z`gdTrkd&`$$Ifl\#7  I$4 la%$!xd0$IfUD2]xa$gd" ()*+,-wcTEE$d0$Ifa$gdT$d0$Ifa$gdTZd0$If^Z`gdTrkd`$$Ifl\#7  I$4 la$xd0$IfUD2]xa$gd"-.ABCDxiZZ$d0$Ifa$gdT$d0$Ifa$gdTZd0$If^Z`gdTrkd4a$$Ifl\#7  I$4 laDEXY]azk\\$d0$Ifa$gdT$d0$Ifa$gdTld0$IfVD-^lgd"rkda$$Ifl\#7  I$4 laabzk\\$d0$Ifa$gdT$d0$Ifa$gdTd0$IfVDG^gd"rkdBb$$Ifl\#7  I$4 lazk\\$d0$Ifa$gdT$d0$Ifa$gdTd0$IfVDG^gd"rkdb$$Ifl\#7  I$4 lazk\\$d0$Ifa$gdT$d0$Ifa$gdTd0$IfVDG^gd"rkdPc$$Ifl\#7  I$4 lazk\\$d0$Ifa$gdT$d0$Ifa$gdTd0$IfVDG^gd"rkdc$$Ifl\#7  I$4 la129@zk\\$d0$Ifa$gdT$d0$Ifa$gdTd0$IfVDG^gd"rkd^d$$Ifl\#7  I$4 la@A`aipzk\\$d0$Ifa$gdT$d0$Ifa$gdTd0$IfVDG^gd"rkdd$$Ifl\#7  I$4 la@`depÌӌ׌، >EKvxyōǍݍ&/0UX]^_`fghryҝ)hHeh"hCJPJaJnHo(tH#hHehjy}CJPJaJnHo(tHhHeh"5CJ\aJ#hHeh"CJPJaJnHo(tH hHeh"CJPJaJnHtHhHeh"CJaJ>pqzkSS$d0$&dIfPa$gdT$d0$Ifa$gdTd0$IfVDG^gd"rkdle$$Ifl\#7  I$4 laxiZZ$d0$Ifa$gdT$d0$Ifa$gdTZd0$If^Z`gdTrkde$$Ifl\#7  I$4 laxiQQ$d0$&dIfPa$gdT$d0$Ifa$gdTZd0$If^Z`gdTrkdzf$$Ifl\#7  I$4 laxiZZ$d0$Ifa$gdT$d0$Ifa$gdTZd0$If^Z`gdTrkdg$$Ifl\#7  I$4 laÌČŌƌxiZZ$d0$Ifa$gdT$d0$Ifa$gdTZd0$If^Z`gdTrkdg$$Ifl\#7  I$4 laƌnjӌԌ܌zk\\$d0$Ifa$gdT$d0$Ifa$gdTd0$IfVDG^gd"rkdh$$Ifl\#7  I$4 la zk\\$d0$Ifa$gdT$d0$Ifa$gdTd0$IfVDG^gd"rkdh$$Ifl\#7  I$4 la>?EKzk\\$d0$Ifa$gdT$d0$Ifa$gdTd0$IfVDG^gd"rkdi$$Ifl\#7  I$4 laKLvw}zk\\$d0$Ifa$gdT$d0$Ifa$gdTd0$IfVDG^gd"rkdi$$Ifl\#7  I$4 lazk\\$d0$Ifa$gdT$d0$Ifa$gdTd0$IfVDG^gd"rkd+j$$Ifl\#7  I$4 laƍzk\\$d0$Ifa$gdT$d0$Ifa$gdTd0$IfVDG^gd"rkdj$$Ifl\#7  I$4 laƍǍݍލzk\\$d0$Ifa$gdT$d0$Ifa$gdTd0$IfVDG^gd"rkd9k$$Ifl\#7  I$4 lazkSS$d0$&dIfPa$gdT$d0$Ifa$gdTd0$IfVDG^gd"rkdk$$Ifl\#7  I$4 laxiZZ$d0$Ifa$gdT$d0$Ifa$gdTZd0$If^Z`gdTrkdGl$$Ifl\#7  I$4 la'/qbb$d0$Ifa$gdT$d0$Ifa$gdT d0$IfgdTrkdl$$Ifl\#7  I$4 la/0VW^`qYY$d0$&dIfPa$gdT$d0$Ifa$gdT d0$IfgdTrkdUm$$Ifl\#7  I$4 la`abcdexiZZ$d0$Ifa$gdT$d0$Ifa$gdTZd0$If^Z`gdTrkdm$$Ifl\#7  I$4 laefghrzxiQQ$d0$&dIfPa$gdT$d0$Ifa$gdTZd0$If^Z`gdTrkdcn$$Ifl\#7  I$4 laz{|}~xiZZ$d0$Ifa$gdT$d0$Ifa$gdTZd0$If^Z`gdTrkdn$$Ifl\#7  I$4 laxiZZ$d0$Ifa$gdT$d0$Ifa$gdTZd0$If^Z`gdTrkdqo$$Ifl\#7  I$4 layĎ$%&'./9:>?BKQRSZcdefghi|}ÏΏϏЏяҏӏԏ !)CEFQnsòòòòòòòòòòòòòòò hHeh"CJPJaJnHtH#hHeh"CJPJaJnHo(tH#hHehjy}CJPJaJnHo(tHhHeh"5CJ\aJhHeh"CJaJFĎzk\\$d0$Ifa$gdT$d0$Ifa$gdTd0$IfVDG^gd"rkdo$$Ifl\#7  I$4 laĎŎzk\\$d0$Ifa$gdT$d0$Ifa$gdTd0$IfVDG^gd"rkdp$$Ifl\#7  I$4 lazk\\$d0$Ifa$gdT$d0$Ifa$gdTd0$IfVDG^gd"rkdq$$Ifl\#7  I$4 la%&(.zk\\$d0$Ifa$gdT$d0$Ifa$gdTd0$IfVDG^gd"rkdq$$Ifl\#7  I$4 la./:;CKzkSS$d0$&dIfPa$gdT$d0$Ifa$gdTd0$IfVDG^gd"rkdr$$Ifl\#7  I$4 laKLMNOPxiZZ$d0$Ifa$gdT$d0$Ifa$gdTZd0$If^Z`gdTrkdr$$Ifl\#7  I$4 laPQRS[cxiQQ$d0$&dIfPa$gdT$d0$Ifa$gdTZd0$If^Z`gdTrkd"s$$Ifl\#7  I$4 lacdefghxiZZ$d0$Ifa$gdT$d0$Ifa$gdTZd0$If^Z`gdTrkds$$Ifl\#7  I$4 lahi|}xiQQ$d0$&dIfPa$gdT$d0$Ifa$gdTZd0$If^Z`gdTrkd0t$$Ifl\#7  I$4 laxiZZ$d0$Ifa$gdT$d0$Ifa$gdTZd0$If^Z`gdTrkdt$$Ifl\#7  I$4 laďΏxiQQ$d0$&dIfPa$gdT$d0$Ifa$gdTZd0$If^Z`gdTrkd>u$$Ifl\#7  I$4 laΏϏЏяҏӏxiZZ$d0$Ifa$gdT$d0$Ifa$gdTZd0$If^Z`gdTrkdu$$Ifl\#7  I$4 laӏԏxiZZ$d$Ifa$gdT$d$Ifa$gdTZd$If^Z`gdTrkdLv$$Ifl\#7  I$4 la |m^^$d$Ifa$gdT$d$Ifa$gdTd$IfVDG^gd"pkdv$$Ifl\#7  I$4 la !)|m^^$d$Ifa$gdT$d$Ifa$gdTd$IfVDG^gd"pkdVw$$Ifl\#7  I$4 la)*BCJQ|mUU$d$&dIfPa$gdT$d$Ifa$gdTd$IfVDG^gd"pkdw$$Ifl\#7  I$4 laQRSTUVzk\\$d$Ifa$gdT$d$Ifa$gdTZd$If^Z`gdTpkd\x$$Ifl\#7  I$4 laVWzk\\$d$Ifa$gdT$d$Ifa$gdTZd$If^Z`gdTpkdx$$Ifl\#7  I$4 lasϐАِ +,678;<@BKSZ[]_bcdestuvw{5hHehg5@CJOJPJQJ\aJnHo(tHhHeh"CJOJQJaJhHeh"CJaJo(hHeh"5CJ\aJ#hHeh"CJPJaJnHo(tH hHeh"CJPJaJnHtHhHeh"CJaJ2zkSS$d$&dIfPa$gdT$d$Ifa$gdTZd$If^Z`gdTpkdby$$Ifl\#7  I$4 lazk\\$d$Ifa$gdT$d$Ifa$gdTZd$If^Z`gdTpkdy$$Ifl\#7  I$4 laϐАڐzkSS$d$&dIfPa$gdT$d$Ifa$gdTZd$If^Z`gdTpkdhz$$Ifl\#7  I$4 lazk\\$d$Ifa$gdT$d$Ifa$gdTZd$If^Z`gdTpkdz$$Ifl\#7  I$4 lazk\\$d$Ifa$gdT$d$Ifa$gdTZd$If^Z`gdTpkdn{$$Ifl\#7  I$4 la%+|m^^$d$Ifa$gdT$d$Ifa$gdTd$IfVDG^gd"pkd{$$Ifl\#7  I$4 la+,78@B|m^^$d$Ifa$gdT$d$Ifa$gdTd$IfVDG^gd"pkdt|$$Ifl\#7  I$4 laBCST[]|mUU$d$&dIfPa$gdT$d$Ifa$gdTd$IfVDG^gd"pkd|$$Ifl\#7  I$4 la]^_`ab|m^^$d$Ifa$gdT$d$Ifa$gdTd$IfVDG^gd"pkdz}$$Ifl\#7  I$4 labcdemspaII$d$&dIfPa$gdT$d$Ifa$gdT%!Zd$If^Z`gdTukd}$$Ifl\#7  I$4 lagmstuvwxufWW$d$Ifa$gdT$d$Ifa$gdT%!Zd$If^Z`gdTpkd~$$Ifl\#7  I$4 laxyz{zkSS$d$&dIfPa$gdT$d$Ifa$gdTZd$If^Z`gdTpkd$$Ifl\#7  I$4 laՑ֑opzueed^`gds"gd1Ydd^`gd1Ydrkd$$Ifl?\#7  I$4 la ԑՑّ֑cؽأ~bS=&-hHeh1YdB*CJOJQJaJnHphtH+hHeh0 CJOJPJQJaJnHo(tHhHeh1Yd5CJ\aJo(6hHehHz5CJKHOJPJQJ\^JaJnHtHhHeh1Yd5CJ\aJ-hHeh0 5@CJPJ\aJnHo(tH2hHehm5@CJOJPJQJ\aJnHtH5hHeh;[5@CJOJPJQJ\aJnHo(tH&hHeh0 5@CJOJQJ\aJ&hHeh 5@CJOJQJ\aJ cdefnoefnoptu˲o`K=.hHehHz5CJ\aJo(hHehHz5CJ\aJ)hHeh@5CJPJ\aJnHo(tHhHeh1Yd5CJ\aJo((hHeh1YdCJOJPJQJaJnHtH-hHeh1YdB*CJOJQJaJnHphtH-hHehhB*CJOJQJaJnHphtH0hHehhB*CJOJQJaJnHo(phtH4hHehhB*CJOJPJQJaJnHo(phtH1hHeh1YdB*CJOJPJQJaJnHphtHՓ !"#*6MUV]l” !˕(fpuٖ)./13Vŷťť#hHehHzCJPJaJnHo(tHhHehHzPJnHo(tHhHehHzCJaJo(hHehHzCJaJhHehHz5CJ\aJ)hHeh7m 5CJPJ\aJnHo(tHAUVlvJkd$$If0p#/ | 4 aS$|$If^`|a$gdT $IfgdT$7$8$H$^a$gdHz$JdVD_^Ja$gdHz”۔ !;LJkd$$If0p#/ | 4 aS$|$If^`|a$gdT $IfgdTJkd$$If0p#/ | 4 aS;Õĕ~3Jkdˁ$$If0p#/ | 4 aS$|$If^`|a$gdT $IfgdTJkd^$$If0p#/ | 4 aS$|$If^`|a$gdToFĕؕ '(LJkd$$If0p#/ | 4 aSJkd8$$If0p#/ | 4 aS$|$If^`|a$gdT $IfgdT(PQfgz $IfgdTJkd$$If0p#/ | 4 aS$|$If^`|a$gdT$$IfWD^`$gdTٖږL;|$If^`|gdTJkd$$If0p#/ | 4 aS$|$If^`|a$gdT $IfgdTJkd$$If0p#/ | 4 aS 3VWkO;$|$If^`|a$gdTJkdƄ$$If0p#/ | 4 aS|$If^`|gdT $IfgdTJkdY$$If0p#/ | 4 aSVWk&lnp09{|lmop^_añ׎|hñZhHehHz6CJ]aJ&hHehHz>*CJPJaJnHo(tH#hHehJnCJPJaJnHo(tH hHehHzCJPJaJnHtH#hHehHz6CJPJaJnHtH#hHehHz>*CJPJaJnHtH&hHehHz5>*CJPJaJnHtH#hHehHzCJPJaJnHo(tHhHehHzCJaJo(hHehHzCJaJ mnopLCC^gdHzJkd$$If0p#/ | 4 aS$|$If^`|a$gdT $IfgdTJkd3$$If0p#/ | 4 aSp019{|lm3op^_$7$8$H$^a$gdHz$7$8$H$^a$gdHz $da$gdHz^gdHz$JdVD_^Ja$gdHzabhiuvUWfnoq4Hɽ}i}}}}\hHehHzCJPJaJ&hHehHz>*CJPJaJnHo(tHhHehHzCJaJ hHehHzCJPJaJnHtH#hHehE~CJPJaJnHo(tH#hHehHzCJPJaJnHo(tHhHehHzCJ]aJhHehHz6CJ]aJ)hHehHz6CJPJ]aJnHo(tH&hHehHz6CJPJ]aJnHtH#_9:34Hl$d$7$8$H$Ifa$gdT $da$gdHz$d7$8$H$^a$gdHz $7$8$H$a$gdT$7$8$H$^a$gdHz$Rd7$8$H$VDb^Ra$gdHz$d7$8$H$VD^a$gdHz$4d7$8$H$VDWD^`4a$gdHz Hi)*+,4?@_`aԣfghop}ڤۤܤݤz&hHehHzCJH*PJaJnHo(tHhHehHzCJPJaJo(#hHehHzCJPJ]aJnHtH#hHehHzCJH*PJaJnHtH&hHehHzCJH*PJaJnHo(tHhHehHzCJH*PJaJhHehHzCJPJaJ hHehHzCJPJaJnHtH0Hww$d$7$8$H$Ifa$gdTUkd$$If0p#/ | t 6.44 la1$$d$7$8$H$IfWD^`$a$gdTˢ+?Ukd݆$$If0p#/ | t 6.44 la1$d$7$8$H$Ifa$gdTUkdu$$If0p#/ | t 6.44 la1+,@aw$d$7$8$H$Ifa$gdT$nd$7$8$H$IfWD^n`a$gdTUkdE$$If0p#/ | t 6.44 la1abv?Ukd$$If0p#/ | t 6.44 la1$d$7$8$H$Ifa$gdTUkd$$If0p#/ | t 6.44 la1ԣ?Ukd$$If0p#/ | t 6.44 la1$d$7$8$H$Ifa$gdTUkd}$$If0p#/ | t 6.44 la1hi}y[$$d$7$8$H$IfWD^`$a$gdT$d$7$8$H$Ifa$gdTUkdM$$If0#/  t 644 la1$$d$7$8$H$If^`$a$gdTŤܤݤ?Ukd$$If0p#/ | t 6.44 la1$d$7$8$H$Ifa$gdTUkd$$If0p#/ | t 6.44 la1ݤHwY$$d$7$8$H$IfWD^`$a$gdTUkd$$If0p#/ | t 6.44 la1$d$7$8$H$Ifa$gdT$nd$7$8$H$IfWD^n`a$gdT FGHITUVX[֥ץإ٥ڥۥ󱝏tcUhHehHzCJH*]aJ hHehHzCJPJaJnHtHhHehHzCJPJaJhHehHzCJH*PJaJhHehHzCJPJaJo(&hHehHzCJH*PJaJnHo(tH#hHehHzCJPJaJnHo(tH#hHehHzCJPJ]aJnHtHhHehHzCJ]aJ#hHehHzCJH*PJaJnHtHhHehHzCJPJaJ HI\w$d$7$8$H$Ifa$gdT$nd$7$8$H$IfWD^n`a$gdTUkd$$If0p#/ | t 6.44 la1إm$$d$7$8$H$IfWD^`$a$gdT$nd$7$8$H$IfWD^n`a$gdTUkdU$$If0p#/ | t 6.44 la1إ٥ڥǦRy^^C$Dd7$8$H$VD?WD^`Da$gdHz$Dd7$8$H$VD@WD^`Da$gdHz$d7$8$H$VDbWDj^`a$gdHz$Rd7$8$H$VDb^Ra$gdHzUkd$$If0p#/ | t 6.44 la1ۥݥޥæŦǦȦ˦ NPQRSVҧԧէקۧݧާߧ3<ٌٌ&hHehHzCJH*PJ]aJnHtHhHehHzCJ]aJ&hHehHzCJPJ]aJnHo(tHhHehHzCJH*]aJhHehHzCJaJ hHehHzCJPJaJnHtH)hHehHzCJH*PJ]aJnHo(tH1Rߧ34˰̰}xgdTd^`gds"$7$8$H$^a$gdHz$7$8$H$^a$gdHz$d7$8$H$^a$gdHz$d7$8$H$^a$gdHz$d^a$gdHz$Dd7$8$H$VD@WD^`Da$gdHz <QO&'ɬӬ٬IJTUbe}˰̰xܿʿʿʿܿܤyjZjZjhHehT6CJPJnHtHhHehTCJPJnHtHhHehTPJnHo(tHhHehT5CJ\aJhHehT5CJ\aJo(5hHeh1Yd5CJKHOJPJQJ\aJnHo(tHhHehHzCJaJ#hHehHzCJPJaJnHo(tH hHehHzCJPJaJnHtH#hHehHz6CJPJaJnHtH̰KLMNnLkd%$$If0p#/ | 4 aS$d$Ifa$gdT d$IfgdT$d^a$gdT $da$gdT$d^a$gdT &'2Ǵشݴ56_KLOP]^̶϶жųųųŖųŊųŊųųŊhHehTCJ]aJhHehT>*CJaJ hHehTCJPJaJnHtH#hHehTCJPJaJnHo(tHhHehTCJaJhHehatiCJPJnHo(tHhHehTCJPJnHtHhHehTCJPJnHo(tH6NO]JLkd$$Ifq0p#/ | 4 aS d$IfgdT$d$Ifa$gdTLkd$$If0p#/ | 4 aSζ϶JLkd$$If0p#/ | 4 aS$d$Ifa$gdT d$IfgdTLkd~$$If0p#/ | 4 aS defgJLkd$$If0p#/ | 4 aS$d$Ifa$gdT d$IfgdTLkdr$$If0p#/ | 4 aS +9defhi ʸ˸GHOPʹ~m~m~m~mc֐hHehT>*CJ hHehTCJPJaJnHtH#hHehTCJPJaJnHo(tHhHehTCJaJhHehT>*CJaJ#hHehT>*CJPJaJnHtH hHehTCJPJaJnHtHhHehTCJaJo(hHehTCJaJhHehTCJ]aJ#hHehTCJPJaJnHo(tH!ghi &'~}}h}h}h$\d$VDQ^\`a$gdT$\#d$VDQ^\`#a$gdT$RdVDb^Ra$gdT$d^a$gdTLkdf$$If0p#/ | 4 aS ʸ$d$$&dIfPa$gdT&d$$If^`&gdT,&d$$If^`&gdTkd$$If֞  yY!%nnn0"4 aS'/7?G$d$$Ifa$gdToԦ$d$$Ifa$gdTGHI,&d$$If^`&gdTkd$$If֞  yY!%nnn0"4 aSIJKLMNO$d$$Ifa$gdToԦ$d$$Ifa$gdTOPX,&d$$If^`&gdTkd$$If֞  yY!%nnn0"4 aSPWX\]^_`apvwyzƹǹ͹ι׹зjjjjjjББББ)hHehThewCJPJaJnHo(tH#hHeh[?CJPJaJnHo(tH#hHehTCJPJaJnHo(tH&hHehTCJPJ]aJnHo(tHhHehTCJaJhHehTh CJaJ hHehTCJPJaJnHtHhHehTCJ]aJ#hHehTCJPJ]aJnHtH#XYZ[\]^$d$$Ifa$gdToԦ$d$$Ifa$gdT^_p,&d$$If^`&gdToԦkd$$If֞  yY!%nnn0"4 aSpz$d$$Ifa$gdToԦ,qd$$IfVDWD^`qgdTkd$$If֞  yY!%nnn0"4 aSǹιعڹ$d$$&dIfPa$gdToԦ$d$$&dIfPa$gdT׹عڹ۹ܹ  !"()189@AGHNOPUVøæڕڕڕڕڕøæڕڕlڕ)hHehThrCJPJaJnHo(tH&hHehTCJPJ]aJnHo(tH hHehTCJPJaJnHtH#hHehTCJPJ]aJnHtHhHehTCJaJhHehTCJ]aJhHehTCJaJ#hHehTCJPJaJnHo(tH&hHehThewCJPJaJnHtH$ڹ۹ܹ,&d$$If^`&gdTkd $$If֞  yY!%nnn0"4 aSܹݹ޹߹$d$$Ifa$gdToԦ$d$$Ifa$gdT,qd$$IfVDWD^`qgdTkd$$If֞  yY!%nnn0"4 aS  $d$$&dIfPa$gdT !",&d$$If^`&gdTkd$$If֞  yY!%nnn0"4 aS"#$%&'($d$$Ifa$gdToԦ$d$$Ifa$gdT()9,qd$$IfVDWD^`qgdTkd'$$If֞  yY!%nnn0"4 aS9AHPVW_$d$$Ifa$gdT$d$$Ifa$gdToԦ$d$$&dIfPa$gdTVW^_`aghvźƺʺ˺ӺԺպĸěsćsćsĸsĸ&hHehThewCJPJaJnHtH&hHehTCJPJ]aJnHo(tH#hHehTCJPJ]aJnHtHhHehTCJaJhHehTCJ]aJhHehTCJaJ hHehTCJPJaJnHtH#hHehTCJPJaJnHo(tHhHehThewCJaJ-_`a,&d$$If^`&gdTkd1$$If֞  yY!%nnn0"4 aSabcdefg$d$$Ifa$gdToԦ$d$$Ifa$gdTgh,&d$$If^`&gdTkd;$$If֞  yY!%nnn0"4 aS$d$$Ifa$gdToԦ$d$$Ifa$gdT,&d$$If^`&gdTkdE$$If֞  yY!%nnn0"4 aS$d$$Ifa$gdToԦ$d$$Ifa$gdTƺ,&d$$If^`&gdTkdO$$If֞  yY!%nnn0"4 aSƺǺȺɺʺ˺Ժ$d$$Ifa$gdToԦ$d$$Ifa$gdTԺպ,&d$$If^`&gdTkdY$$If֞  yY!%nnn0"4 aS$d$$Ifa$gdToԦ$d$$Ifa$gdT,&d$$If^`&gdTkdc$$If֞  yY!%nnn0"4 aS$d$$&dIfPa$gdT$d$$Ifa$gdToԦ$d$$Ifa$gdT,&d$$If^`&gdTkdm$$If֞  yY!%nnn0"4 aS"$%,8<=EFGMNOPqstuwͻݻ 'צ̀nbnbהההX̺hHehT>*CJhHehT>*CJaJ#hHehT>*CJPJaJnHtH&hHehT>*CJPJaJnHo(tH#hHehTCJPJaJnHo(tH&hHehThewCJPJaJnHtH#hHehTCJPJ]aJnHtHhHehTCJaJ hHehTCJPJaJnHtHhHehTCJaJhHehTCJ]aJ" !"#$$d$$Ifa$gdToԦ$d$$Ifa$gdT$%8,&d$$If^`&gdTkdw$$If֞  yY!%nnn0"4 aS89:;<=E$d$$&dIfPa$gdT$d$$Ifa$gdTEFG,&d$$If^`&gdTkd$$If֞  yY!%nnn0"4 aSGHIJKLM$d$$Ifa$gdToԦ$d$$Ifa$gdTMNO,! $d$a$gdTkd$$If֞  yY!%nnn0"4 aSOstuvλϻлݻ޻߻$d$$&dIfPa$gdT&d$$If^`&gdT$\d$VDQ^\`a$gdT$\.d$VDQ^\`.a$gdT'&d$$If^`&gdTkd$$If֞  yY!%nnn0"4 aSgy$d$$Ifa$gdToԦ$d$$Ifa$gdT,&d$$If^`&gdTkd$$If֞  yY!%nnn0"4 aS$d$$Ifa$gdToԦ$d$$Ifa$gdT (,&d$$If^`&gdTkdå$$If֞  yY!%nnn0"4 aS'(,-./1@IJQRXY`abclmnɵ||||h|ɣh]hHehTCJaJ&hHehThewCJPJaJnHtH)hHehThewCJPJaJnHo(tH#hHehTCJPJaJnHo(tH#hHehTCJPJ]aJnHtH&hHehTCJPJ]aJnHo(tHhHehTCJaJhHehTh CJaJ hHehTCJPJaJnHtHhHehTCJ]aJ$()*+,-.$d$$Ifa$gdToԦ$d$$Ifa$gdT./@,&d$$If^`&gdTkdͦ$$If֞  yY!%nnn0"4 aS@JRYacm$d$$Ifa$gdToԦmn,qd$$IfVD&WD^`qgdTkdק$$If֞  yY!%nnn0"4 aS$d$$&dIfPa$gdToԦ$d$$&dIfPa$gdT,&d$$If^`&gdTkd$$If֞  yY!%nnn0"4 aS$d$$Ifa$gdToԦ$d$$Ifa$gdT,qd$$IfVDWD^`qgdTkd$$If֞  yY!%nnn0"4 aSüļ˼̼ҼӼڼۼ#$)*+1234:;IX\]cde{|ŴŴŴŴŠŴŴŴŴŴŴ鴠Ŵ״Ŵ&hHehTCJPJ]aJnHo(tHhHehTCJaJ&hHehThewCJPJaJnHtH hHehTCJPJaJnHtH#hHehTCJPJaJnHo(tH#hHehTCJPJ]aJnHtHhHehTCJ]aJhHehTCJaJ2ļ̼Ӽۼ$d$$&dIfPa$gdT,&d$$If^`&gdTkd$$If֞  yY!%nnn0"4 aS$d$$Ifa$gdToԦ$d$$Ifa$gdT,qd$$IfVDWD^`qgdTkd$$If֞  yY!%nnn0"4 aS$*+2$d$$Ifa$gdT$d$$Ifa$gdToԦ$d$$&dIfPa$gdT234,&d$$If^`&gdTkd $$If֞  yY!%nnn0"4 aS456789:$d$$Ifa$gdToԦ$d$$Ifa$gdT:;X,&d$$If^`&gdTkd$$If֞  yY!%nnn0"4 aSXYZ[\]d$d$$Ifa$gdToԦ$d$$Ifa$gdTde|, d$$IfgdTkd$$If֞  yY!%nnn0"4 aS|}~$d$$Ifa$gdToԦ$d$$Ifa$gdT,&d$$If^`&gdTkd'$$If֞  yY!%nnn0"4 aS½ýĽŽνսٽ ϻϞϻϞϻtϞiϞW#hHehTCJPJ]aJnHtHhHehTCJaJhHehThL(CJaJ hHehTCJPJaJnHtHhHehTCJaJhHehTCJaJ#hHehTCJPJaJnHo(tH&hHehThewCJPJaJnHtH hHehTCJPJaJnHtHhHehTCJ]aJ&hHehTCJPJ]aJnHo(tH"$d$$Ifa$gdToԦ$d$$Ifa$gdT,&d$$If^`&gdTkd1$$If֞  yY!%nnn0"4 aSĽ$d$$Ifa$gdToԦ$d$$Ifa$gdTĽŽ,&d$$If^`&gdTkd;$$If֞  yY!%nnn0"4 aS$d$$&dIfPa$gdT$d$$Ifa$gdToԦ$d$$Ifa$gdT,&d$$If^`&gdTkdE$$If֞  yY!%nnn0"4 aS$d$$Ifa$gdToԦ$d$$Ifa$gdT ,&d$$If^`&gdTkdO$$If֞  yY!%nnn0"4 aS $d$$&dIfPa$gdT$d$$Ifa$gdT  !"ؾ,1:ANOпп~ll~l~l~_~M#hHehT>*CJPJaJnHtHhHehTPJnHtH#hHehTCJPJaJnHo(tH hHehTCJPJaJnHtHhHehTPJnHo(tHhHehTCJ]aJhHehTCJaJhHehTCJaJ hHehTCJPJaJnHtHhHehTCJaJ&hHehThewCJPJaJnHtH hHehTCJPJaJnHtH,&d$$If^`&gdTkdY$$If֞  yY!%nnn0"4 aS $d$$Ifa$gdToԦ$d$$Ifa$gdT !",'gdTkdq$$If֞  yY!%nnn0"4 aS"ٿڿ67uu$d$$&dIfPa$gdT&d$$If^`&gdTgdT$\d$VDQ^\`a$gdT$\#d$VDQ^\`#a$gdT WDh`gdT$dWDh^`a$gdT$d^a$gdT/0167EFOP_`qrstyzȶȚȚ}Ți}i}&hHehTCJPJ]aJnHo(tH#hHehTCJPJ]aJnHtHhHehTCJaJhHehTCJaJ hHehTCJPJaJnHtH#hHehTCJPJaJnHo(tHhHehTCJ]aJhHehTPJnHtH#hHehT>*CJPJaJnHtHhHehT>*CJaJ)$d$$&dIfPa$gdT?+$d$$Ifa$gdT&d$$If^`&gdTkd$$Ifֈ` $ nnt0"4 aS'/00kd$$Ifֈ` $ nnt0"4 aS$d$$Ifa$gdT0123456$d$$Ifa$gdT&d$$If^`&gdT67FP?+$d$$Ifa$gdT&d$$If^`&gdTkd$$Ifֈ` $ nnt0"4 aSPX`hrs0kd$$Ifֈ` $ nnt0"4 aS$d$$Ifa$gdTstuvwxy$d$$Ifa$gdT&d$$If^`&gdTyz?+$d$$Ifa$gdT&d$$If^`&gdTkd$$Ifֈ` $ nnt0"4 aS$d$$&dIfPa$gdT$d$$Ifa$gdT#$-.9:;?FGHIǻǩǻǻǻǕ~ohHehTh CJ]aJ,hHehTh^TCJPJ]aJnHo(tH&hHehTCJPJ]aJnHo(tH#hHehTCJPJ]aJnHtHhHehTCJ]aJhHehTCJaJ#hHehTCJPJaJnHo(tH hHehTCJPJaJnHtHhHehTCJaJ(?+$d$$Ifa$gdT&d$$If^`&gdTkd$$Ifֈ` $ nnt0"4 aS0kd$$Ifֈ` $ nnt0"4 aS$d$$Ifa$gdT$d$$&dIfPa$gdT$d$$Ifa$gdT&d$$If^`&gdT?+$d$$Ifa$gdT&d$$If^`&gdTkd$$Ifֈ` $ nnt0"4 aS0kd$$Ifֈ` $ nnt0"4 aS$d$$Ifa$gdT$d$$Ifa$gdT&d$$If^`&gdT?+$d$$Ifa$gdT&d$$If^`&gdTkd$$Ifֈ` $ nnt0"4 aS0kd$$Ifֈ` $ nnt0"4 aS$d$$Ifa$gdT;<=>?G$d$$&dIfPa$gdT$d$$Ifa$gdT&d$$If^`&gdTGHIJ?+$d$$Ifa$gdT&d$$If^`&gdTkd$$Ifֈ` $ nnt0"4 aSIJKLMNO\hlstuvx°͒m[Om[B́hHehTPJnHtHhHehT>*CJaJ#hHehT>*CJPJaJnHtH&hHehT>*CJPJaJnHo(tH hHehTCJPJaJnHtH#hHehTCJPJaJnHo(tHhHehTCJ]aJ#hHehTCJPJ]aJnHtHhHehTCJaJhHehTCJaJ&hHehTh5CJPJaJnHtH&hHehTh CJPJaJnHtHJKLMNO0kd$$Ifֈ` $ nnt0"4 aS$d$$Ifa$gdTOhijklt$d$$&dIfPa$gdT$d$$Ifa$gdT&d$$If^`&gdTtuv?4$\#d$VDQ^\`#a$gdT $d$a$gdTkd$$Ifֈ` $ nnt0"4 aS$d$$&dIfPa$gdT&d$$If^`&gdTgdT )*JQSTUV[\hiryz|}~ǻǻǻ㝋ǻwwҋǻǩf hHehTCJPJaJnHtH&hHehTCJPJ]aJnHo(tH#hHehTCJPJaJnHo(tHhHehTCJaJo(#hHehTCJPJ]aJnHtHhHehTCJ]aJhHehTCJaJ hHehTCJPJaJnHtH#hHehTCJPJaJnHo(tHhHehTCJaJ(?+$d$$Ifa$gdT&d$$If^`&gdTkd$$Ifֈ` $ nnt0"4 aS 0kd$$Ifֈ` $ nnt0"4 aS$d$$Ifa$gdT$d$$Ifa$gdT&d$$If^`&gdT*4?+$d$$Ifa$gdT&d$$If^`&gdTkd$$Ifֈ` $ nnt0"4 aS4<CJTU0kd$$Ifֈ` $ nnt0"4 aS$d$$Ifa$gdTUVWXYZ[$d$$Ifa$gdT&d$$If^`&gdT[\z{?+$d$$Ifa$gdT&d$$If^`&gdTkd$$Ifֈ` $ nnt0"4 aS{|}~$d$$&dIfPa$gdT$d$$Ifa$gdT?+$d$$Ifa$gdT&d$$If^`&gdTkd$$Ifֈ` $ nnt0"4 aS0kd$$Ifֈ` $ nnt0"4 aS$d$$Ifa$gdT$d$$&dIfPa$gdT$d$$Ifa$gdT&d$$If^`&gdT&'()ĹۨĹЉwwfWhHehTh CJ]aJ hHehTCJPJaJnHtH#hHehTCJPJ]aJnHtH&hHehTCJPJ]aJnHo(tHhHehTCJaJ hHehTCJPJaJnHtHhHehTCJaJhHehTCJ]aJhHehTCJaJ#hHehTCJPJaJnHo(tH#hHehTCJPJaJnHo(tH?+$d$$Ifa$gdT&d$$If^`&gdTkd$$Ifֈ` $ nnt0"4 aS0kd$$Ifֈ` $ nnt0"4 aS$d$$Ifa$gdT$d$$Ifa$gdT&d$$If^`&gdT?+$d$$Ifa$gdT&d$$If^`&gdTkd$$Ifֈ` $ nnt0"4 aS0kd$$Ifֈ` $ nnt0"4 aS$d$$Ifa$gdT'$d$$&dIfPa$gdT$d$$Ifa$gdT&d$$If^`&gdT'()*?+$d$$Ifa$gdT&d$$If^`&gdTkd$$Ifֈ` $ nnt0"4 aS)*+,-./<HLQRSTUVZ[\]°͙vd°͙VE hHehTCJPJaJnHtHhHehTPJnHo(tH#hHehTCJPJaJnHo(tH#hHehTCJPJaJnHo(tH hHehTCJPJaJnHtHhHehTCJaJhHehTCJ]aJ#hHehTCJPJ]aJnHtHhHehTCJaJhHehTCJaJ&hHehTh5CJPJaJnHtH&hHehTh CJPJaJnHtH*+,-./0kd$$Ifֈ` $ nnt0"4 aS$d$$Ifa$gdT/HIJKLT$d$$&dIfPa$gdT$d$$Ifa$gdT&d$$If^`&gdTTUVW?+$d$$Ifa$gdT&d$$If^`&gdTkd$$Ifֈ` $ nnt0"4 aSWXYZ[\0kd$$Ifֈ` $ nnt0"4 aS$d$$Ifa$gdT\]DEmn}&d$$If^`&gdT$\d$VDQ^\`a$gdT$\#d$VDQ^\`#a$gdTz`gdT$d^a$gdT$ & Fda$gdT VD^gdT$`VDh^`a$gdTgdT $H[eh>@CElmnͽͽͽͽͽͽͤͤͽͽͽ͚thtZhHehTPJnHo(tHhHehT>*CJaJ#hHehT>*CJPJaJnHtH'hHehTCJOJPJQJnHo(tHhHehTCJo(hHehTCJhHehDrqCJPJnHo(tHhHehTCJPJnHo(tHhHehTCJPJnHtH hHehTCJPJaJnHtH#hHehmCJPJaJnHo(tH" !<=RZ[\H`ab}±±±¦ԦԦ›~›±jԉ±j&hHehTCJPJ]aJnHo(tHhHehTCJaJ#hHehTCJPJ]aJnHtHhHehTCJaJhHehTCJaJ hHehTCJPJaJnHtH#hHehTCJPJaJnHo(tHhHehTCJ]aJhHehTPJnHtH#hHehTCJPJaJnHo(tH) =STZ$d$$&dIfPa$gdTZ[\d?+$d$$Ifa$gdT&d$$If^`&gdTkd$$Ifֈ` $ nnt0"4 aSdlt|0kd$$Ifֈ` $ nnt0"4 aS$d$$Ifa$gdT$d$$Ifa$gdT&d$$If^`&gdT?3$$$d$$Ifa$gdT d$$IfgdTkd$$Ifֈ` $ nnt0"4 aS0kd$$Ifֈ` $ nnt0"4 aS$d$$Ifa$gdT $d$$Ifa$gdT&d$$If^`&gdTHO?+$d$$Ifa$gdT&d$$If^`&gdTkd$$Ifֈ` $ nnt0"4 aSOUWZab0kd$$Ifֈ` $ nnt0"4 aS$d$$Ifa$gdTb$d$$Ifa$gdT&d$$If^`&gdT?+$d$$Ifa$gdT&d$$If^`&gdTkd$$Ifֈ` $ nnt0"4 aS$%&',-. IJPQhijͻỪ󔟀ndhHehT>*CJ#hHehTCJPJaJnHo(tH&hHehT>*CJPJaJnHo(tHhHehTCJaJhHehTCJaJ hHehTCJPJaJnHtH#hHehTCJPJaJnHo(tH&hHehTCJPJ]aJnHo(tH#hHehTCJPJ]aJnHtHhHehTCJ]aJ!$d$$Ifa$gdT:&&d$$If^`&gdTkd$$Ifֈ` $ nnt0"4 aSg&!%$d$$Ifa$gdT%&'(?+$d$$Ifa$gdT&d$$If^`&gdTkd$$Ifֈ` $ nnt0"4 aS()*+,-0kd+$$Ifֈ` $ nnt0"4 aS$d$$Ifa$gdT-.$d$$&dIfPa$gdT&d$$If^`&gdTHdVD^^HgdT $d$a$gd& !)?+$d$Ifa$gdT&d$If^`&gdTkd;$$Ifֈ  yY9!nn0t4 aS)19AIJ0kd$$Ifֈ  yY9!nn0t4 aS$d$Ifa$gdTJKLMNOP$d$Ifa$gdT&d$If^`&gdTPQik?+$d$Ifa$gdT&d$$If^`&gdTkd$$Ifֈ  yY9!nn0t4 aSjkqrstuv|}~9:;͹͹͓vbPDbPhHehT>*CJaJ#hHehT>*CJPJaJnHtH&hHehT>*CJPJaJnHo(tHhHeh|6)CJaJ#hHeh|6)CJPJaJnHo(tH&hHeh|6)CJPJ]aJnHo(tH#hHehTCJPJ]aJnHtH&hHehTCJPJ]aJnHo(tHhHehTCJaJ#hHehTCJPJaJnHo(tH)hHehThewCJPJaJnHo(tHkrtv}~0kd$$Ifֈ  yY9!nn0t4 aS$d$Ifa$gdT~$d$Ifa$gdT&d$$If^`&gdT?+$d$Ifa$gdT&d$$If^`&gdTkd$$Ifֈ  yY9!nn0t4 aS0kd$$Ifֈ  yY9!nn0t4 aS$d$Ifa$gdT $d$&dIfPa$gdYZ&d$$If^`&gdT?*$\d$VDQ^\`a$gdTkd$$Ifֈ  yY9!nn0t4 aS;<$d$$&dIfPa$gdT&d$$If^`&gdT$`VDh^`a$gdTgdT$\#d$VDQ^\`#a$gdT ;<A[bcd|||jX|j#hHehTCJPJaJnHo(tH#hHehTCJPJ]aJnHtHhHehTCJaJhHehTCJaJ hHehTCJPJaJnHtH#hHehTCJPJaJnHo(tHhHehTCJ]aJhHehTPJnHtH#hHehTCJPJaJnHo(tH hHehTCJPJaJnHtHhHehTPJnHo(tH ?+$d$$Ifa$gdT&d$$If^`&gdTkd$$Ifֈ` $ nnt0"4 aS 0kd$$Ifֈ` $ nnt0"4 aS$d$$Ifa$gdT$d$$Ifa$gdT&d$$If^`&gdTAIP?3$$$d$$Ifa$gdT d$$IfgdTkd$$Ifֈ` $ nnt0"4 aSPW[cd0kd$$Ifֈ` $ nnt0"4 aS$d$$Ifa$gdTd$d$$Ifa$gdT&d$$If^`&gdT',-./CUVadefǵ滛sggsgsU#hHehs'CJPJ]aJnHtHhHehTCJ]aJ&hHehTCJPJ]aJnHo(tH hHehTCJPJaJnHtH#hHehTCJPJaJnHo(tHhHehTCJaJ#hHehTCJPJaJnHo(tH#hHehTCJPJ]aJnHtHhHehTCJaJhHehTCJaJ hHehTCJPJaJnHtH?+$d$$Ifa$gdT&d$$If^`&gdTkd$$Ifֈ` $ nnt0"4 aS$d$7$8$H$Ifa$gdT$d$$Ifa$gdT?+$d$$Ifa$gdT&d$$If^`&gdTkd$$Ifֈ` $ nnt0"4 aS!#'-.0kd$$Ifֈ` $ nnt0"4 aS$d$$Ifa$gdT.VZ\^ae$d$$Ifa$gdT&d$$If^`&gdTef:&&d$$If^`&gdTkd$$Ifֈ` $ nnt0"4 aSg&$d$$&dIfPa$gdYZ-.0FGSTqƺooooeQ&hHehTCJPJ]aJnHo(tHhHehT>*CJ hHehTCJPJaJnHtH#hHehTCJPJaJnHo(tH#hHehTCJPJaJnHo(tHhHehTCJaJhHehTCJaJhHehTCJ]aJhHehs'CJaJ hHehs'CJPJaJnHtHhHehs'CJaJ#hHehs'CJPJaJnHo(tH?+$d$$Ifa$gdT&d$$If^`&gdTkd$$Ifֈ` $ nnt0"4 aS0kd$$Ifֈ` $ nnt0"4 aS$d$$Ifa$gdT,-./DEFSpq$d$$&dIfPa$gdT&d$$If^`&gdTHdVD^^HgdTgdT?+$d$Ifa$gdT&d$If^`&gdTkd$$Ifֈ  yY9!nn0t4 aS0kd$$Ifֈ  yY9!nn0t4 aS$d$Ifa$gdT$d$Ifa$gdT&d$If^`&gdT?+$d$Ifa$gdT&d$If^`&gdTkd$$Ifֈ  yY9!nn0t4 aS()7[\oƻەۻۻodR#hHehTCJPJaJnHo(tHhHehi%CJaJ#hHehi%CJPJaJnHo(tH&hHehi%CJPJ]aJnHo(tH#hHehVCJPJaJnHo(tH&hHehTCJPJ]aJnHo(tHhHehTCJaJ)hHehThewCJPJaJnHo(tH#hHehTCJPJaJnHo(tH#hHehTCJPJ]aJnHtH0kd$$Ifֈ  yY9!nn0t4 aS$d$Ifa$gdT "($d$Ifa$gdT$d$Ifa$gdT&d$If^`&gdT()7@?+$d$Ifa$gdT&d$If^`&gdTkd$$Ifֈ  yY9!nn0t4 aS@HLR[\0kd$$Ifֈ  yY9!nn0t4 aS$d$Ifa$gdT\ow$d$&dIfPa$gdYZ&d$If^`&gdT?+++$uVDaWD^u`a$gdTkds$$Ifֈ  yY9!nn0t4 aS#$4;ghҼҭrbrbrbrbhHehT>*CJOJQJaJ"hHehT>*CJOJQJaJo('hHehT>*CJOJQJaJnHtH(hHehTCJOJPJQJaJnHtHhHehTCJOJQJaJ+hHehTCJOJPJQJaJnHo(tHhHehTCJaJ#hHehTCJPJaJnHo(tH hHehTCJPJaJnHtH&fghhMkdg$$If40#& 9!4 aSf4%$!d$Ifa$gdT$d$IfWD^`$gdT6VDWD^`6gdT$RVDb^Ra$gdT w$d$IfWD^`$gdT]kd$$IfFu#&9!    4 aS%$!d$Ifa$gdT||$d$Ifa$gdT$d$IfWD^`$gdT]kdc$$IfFu#&9!    4 aS$d$Ifa$gdT d$IfgdT]kd$$IfFu#&9!    4 aS$d$Ifa$gdT d$IfgdT]kdo$$IfFu#&9!    4 aS ")*128AKTUfrŐzkhHehT5CJ\aJo(+hHehmCJOJPJQJaJnHo(tH#hHeh=]CJPJaJnHo(tH hHehXCJPJaJnHtH#hHehXCJPJaJnHo(tHhHehTCJaJo(hHehTCJaJ hHehTCJPJaJnHtH#hHehTCJPJaJnHo(tH$$d$Ifa$gdT d$IfgdT]kd$$IfFu#&9!    4 aS $d$Ifa$gdT d$IfgdT]kdu$$IfFu#&9!    4 aS"*2}}$d$&dIfPa$gdT d$IfgdT]kd$$IfFu#&9!    4 aS23456$d$Ifa$gdT d$IfgdT]kd{$$IfFu#&9!    4 aS678BL}}$d$&dIfPa$gdT d$IfgdT]kd$$IfFu#&9!    4 aSLMN$%ttrbZdgdTd^`gds"$d^a$gdX$d^a$gdT$d^a$gdT]kd$$IfFu#&9!    4 aS #$%&*015;<>DGHIORSThi͸qq_O_O_O_O> hHehTCJOJPJ QJaJhHehT>*CJOJQJaJ"hHehT>*CJOJQJaJo(.hHehT>*CJOJPJQJaJnHo(tH(hHehTCJOJPJQJaJnHtHhHehTCJOJQJaJhHehTCJaJ)hHehT5CJPJ\aJnHo(tHhHehT5CJ\aJo(hHehT5CJ\aJ)hHeh@5CJPJ\aJnHo(tH%&1<=>ITy]kd$$IflF$&!    4 la1%$!d$Ifa$gdTHd$If^H`gdTTUV^f~~$d$Ifa$gdTHd$If^H`gdT]kd~$$IflF$&!    4 la1fghijxx'$ d$Ifa$gdTHd$If^H`gdT]kd$$IflF$&!    4 la1ijkxyz{!45678ghijlnpv~пЮЮЮЮМЮЮЮЮЮwhHehT5CJ\aJo(+hHehmCJOJPJQJaJnHo(tH#hHehCJPJaJnHo(tH hHehTCJPJaJnHtH hHehTCJOJPJ QJaJ#hHehTCJPJaJnHo(tHhHehTCJaJ#hHehT>*CJOJPJ QJaJ&jkxyzxx'$ d$Ifa$gdTHd$If^H`gdT]kdx$$IflF$&!    4 la1z{{{$d$Ifa$gdTd$IfWDd`gdTbkd$$IflF$&!    4 la1gN &pp$d$&dIfPa$gdT & F =d$1$If^=`gdT]kdv$$IflF$&!    4 la1||$d$Ifa$gdToP & d$IfgdTbkd$$IflF$&!    4 la1gN &||$d$Ifa$gdToP & d$IfgdTbkdt$$IflF$&!    4 la1gN &157||$d$Ifa$gdToP & d$IfgdTbkd$$IflF$&!    4 la1gN &78bhjxx$d$&dIfPa$gdT d$IfgdTbkd|$$IflF$&!    4 la1gN &jklmn||$d$Ifa$gdToP & d$IfgdTbkd$$IflF$&!    4 la1gN &nopw~xx$d$&dIfPa$gdT d$IfgdTbkd$$IflF$&!    4 la1gN &~zfRR%$!d$Ifa$gdTHd$If^H`gdT0d^`0gdTd^`gds"bkd$$IflF$&!    4 la1gN &͸t^t^L*CJOJQJaJ"hHehT>*CJOJQJaJo(*hHehT>*CJOJQJaJnHo(tH(hHehTCJOJPJQJaJnHtHhHehTCJOJQJaJhHehTCJaJ)hHehT5CJPJ\aJnHo(tH)hHeh5CJPJ\aJnHo(tHhHehT5CJ\aJhHehT5CJ\aJo()hHeh@5CJPJ\aJnHo(tHyy%$!d$Ifa$gdTHd$If^H`gdT]kd$$IflF$&!    4 la1~~$d$Ifa$gdTHd$If^H`gdT]kd$$IflF$&!    4 la1xx'$ d$Ifa$gdTHd$If^H`gdT]kd$$IflF$&!    4 la1 "#$*CJOU[\^bdew~ $-2RvҵҵҵhHehTCJOJQJaJ *hHehTCJaJhHehTCJaJo( hHehTCJPJaJnHtH#hHehTCJPJaJnHo(tHhHehTCJaJ hHehTCJOJPJ QJaJ<$d$Ifa$gdT d$IfgdT]kd$$IflF$&!    4 la1 $d$Ifa$gdT d$IfgdT]kdz$$IflF$&!    4 la1CKO}}$d$&dIfPa$gdT d$IfgdT]kd$$IflF$&!    4 la1OPQRS$d$Ifa$gdT d$IfgdT]kdn$$IflF$&!    4 la1STU\b$d$Ifa$gdT d$IfgdT]kd$$IflF$&!    4 la1bcdef$d$Ifa$gdT d$IfgdT]kdb$$IflF$&!    4 la1fgw}}$d$&dIfPa$gdT d$IfgdT]kd$$IflF$&!    4 la1~~#$d$Ifa$gdTHd$If^H`gdT]kdV$$IflF$&!    4 la1pp$d$&dIfPa$gdT%!Hd$If^H`gdT]kd$$IflF$&!    4 la1ST\]wxvR#9TPL HD@<+{^$dVD'^a$gd2$d^a$gdT $da$gdT]kdJ$$IflF$&!    4 la1HLvwx{~ҴugRG;GRhHeh[CJaJo(hHeh[CJaJ)hHeh[5CJPJ\aJnHo(tHhHeh[5CJ\aJ)hHeh@5CJPJ\aJnHo(tHhHeh[5CJ\aJo(4hHehmB*CJOJPJQJaJnHo(phtH#hHeh[CJPJaJnHo(tHhHehTCJaJo(hHehTCJaJ#hHehTCJPJaJnHo(tH hHehTCJPJaJnHtHxS]kd$$IflF$&!    4 la1%$!d$Ifa$gd!#d$IfWD^`gd!# d`gd[dgd[d^`gd}a *MOU\j89ѹѹthttttthHeh[CJaJo( hHeh[CJPJaJnHtH#hHeh[CJPJaJnHo(tHhHeh[>*CJOJQJaJ"hHeh[>*CJOJQJaJo(.hHeh[>*CJOJPJQJaJnHo(tH(hHeh[CJOJPJQJaJnHtHhHeh[CJOJQJaJhHeh[CJaJ( whh$d$Ifa$gd!#d$IfWD^`gd!#]kd> $$IflF$&!    4 la1%$!d$Ifa$gd!#||#$d$Ifa$gd!#d$IfWD^`gd!#]kd $$IflF$&!    4 la1MU]zz#$d$Ifa$gd!#sd$IfVDWD^`sgd[]kd8 $$IflF$&!    4 la1]^zz#$d$Ifa$gd!#sd$IfVDWD^`sgd[]kd $$IflF$&!    4 la1zz#$d$Ifa$gd!#sd$IfVDWD^`sgd[]kd, $$IflF$&!    4 la1qq#$d$&dIfPa$gd!#sd$IfVDWD^`sgd[]kd $$IflF$&!    4 la1zz#$d$Ifa$gd!#sd$IfVDWD^`sgd[]kd $$IflF$&!    4 la1)19qq#$d$&dIfPa$gd!#sd$IfVDWD^`sgd[]kd $$IflF$&!    4 la19:;<=zz#$d$Ifa$gd!#sd$IfVDWD^`sgd[]kd$$IflF$&!    4 la19:;<=U[`'()*+<=HIJ[\cdefghituvwxy 9CMNOҴ4hHeh[B*CJOJPJQJaJnHo(phtHhHeh[CJaJo(#hHeh,*CJPJaJnHo(tH#hHeh[CJPJaJnHo(tH hHeh[CJPJaJnHtHhHeh[CJaJ;=>U[azz#$d$Ifa$gd!#sd$IfVDWD^`sgd[]kd$$IflF$&!    4 la1abzz#$d$Ifa$gd!#sd$IfVDWD^`sgd[]kd$$IflF$&!    4 la1qq#$d$&dIfPa$gd!#sd$IfVDWD^`sgd[]kd$$IflF$&!    4 la1pp#$d$Ifa$gd!#o&sd$IfVDWD^`sgd[o&]kd$$IflF$&!    4 la1()*uu#$d$Ifa$gd!#sd$IfVDWD^`sgd[bkdv$$IflF$&!    4 la1g&*+=CI#$d$Ifa$gd!# & Fd$1$Ifgd[]kd$$IflF$&!    4 la1IJ\`dxx#$d$&dIfPa$gd!# & Fd$1$Ifgd[]kdz$$IflF$&!    4 la1defgh#$d$Ifa$gd!# d$Ifgd!#]kd$$IflF$&!    4 la1hijnt}}#$d$&dIfPa$gd!# d$Ifgd!#]kdn$$IflF$&!    4 la1tuvwx#$d$Ifa$gd!# d$Ifgd!#]kd$$IflF$&!    4 la1xynn$sd$IfVDWD^`sa$gd[sd$IfVDWD^`sgd[]kdb$$IflF$&!    4 la1 zzzz#$d$Ifa$gd!#sd$IfVDWD^`sgd[]kd$$IflF$&!    4 la1 9CMqq#$d$&dIfPa$gd!#sd$IfVDWD^`sgd[]kd\$$IflF$&!    4 la1MNO_`al}meO;%$!d$Ifa$gd!#{d$IfWD^{`gd!#dgd[d^`gd}a#9TPL HD@<+{^]kd$$IflF$&!    4 la1ORU]^_`aeklpvwy³tdtdtdtdS hHeh[CJOJPJ QJaJhHeh[>*CJOJQJaJ"hHeh[>*CJOJQJaJo(.hHeh[>*CJOJPJQJaJnHo(tH(hHeh[CJOJPJQJaJnHtHhHeh[CJOJQJaJhHeh[CJaJhHeh[5CJ\aJ)hHeh@5CJPJ\aJnHo(tHhHeh[5CJ\aJo(lwxyw{d$IfWD^{`gd!#]kdP$$IflF$&!    4 la1%$!d$Ifa$gd!#||$d$Ifa$gd!#{d$IfWD^{`gd!#]kd$$IflF$&!    4 la1vv'$ d$Ifa$gd!#{d$IfWD^{`gd!#]kdD$$IflF$&!    4 la1vv'$ d$Ifa$gd!#{d$IfWD^{`gd!#]kd$$IflF$&!    4 la1-4>@ACILRS}nYn)h(ph@5CJPJ\aJnHo(tHh(ph[5CJ\aJo(4hHeh[B*CJOJPJQJaJnHo(phtH hHeh[CJPJaJnHtHhHehmSCJaJhHehj}XCJaJ#hHehmSCJPJaJnHo(tH hHeh[CJOJPJ QJaJhHeh[CJaJ#hHeh[CJPJaJnHo(tHABCJKLSssssss$d$&dIfPa$gd!#Pd$IfWD^`Pgd!#]kd>$$IflF$&!    4 la1 STUbRF d^gdhd^`gd}a#9TPL HD@<+{^$d^a$gd[ d^gd[]kd$$IflF$&!    4 la1[i{R]_`anոոɩqfXh(pheu{>*CJaJo(h(pheu{CJaJ)h(pheu{5CJPJ\aJnHo(tHh(pheu{5CJ\aJ)h(ph@5CJPJ\aJnHo(tHh(phh5CJ\aJo( h(phhCJPJaJnHtHh(phhCJaJo(#h(phhCJPJaJnHo(tHh(phhCJaJh(phh5CJ\aJ"o]kd2$$IflF$&!    4 la1$d$Ifa$gd!# d$Ifgd!#dgdeu{$d^a$gdh  )Mbcjtyz '(),NU^lƴƴƴƔƔƁƴƔƔƔk+h(pheu{CJOJPJQJaJnHo(tH$h(pheu{CJOJQJaJnHtHh(pheu{CJOJQJaJ h(pheu{CJPJaJnHtH#h(pheu{CJPJaJnHo(tHh(pheu{CJaJ&h(pheu{>*CJPJaJnHo(tHh(pheu{>*CJaJo(h(pheu{>*CJaJ*ww#$d$Ifa$gd!# d$Ifgd!#]kd$$IflF$&!    4 la1$d$Ifa$gd!#!)#$d$Ifa$gd!# d$Ifgd!#]kd&$$IflF$&!    4 la1)*cktuu#$d$&dIfPa$gd!#d$If^`gd!#]kd$$IflF$&!    4 la1tuvwx#$d$Ifa$gd!# d$Ifgd!#]kd$$IflF$&!    4 la1xyzxx$d$&dIfPa$gd!#%!d$Ifgd!#]kd$$IflF$&!    4 la1 $$Ifa$gd!#%!$Ifgd!#]kd$$IflF$&!    4 la1 $$Ifa$gd!#%!$Ifgd!#]kd$$IflF$&!    4 la1 uu#$d$&dIfPa$gd!#d$If^`gd!#]kd$$IflF$&!    4 la1 $$Ifa$gd!#%!$Ifgd!#]kd|$$IflF$&!    4 la1 '~~$$&dIfPa$gd!#%!$Ifgd!#]kd$$IflF$&!    4 la1'()*+ $$Ifa$gd!#%!$Ifgd!#]kdp$$IflF$&!    4 la1+,NV^~~$$&dIfPa$gd!#%!$Ifgd!#]kd$$IflF$&!    4 la1^_`-.pYJ> d$Ifgd!#$d^a$gdeu{$ d7$8$H$^` a$gdeu{$ldWD^`la$gdeu{$ 7$8$H$^` a$gdeu{dgdeu{]kdd$$IflF$&!    4 la1lsEHtvw-/@#,X]d⮢ *h(pheu{CJaJ&h(pheu{>*CJPJaJnHo(tHh(pheu{>*CJaJh(pheu{>*CJaJo(h(pheu{CJaJo(h95CJaJo( h(pheu{CJPJaJnHtHh(pheu{CJaJ#h(pheu{CJPJaJnHo(tH2 d$Ifgd!#]kd$$IflF$&!    4 la1$d$Ifa$gd!# #$d$Ifa$gd!# d$Ifgd!#]kdX$$IflF$&!    4 la1 $,#$d$Ifa$gd!# d$Ifgd!#]kd$$IflF$&!    4 la1,-X^d#$d$Ifa$gd!# d$Ifgd!#]kdL$$IflF$&!    4 la1de#$d$Ifa$gd!# d$Ifgd!#]kd$$IflF$&!    4 la1}}#$d$&dIfPa$gd!# d$Ifgd!#]kd@ $$IflF$&!    4 la1#$d$Ifa$gd!# d$Ifgd!#]kd $$IflF$&!    4 la1xx$d$&dIfPa$gd!#%!d$Ifgd!#]kd4!$$IflF$&!    4 la147 7<=BCot{ͼ߱߱߼w߼߼߼d߼w$h(pheu{CJOJQJaJnHtHh(pheu{CJaJo(&h(pheu{>*CJPJaJnHo(tHh(pheu{>*CJaJo(h(pheu{>*CJaJh(pheu{CJaJ h(pheu{CJPJaJnHtH# *h(pheu{CJPJaJnHtH#h(pheu{CJPJaJnHo(tHh(pheu{CJOJQJaJ'zczWH$d$Ifa$gd!# d$Ifgd!#$d7$8$H$^`a$gdeu{d^`gdeu{$d^a$gdeu{dgdeu{]kd!$$IflF$&!    4 la1" d$Ifgd!#]kd("$$IflF$&!    4 la1$d$Ifa$gd!#"#$%&#$d$Ifa$gd!# d$Ifgd!#]kd"$$IflF$&!    4 la1&'7=C#$d$Ifa$gd!# d$Ifgd!#]kd#$$IflF$&!    4 la1CDou{#$d$Ifa$gd!# d$Ifgd!#]kd#$$IflF$&!    4 la1{|#$d$Ifa$gd!# d$Ifgd!#]kd$$$IflF$&!    4 la1}}#$d$&dIfPa$gd!# d$Ifgd!#]kd$$$IflF$&!    4 la1#$d$Ifa$gd!# d$Ifgd!#]kd%$$IflF$&!    4 la1xx$d$&dIfPa$gd!#%!d$Ifgd!#]kd~%$$IflF$&!    4 la1BHIOPqx4CDHJKghkp䠲ؒؒh(pheu{>*CJaJo(#h(phAfCJPJaJnHo(tH#h(pheu{CJPJaJnHo(tH&h(pheu{>*CJPJaJnHo(tHh(pheu{>*CJaJh(pheu{CJaJ h(pheu{CJPJaJnHtH5o_KPd$If^`Pgd!#d^`gdeu{$d^`a$gdeu{$d7$8$H$^a$gdeu{ d^gdeu{]kd%$$IflF$&!    4 la1~Pd$If^`Pgd!#]kdr&$$IflF$&!    4 la1$d$Ifa$gd!#~~#$d$Ifa$gd!#Pd$If^`Pgd!#]kd&$$IflF$&!    4 la1 ~~#$d$Ifa$gd!#Pd$If^`Pgd!#]kdf'$$IflF$&!    4 la1CIO~~#$d$Ifa$gd!#Pd$If^`Pgd!#]kd'$$IflF$&!    4 la1OPrvx~~#$d$Ifa$gd!#Pd$If^`Pgd!#]kdZ($$IflF$&!    4 la1xyuu#$d$&dIfPa$gd!#Pd$If^`Pgd!#]kd($$IflF$&!    4 la1~~#$d$Ifa$gd!#Pd$If^`Pgd!#]kdN)$$IflF$&!    4 la1uu$d$&dIfPa$gd!#Pd$If^`Pgd!#]kd)$$IflF$&!    4 la1wcTT$d$Ifa$gd!#Pd$If^`Pgd!#$d^`a$gdeu{$d^a$gdeu{dgdeu{]kdB*$$IflF$&!    4 la1'/~~$d$Ifa$gd!#Pd$If^`Pgd!#]kd*$$IflF$&!    4 la1/0123~~#$d$Ifa$gd!#Pd$If^`Pgd!#]kd6+$$IflF$&!    4 la134>DJ~~#$d$Ifa$gd!#Pd$If^`Pgd!#]kd+$$IflF$&!    4 la1JKhlp~~#$d$Ifa$gd!#Pd$If^`Pgd!#]kd*,$$IflF$&!    4 la1pquu#$d$&dIfPa$gd!#Pd$If^`Pgd!#]kd,$$IflF$&!    4 la1~~#$d$Ifa$gd!#Pd$If^`Pgd!#]kd-$$IflF$&!    4 la1uu$d$&dIfPa$gd!#Pd$If^`Pgd!#]kd-$$IflF$&!    4 la1bcdo~rcrWH$d$Ifa$gd!# d$Ifgd!#$d^a$gdv d^gdvd^`gd}a$0d^`0a$gdeu{]kd.$$IflF$&!    4 la1OXadjmnouxyz{˶zl`lLl`lL`zzz&h(phv>*CJPJaJnHo(tHh(phv>*CJaJh(phv>*CJaJo( h(phvCJPJaJnHtH#h(phvCJPJaJnHo(tHh(phvCJaJh(phv5CJ\aJ)h(ph@5CJPJ\aJnHo(tHh(ph#5CJ\aJo()h(pheu{5CJPJ\aJnHo(tH h(pheu{h<^5CJ\aJoz{| d$Ifgd!#]kd.$$IflF$&}!    4 la1$d$Ifa$gd!##$d$Ifa$gd!# d$Ifgd!#]kd/$$IflF$&}!    4 la1#$d$Ifa$gd!# d$Ifgd!#]kd/$$IflF$&}!    4 la1#$d$Ifa$gd!# d$Ifgd!#]kd/$$IflF$&}!    4 la1 #$d$Ifa$gd!# d$Ifgd!#]kdt0$$IflF$&}!    4 la128=>?DEMTVy[\]adѶѣѶѶydVh(phv5CJ\aJ)h(ph@5CJPJ\aJnHo(tHh(phv5CJ\aJo(4h(phvB*CJOJPJQJaJnHo(phtH$h(phvCJOJQJaJnHtHh(phvCJOJQJaJh(phvCJaJo(h(phvCJaJ h(phvCJPJaJnHtH#h(phvCJPJaJnHo(tH! !28?}}#$d$&dIfPa$gd!# d$Ifgd!#]kd0$$IflF$&}!    4 la1?@ABC#$d$Ifa$gd!# d$Ifgd!#]kdh1$$IflF$&}!    4 la1CDEMU$d$Ifa$gd!#%!d$Ifgd!#]kd1$$IflF$&}!    4 la1UVy}}#$d$&dIfPa$gd!# %d$Ifgd!#]kd\2$$IflF$&}!    4 la1$d$Ifa$gd!# %d$Ifgd!#]kd2$$IflF$&}!    4 la1}}$d$&dIfPa$gd!# %d$Ifgd!#]kdP3$$IflF$&}!    4 la1\][K;0d^`0gdvd^`gd}a#9TPL HD@<+{^$d7$8$H$^a$gdv$d7$8$H$a$gdv]kd3$$IflF$&}!    4 la1QRS^ijkve]kdD4$$IflFrg!a}    4 la$d$Ifa$gd!# d$Ifgd!#0d^`0gdv$dVD^a$gd. RW]^bhijkqtuv| BCFGHINd÷詷j)h(phvhBXCJPJaJnHo(tHh(phvCJaJo(#h(phvCJPJaJnHo(tHh(phv5CJaJh(phv>*CJaJo(h(phv>*CJaJ&h(phv>*CJPJaJnHo(tH h(phvCJPJaJnHtHh(phvCJaJh(phvCJ\aJ)$d$Ifa$gd!# d$Ifgd!#]kd4$$IflFrg!a}    4 la#$d$Ifa$gd!# d$Ifgd!#]kd85$$IflFrg!a}    4 la#$d$Ifa$gd!# d$Ifgd!#]kd5$$IflFrg!a}    4 la#$d$Ifa$gd!#d$If^gd!#]kd,6$$IflFrg!a}    4 la#$d$Ifa$gd!#d$If^gd!#]kd6$$IflFrg!a}    4 laCGIzz#$d$Ifa$gd!#d$IfVDXWDj^`gdv]kd 7$$IflFrg!a}    4 laIJKLM#$d$Ifa$gd!# d$Ifgd!#]kd7$$IflFrg!a}    4 laMNdef#$d$Ifa$gd!# d$Ifgd!#]kd8$$IflFrg!a}    4 lafgzz#$d$Ifa$gd!#Hd$IfVDXWD8^`Hgdv]kd8$$IflFrg!a}    4 la#$d$Ifa$gd!#d$If^gd!#]kd9$$IflFrg!a}    4 la#$d$Ifa$gd!#d$If^gd!#]kd9$$IflFrg!a}    4 la $%9:OQYZAISTy~Ʋxxh(phvCJaJo( h(phKCJPJaJnHtH#h(phKCJPJaJnHo(tHh(phKCJaJ&h(phv5CJPJaJnHo(tHh(phv5CJaJ h(phvCJPJaJnHtH#h(phvCJPJaJnHo(tHh(phvCJaJ, #$d$Ifa$gd!#d$If^gd!#]kd:$$IflFrg!a}    4 laOPRSYzzzz#$d$Ifa$gd!#d$IfVDXWDj^`gdv]kd:$$IflFrg!a}    4 laYZ#$d$Ifa$gd!# d$Ifgd!#]kd:$$IflFrg!a}    4 la#$d$Ifa$gd!# d$Ifgd!#]kdv;$$IflFrg!a}    4 la#$d$Ifa$gd!# d$Ifgd!#]kd;$$IflFrg!a}    4 la#$d$Ifa$gd!#d$If^gd!#]kdj<$$IflFrg!a}    4 la#$d$Ifa$gd!#d$If^gd!#]kd<$$IflFrg!a}    4 la#$d$Ifa$gd!# d$Ifgd!#]kd^=$$IflFrg!a}    4 la#$d$Ifa$gd!# d$Ifgd!#]kd=$$IflFrg!a}    4 laABJKSzzzz#$d$Ifa$gd!#d$IfVDXWDj^`gdv]kdR>$$IflFrg!a}    4 laSTy}zk#$d$Ifa$gdwN#$d$Ifa$gd!#d$IfVDXWDj^`gdv]kd>$$IflFrg!a}    4 laqqq#$d$&dIfPa$gd!#d$IfVDXWDj^`gdv]kdF?$$IflFrg!a}    4 la#$d$Ifa$gd!# d$Ifgd!#]kd?$$IflFrg!a}    4 laF}bSb}b$nd^na$gdv$ & F;d1$^`;a$gdv d^gdvd^`gdvdgdv]kdF@$$IflFrg!a}    4 la ;Y>?xz~>?FGH^mZJhmB*CJOJQJaJph%hm5B*CJOJQJ\aJph%h(phmB*CJOJQJaJph1h(phmB*CJOJPJQJaJnHphtH4h(ph[B*CJOJPJQJaJnHo(phtHh(phvCJ\aJo(#h(phvCJPJ\aJnHtHh(phrCJ\aJh(phvCJ\aJ&h(phvCJPJ\aJnHo(tHFGH^,;Lq $7$8$H$If)$a$$^a$ $ ^ a$gdq"$0TPL HD@< ^ a$$ ^ a$#9TPL HD@<+{^DEq׀ٸzrdrdrdbXFXrX>rhmKHaJ"hmB*KHPJnHo(phtHhmB*KHphUhmOJPJQJnHtHhmOJQJ+hmB*CJOJPJQJaJnHphtHhmB*CJOJQJaJph.hmB*CJOJPJQJaJnHo(phtH@hqhm56B*CJOJPJQJ\]aJnHo(phtH%hm6B*CJOJQJ]aJph%hm5B*CJOJQJ\aJphExecutive Directors:Ms. Guo Qin (Chairman)Mr. Ren FulongMr. Zhao SongguoIndependent Non-executive Directors:Mr. Zhu BaoquanMr. Sun MinggaoMr. Kwong Chi Kit, VictorNon-executive Directors: Mr. Liu Zhenwen Mr. Zhao Bin PAGE PAGE 28qƀ׀][GkdA$$If0!64 aGkd@$$If0!64 a $7$8$H$If )$$Ifa$ ׀    ûhm hTo(hq0J$mHnHuhT hT0J$jhT0J$Uh#jh#U%hmCJOJPJQJaJnHo(tHhmKHaJhmB*KHphhmOJQJhmOJPJQJnHo(tH  #$a$##&`#$/0P/ =!"#$n% nu*l?xK-PNG  IHDRryJzgAMA pHYsLLXtcPLTE#$ 84*&'"51;7.*?;2-2./+40)%(#,(=9950,+'=83.627383B>B?A=C?@=QNUQNJFBJFXU\Y^[DAZWIF]ZOKHDWSQMMJKHSOD@YUVSLISPFCYV[W^ZROLHOLWTb_`\a^b^`]iftrfc}pn|ymjxupmvtywc`li~{}{wt}{rogdvsda~{xuebnkkgkholtqheqnpnspzw{x~}ƵG'IDATx}|yNg˲$Dz6d[r^ 8&!iP*`Ԙ˒lbh^ZQ@!M#'MI4mt/kvӦMO$nwvgyfgwgt7<3(Z8˱!}t%O_dKU}*meDW܇lL7{]+>IcMC|l4IzO̚*Irìi.! gKz8T*%,佫X ˏ<&K$]vUtɑ,VEzIyH.#Ϛ!tifPIѳf$]Nfx$]F䜳fX$]>.fpHl]Κatg&o#K>k.8ietgƾUFI9|֌4&(D2I$ʴ[K\Co~$]YgȎ*FC$A#eY/c#"OFj+ <#۠1kZǮWM?f5$=Y!R+K.>k*qبPެM`$oY _&I1k̊/ 6/~"G̚J]Y͠E-%B$cJME.s`SϒrĬ9ö"^}2JOfdGʶ*Fwt%YSYw-V21 1y oU2l"lJK=G5ڠ}>i&{1kF%03%)Iy?|Tjzώ|vK{Áw돳L&)sI:i<";ZKܔ{< 5$1FT=twLW|^2? 6{) _%R;I1fI~3Dv F)+I3kFf4b[jNv)I3k* 5lc557{"bcfMsWz_&[lJ@E"̚ K,iM%]r̬IUlr̙p +颐cfM ߽٨Ɇ7t1QQai˿.9fdUll)] @5mB*ëN* tQ~͗26w_pS Iw5km{ޕCL3u B]!G͚,6gt9fִ: qsѪ”%(Y(iD TW#fMA$)/pY AA8z=CfMQ`J/{]MYS:Naq&(D08J;0tCfMQ@ "4\ҝfȶsidz?t;"G͚DtGaJJrܬs"paL IE5yBRlLB ͚.BSl鱊1;K;O9kz~"bsz s[QG#gMe~6iDjcLI!GΚ~ؤS\m%]Κ~$N#)}BܬQ`]j]|sa\Q#y0Y >/ <ʔ>&FzQœt/8EXlFt<ʔ_k=+= 071ox ɕpAqQj] *>~.6Q,tzM (Q_6\#frRLQB]uIRvpzM eۣ|mwJ63;VVX RԣLQ']iѧ3O޵ˍznq(ybE>)ΉFIX88S:U ,U3sdθT`"NBBonaEBORVV+x2j ' s%NR08E=ƓGVhbf#i+zbiӪ8SR"DKnb5rSWMu;6rH[!V#3S0Ow.Bd.A#[̕`XPg #ȂE#/93fZeɌ\S{<03Ol#4 2)J{d<=`[Sԗ ˀ\S%-x,-|@u=݅}55FJ77(\dcs'`}IIFKgnFmNڳw8B?Hz,s-ډ-}ֽ-V,a \954O|\*Kѹ\nW"ZO_^6MSa&y <07t|-s<7{<2*C6m,^YZ=@9Q(iE0b+ANlzQ~O9Q_\jVv^X !*y{F0DiR#ϲӓO5||@c|ȋA^Ɍ=t*"GIgPݙ-M> 9RP86uimڰJsp>/;|(|=i :\2noi@ Wߍ}kj qg@>a19i?K]~되>>7xlgߗ@g sh.~K|~ xs>"¹7U­Ůһ4vvg^i4so8xgkSdpG+'rmS}̈́ð)wh39jkku?ʒa@VfN6:%BwSTjc9u h5#p%k _=ANWvm)eͯlW+RuKw)]zYv})K-_%)kxb[nZ TVdxN~Uwjb;? bPVWȵ!|,<}qP ~9kZgL/g}lIV6z tNyPw\ܵ!1[gtwA[h%#N0y@d z|+C ŕ5G.Yn1<'`MMM7}dy(B#,yKg\7S;w²n r<0w :ҹ0)oux9֖~e⯖gs4[_Sۿ[ rf;G^8}EO{뢂G\Y/XId(Wp=Lh+ve7(so+}Gi'Mp_kk'KD74mфG-1 >cUƱe9 +5?r/:i@~D Gu݅fIZ`UEN 'D%=u\ 3A~ YoaEٷs7Dޠ_E8@-J1|s )rOAO.мE%!185<Ӧi_r`/qc/*!wR?̱+[=aǎ0{̱~}ee];Mf-nz1_W<o5O_cc>YF3>xפ@r.GΏcM]G}EuT)My+78ϻﵱ7Wa=U=_sYjr uK7xCuQ_?Yf n% ؜G-Y`n9 R9؆۳˔F„܀?mG^ {:Fߘ2C7CTk=\@pFk}j&'jv r5qC[:+@ުv߈MarCij BNԓ~P-w9j| 4E"G9 eljUc9!~sS̊PSFF:"YeSC\yHf GL2;6h3c&TiWyf|;tk$o59Yh{w{QȉJN,tΐH#\2*ّ$ʥ ~G0M}"'߇ǽ#FCx#;]vkr"']yVjMN\wn^ZǡWZ#Oo3w,J1G%EBOM_!X#ׯͦۡ"'rLQ5r})mx }M(%r3>QH}/yfN^܌ur"ȹOf5Z.\F|ߩch !~ kn*e#7vReUS8%!G~e`[pCheeAUsn+dz.~#GF3ܟ 9fu<' tW:H<:Kg I;N]:֜op?vԼ,Bkm܍VE8'w c$a_SPTVn58pi.7Ȋ|֜N)meX>wK*)07f^xz)G4w0oVjtP\RQ^so= PկMAwoIң_:û]ul#t0tHq}g:v.;'ѻ\^Vz9WʽRm5ݪ~yv N}Y!Pr&lj&(9f4@k|9!KE\oEqo*<#Z8kcu#QMe"w,:p/ė%"'W+S3'rN"Cr{\]^-P:~pOqL /r[+:@0#ֳ!9bb0,~[;|oB-l$rS't| !G4>ޱ ANg\RSVtDåZ-rTuif=˿1ȭ$K!O8f;`ŽsݦFvzozpWލ+++^=aG>@W2۱ή^=":۷{Eeu}sǂX>h#'Jg 3'U y>K ;rMyUQ v77- ?r*3arCޛ}u7^=n^n7]Vjz~T,PT|' %zo^ IL]" *^e6rg2OCy|l oPVmR rK?1f>B7pvk^77eT$r*gFE/AFj69iF= )N75u cy~iFƧ s|n14#kꑎ,EwA"^(m<x$|Drn=2P Wʻ Sp J<񉲋Jܔ3U=F/5>JtM"@4j|:@ !,rE/*քU5lώU}Mmy=wMu%{nA܇+ߒnzkݼhMBt#`+iyWw T?%EeM}'jӖb76f5`D<$Z $}7uQdk"%Z CrŃ⏤79#㦪5ǥDxOQEWaTnePu}?L(*hc^*R^QbEP/{ |%.#;f?d ?iKz $"l+is=x(J|kc.85`(hJ(l_sY^c%NQHiЕĶXĻCY#+=raDF+CBb~X?ĉx >< ptAwEԜӇjZRI7f. qmZ8CbeA!x%%p/ =K5Q$ݴkG\#^UC6I7rfU;o6n^6 _)ꊝeml 1vi,w.x4̉J.8IoIýlw'kmb JSQ>c釐<7 HһGGZSKG{WD{s{i\^6 <$=ߍq3htcS<W} 4|lMbϛvU*=8N1g,3{6]"Iqԋ[$|V'[g 4rgrH:X^6rWoqH8*n+t0E}hW f%&PQ U籤CE<L%.Iq`JmDCBO> NotesdB*CJaJphO Body textc$>TPL HD@<Td1$7$8$H$^Ta$-B*CJOJQJ_HaJmH nHphsH tHHOH Subhead 1Td^T ;CJaJ~O~ Subhead 2B$'PL HD@<Q^`a$5B*\phDZ@D ~e,g$a$CJOJPJQJ aJnHtH<O< write $a$CJPJnHtHpOpChar Char Char Char!d1$CJKHPJaJmHnHtHu.". yblFhe,g"CJaJ6 @26 u#9r G$CJaJ)@A uxP@RP u w%!d1$CJKHOJPJ QJaJtH 0b0 le,g&G$CJaJPOrP Anrede' 1$KHOJPJQJaJtH VOV W[CQ W[CQ(d1$CJKHPJaJmHnHtHudOd Default)1$7$8$H$-B*CJOJ QJ _HaJmH nHphsH tH O med1HH  Balloon Text+CJOJQJ^JaJ4O4 cke1,B*OJQJph0`@0 HTML 0W@W-6]Be@B  HTML @P h/$<@&a$5CJ OJPJQJ\^JaJ K@ y|T0([@( 5uP[N~{T1\J@"\ oRh2$d8<@&a$"5CJ KHOJPJQJ\^JaJ -2 [e,g43 ` @ 1$3$5$7$8$G$0CJKHOJ PJQJ ^J _HaJmH nHsH tH6%@B6 [ON0W@W4G$ OJQJ^J.?@R. ~_g5dVD4^d4/@b4 Rh68WD8^`8<2@r< Rh 27d8VDWD8^d`8<3@< Rh 38d8VDWD8^d`8<4@< Rh 49d8VDXWD8^d`8<5@< Rh 5:d8VD WD8^d`8,1@, RhS ; & F 0:@0 RhS 2 < & F0;@0 RhS 3 = & F0<@0 RhS 4 > & F0=@0 RhS 5 ? & F4D@4 Rhc~@xVD^8E@8 Rhc~ 2AHxVD^H8F@"8 Rhc~ 3BxVDX^8G@28 Rhc~ 4CxVD ^8H@B8 Rhc~ 5D4xVD^400@R0 Rhyv&{S E & F46@b4 Rhyv&{S 2 F & F47@r4 Rhyv&{S 3 G & F48@4 Rhyv&{S 4 H & F49@4 Rhyv&{S 5 I & F$$vU_ 1J00vU_ 2KVD^00vU_ 3LHVD^H00vU_ 4MVDX^00vU_ 5NVD ^00vU_ 6O4VD^400vU_ 7P VD^ 00vU_ 8Q| VDx^| 00vU_ 9R VD@^ $2$ ybleW[S*j12* ybl;NT5\(^@R( nf(Qz)U,@@b, ~{TVdVD4^d,L@, egWdVD ^dX$@X 6eON0W@W(Xd&+D/G$VDx^d OJQJ^J$ $"}_ 1Y0 0"}_ 2ZVD^0 0"}_ 3[VD^00"}_ 4\XVDX^X00"}_ 5] VD ^ 00"}_ 6^VD^00"}_ 7_VD^00"}_ 8`xVDx^x00"}_ 9a@VD@^@6!6 "}_hb5OJQJ\^J8"8 lcCJOJPJ QJ^JaJ4#4 VhvU_d8VDWD8`8(+R( >\le,geG$>T@b> e,gWWfxUDVD]^8Yr8 ech~gVg-D M I@ Oo`hoh8$d%d&d'd-DM NOPQVDWD ^8` OJQJ^J0,0 _evU_iVD^<.< _evU_hjxOJPJQJ^J(B@( ckee,gkx4M@4 ckeL)ۏlWDd`8C@8 ckee,g)ۏmxVD^8N@8 ckeL)ۏ 2nWD`0@0 cke)ۏoWD`2P@2 ckee,g 2 pdx4Q@4 ckee,g 3qxCJaJBR@"B ckee,g)ۏ 2rdxVD^DS@2D ckee,g)ۏ 3sxVD^CJaJ*O@* lʑht$a$6OQ6 short_text1CJaJ8Oa8 medium_text1CJaJ4Oq4 long_text1CJaJvOv T Report Text-x$d1$5$7$8$9DH$^a$KHPJ aJmH sH tH JOJ T body textyxx1$CJKHaJtH VOV TRQk=zd1$WD`CJKHOJPJ QJaJtH NObc /067kl0000ܰ0000 00 0 0 L)0 0 L)0 0B0 0B00C00C00H*K00N000*00*@000C@0fn/Xͼ00D0K00 O000G00G00 t00,H00 00,H00 00,H00G00,H00,H00hK0 0 p00 0! 00qrsuv*KL */78@KVaby LT\defghij ()<ENWX  / 4 8 9 : ; < = M \ ] n     T c q y  ! . / W f u }  " 3 D E | 9>CINST}z{| '8IJrGVcsNTZixy,-  !!!!^#_#+$,$$$8%9%%%#&$&&&,'-'H*I*]*^*,,e,f,..0000n1o1}3~3!5"5556688t9u9d:e:<<'?(?=A>AKALABBDD@EAEEEJGKGBICIIIlJmJLLlNmNNNPPQQSSTTJTKTUUwWxW[X\XZZ$Z%ZsXshswsssssssssstt&t5tDtEtttttttt uu1uHuIu_uaucueuguhuuuuuuuuuuuuuuvv$v5v6vTvdvuvvvvv ww4wKwLwwwwwwwwwwwxxlymyyyyyyyyyyyyyyyyyzzzzzzzzzzz z!z)z+z5z?z@zAzBzCzDzEzSzTz`zlzmznzozpzqzrzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzz{{{ { { { {.{/{9{C{D{E{F{G{H{I{a{b{l{v{w{x{y{z{{{|{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{|||| |!|"|#|$|%|8|:|C|K|L|M|N|O|P|Q|e|g|o|v|w|x|y|z|{||||||||||||||||||||||||||}}}}}} } } } }}}5}7}@}U}V}W}X}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}~ ~ ~ ~ ~~~~+~,~-~.~/~]~^~c~i~j~~~~~~~~  MNOVWabcdefg$%&'()*+,4>?@mnou΀πӀ׀؀!"*12\]emnցׁ߁ $%&'()*9:;<=IJRZ[wy‚ !126<=ST[bcz{̃̓ԃփ׃؃كڃۃ܃݃ރ '*2:;VW[abnouyz„ÄĄńƄDŽȄɄфلڄۄ܄݄ބ߄ /0:DEFGHIJ_`abcqrzDžȅɅʅ˅̅ͅ#$+2345678EFPZ[\]^_`vwxyzɆʆцӆԆՆֆ׆؆نچۆKLdeˉ̉'78Q9:NƋNj܋݋ OPč͌pq-.vwԒՒ./A]^qטؘ56Jyzޙߙ();RS\stҚNOP=ȜUV de%&ABvwpq«ëīūӫ#$%&'DEz{|}~ڬ۬ܬݬެ߬~123@]^tuv®îĮŮƮήϮЮѮҮӮԮծ'-5=DNPQRSTUVWXY`jrzƯ̯ͯկ֯ׯدٯگۯܯݯޯ !"#,-<=>?@AJKYZ[\]^gh°ðİŰ-.DEFSTU[\]emu}ȱϱױٱ !"#$%&'()0:BIQ[efghijklmnβϲвѲҲӲڲ۲,-./01:;Z[\]^_fghijklmnoOP34A^tu{|}ƶζֶ޶ !56789CDEFGHIJK_gov}·÷ķŷ޷߷%BXY_`aiqyʸ˸̸͸θϸиѸҸ&'()*+,-.BJQW^fghijklmn¹ʹ˹̹͹ιϹйѹҹӹ01#$qrsɽʽнѽҽڽ)18@DLMkryž˾;о׾ؾ %*.45]adfjno2345JKLYvw *3;?ENObjrz$AWX^_`hpx KQWY\bc '/01234567OU\bdkl| uv $/019ABCDEFJT^_fnvwpq%,-cgijklmnov}~'()4?@AIQRSTUVpqrs  MNOZefgr}~<BHIlpvwxyz{MSYZ[\]^%)/0opxyZ[\]^[\uvyz !DEFQ\]^fnopqrs18?@ySTU`klmu}~ #%)*+,-./7?@A,-nop{ $()?AEFGHIJPV\]^UVW\abckstuvwx$%&'()5;BCD )/568XY'(SY_` FLRSdhlm#$@GOP`dhi}4:ABVY\]^_`ayz{|023:;<=>?@HI ,-uv!"<M[\]^`acdfgijstu000000000000000000000 0 00 00 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 t0 0 0 0 0 00000000 00 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0000 00 00 0 00 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 000000000 00 00 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000 00 00 0 00 0 0 0 t 0 0 0  0 0 0  0 0 0  0 0 0  0 0 0  0 0 0  0 0 0  0 0 0  0 0 0 0 0 0 0  0 0 0  0 0 0 0 0 0 0  0 0 0  0 0 0  0 0 0 00000000000000000000000000000000000000000000000 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0  0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0  0 0 0 0 0 0 0 0 0 0 0  0 0 0 0 0 0 0 0 0 0 0  0 0 0 0 0 0 0 0 0 0 0  0 0 0 0 0  0 0 0 0 0  0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0  0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0  0 0 0 0 0  0 0 0 0 0  0 0 0 0 0  0 0 0 0 0  0 0 0 0 0  0 0 0 0 0 0000000000000 %0 %0 %0 0 0 %0 %0 %0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0  0 0 0 0  0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 #0 #0 0 00000 0 %0 %0 0 0 0 %0 %0 0 0 0 %0 %0 0 0 0 %0 %0 0 0 0 %0 %0 0  0 %0 %0 0 0 0 %0 %0 0 0 0 %0 %0 0 0 0 %0 %0 0 0 0 %0 %0 0  0 %0%0 %0%0 0  0 %0%0 %0%0 0 0 0 %0 %0 0 0 0 %0%0 %0%0 0 0 0 %0 %0 0 0 0 %0 %0 0 0 0 %0 %0 0 %0 0 0 0 %0 %0 0  0 %0 %0 0  0 %0 %0 0 0 0 %0 %0 0 0 0 %0 %0 0 0000 %0 % % 0 0 0   0 0 0 0 0 0 0 0 0 0 0  0 0 0 0  0 0 0 0  0 0 0 0  0 0 0 0  0 0 0 0  0 0 0 0  0 0 0 0  0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0  0 0 0 0  0 0 0 0  0 0 0 0  0 0 0 0  0 0 0 0  0 0 0 0  0 0 0 0  0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0  0 0 0 0  0 0 0 0  0 0 0 0  0 0 0 0  0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0  0 0 0 0  0 0 0 0  0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0  0 0 0 0  0 0 0 0  0 0 0 0  0 0 0 0 %0 0 0 0 0 %0 0 0 0 0 0 0 0 0 0 00000000000 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0  00 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 00000000000000000000000000  0 0 0 0 0 0 0 0 0 0  0 0 0 0 0 0 0 0 0 0 0 0 0 0 0  0 0 0 0  0 0   0  0 0   0 000000000000000 0 0 0 0 0 0 0 0 0 0 0 00 0 0 0 0 0 00 0 0 0 0 0 00 00 000 0 00 000 000 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0  0 0 0 0 0 0 0 0 0 0 0 0 0 0 0  0 0 0 0 0 0 0 0 0 0 0 0 0 0 0  0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 00 00 000 0 00 000 000 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0  0 0 0 0 0 0 0 0 0 0 0 0 0 0 0  0 0 0 0 0 0 0 0 0 0 0 0 0 0 0  0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0000 0 00 0 0 00 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 000 0 00 0 0 00 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 00 0z000 0 00 0 0 00 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 00 00 000 0 00 000 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 000 0 00 0 0 00 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 00 00 000 0 00 000 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0  %0 0  %0 %0 0  %0 %0 0  0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0000000000 %0 %0 0 0 %0 %0 0 0 0 0 0 0 '0 '0 0 0 '0 '0 0  0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0000 %0 %0 0 0 %0 %0 0 0 0 0 0 0 '0 '0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 #0 #0 0 %0 0 0 0 0000000000 %0 %0 0  %0 %0 0  0 0 0  #0 #0 0  #0 #0 0  #0 #0 0  #0 #0 0  #0 #0 0  #0 #0 0  #0 #0 0  #0 #0 0  #0 #0 0  #0 #0 0  #0 #0 0  #0 #0 0  #0 #0 0  0 #0 #0 0  0 #0 #0 0 0 #0 #0 0 0 #0 #0 0 0 #0 #0 0    0  #0#0 #0#0 0  #0 #0 0 000 %0 %0 0  %0 %0 0  0 0 0  '0 '0 0  '0 '0 0  000 000 0 000000000000 0 0 0 0 0 0 0 0 #0 #0 0 0 #0 #0 0 0 #0 #0 0 0 #0 #0 0 %0 0 0 0 %0 0 0 0 %0 0 0 0 0 #0 #0 0 %0 0 0 0 %0 0 0 0 %0 0 0 0 %0 0 0 0 00000 0 0 0 0 0 0 0 0 #0 #0 0 0 #0 #0 0 0 #0 #0 0 0 #0 #0 0 0 #0 #0 0 0 #0 #0 0 %0 0 0 0 000000 0 0 0 0 0 0 0 0 #0 #0 0 0 #0 #0 0 0 #0 #0 0 0 #0 #0 0 0 #0 #0 0 0 #0 #0 0 %0 0 0 0 000000 0 0 0 0 0 0 0 0 #0 #0 0 0 #0 #0 0 0 #0 #0 0 0 #0 #0 0 0 #0 #0 0 0 #0 #0 0 0 0 0 0 0000 0 0 0 0 0 0 0 0 #0 #0 0 0 #0 #0 0 0 #0 #0 0 0 #0 #0 0 0 #0 #0 0 0 0 0 0 000000 0 0 0 0 0 0 0 0 #0 #0 0 0 #0 #0 0 0 #0 #0 0 0 #0 #0 0 0 #0 #0 0 0 #0 #0 0 %0 0 0 0 %0 #0 #0 0 %0 0 0 0 %0 0 0 0 0000000 0 0 0 0 0 0 0 0 0 0 0 0 #0 #0 0 0 #0 #0 0 0 #0 #0 0 0 #0 #0 0  #0 #0 0 0 #0 #0 0 0 #0 #0 0  #0 #0 0 0 #0 #0 0 0 #0 #0 0 0 #0 #0 0  #0#0 #0#0 0 0 #0 #0 0 0 #0 #0 0 0 #0 #0 0 0 #0 #0 0 0 #0 #0 0 0 #0 #0 0 0 #0 #0 0  #0#0 #0#0 0  #0 #0 0  #0 #0#0 0 0 #0 #0 0 000 00 00 000000000)0)00000 0)000 0 )0)0)0 0 0 0@0I00@0I00@0I00@0I00@#0@#0@0@#0@#0@0I000000pqrsuv*KL */78@KVaby LT\defghj ()<ENWX  / 4 8 9 : ; < = M \ ] n     T c q y  ! . / W f u }  " 3 D E | 9>CINST}z{| '8IJrGVcsNTZixy,-  !!!!^#_#+$,$$$8%9%%%$&&&,'-'H*I*]*^*>AKALAZ$Z%ZsXshswsssssssssstt&t5tDtEtttttttt uu1uHuIu_uaucueuguhuuuuuuuuuuuuuuvv$v5v6vTvdvuvvvvv ww4wKwLwwwwwwwwwwxxlymyyyyyyyyyyyyyyyyyzzzzzzzzzzz z!z)z+z5z?z@zAzBzCzDzEzSzTz`zlzmznzozpzqzrzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzz{{{ { { { {.{/{9{C{D{E{F{G{H{I{a{b{l{v{w{x{y{z{{{|{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{|||| |!|"|#|$|%|8|:|C|K|L|M|N|O|P|Q|e|g|o|v|w|x|y|z|{||||||||||||||||||||||||||}}}}}} } } } }}}5}7}@}U}V}W}X}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}~ ~ ~ ~ ~~~~+~,~-~.~/~]~^~c~i~j~~~~~~~~  MNOVWabcdefg$%&'()*+,4>?mnou΀πӀ׀؀!"*12\]emnցׁ߁ $%&'()*9:;<=IJRZ[wy‚ !126<=ST[bcz{̃̓ԃփ׃؃كڃۃ܃݃ރ '*2:;VW[abnouyz„ÄĄńƄDŽȄɄфلڄۄ܄݄ބ߄ /0:DEFGHIJ_`abcqrzDžȅɅʅ˅̅ͅ#$+2345678EFPZ[\]^_`vwxyzɆʆцӆԆՆֆ׆؆نچۆKLdeˉ̉'78Q9:NƋNj܋݋ OPč͌pq-.vwԒՒ./A]^qטؘ56Jyzޙߙ();RS\stҚNOP=ȜUV de%&ABvwpq«ëīūӫ#$%&'DEz{|}~ڬ۬ܬݬެ߬~123@]^tuv®îĮŮƮήϮЮѮҮӮԮծ'-5=DNPQRSTUVWXY`jrzƯ̯ͯկ֯ׯدٯگۯܯݯޯ !"#,-<=>?@AJKYZ[\]^gh°ðİŰ-.DEFSTU[\]emu}ȱϱױٱ !"#$%&'()0:BIQ[efghijklmnβϲвѲҲӲڲ۲,-./01:;Z[\]^_fghijklmnoOP34A^tu{|}ƶζֶ޶ !56789CDEFGHIJK_gov}·÷ķŷ޷߷%BXY_`aiqyʸ˸̸͸θϸиѸҸ&'()*+,-.BJQW^fghijklmn¹ʹ˹̹͹ιϹйѹҹӹ01#$qrsɽʽнѽҽڽ)18@DLMkryž˾;о׾ؾ %*.45]adfjno2345JKLYvw *3;?ENObrz$AWX^_`hpx KQWY\bc '/01234567OU\bdkl| uv $/019ABCDEFJT^_fnvwp%,-cgijklmnov}~'()4?@AIQRSTUVpqrs  MNOZefgr}~<BHIlpvwxyz{MSYZ[\]^%)/0opxyZ[\]^[\uvyz !DEFQ\]^fnopqrs18?@ySTU`klmu}~ #%)*+,-./7?@A,-nop{ $()?AEFGHIJPV\]^UVW\abckstuvwx$%&'()5;BCD )/568XY'(SY_` FLRSdhlm#$@GOP`dhi}4:ABVY\]^_`ayz{|023:;<=>?@HI!"\]0000000000000000000000 00 00 00 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 t0 0 0 0 0 0000@000 00 00 00 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0000 00 00 0 00 0  0  0  0  0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0000000 0000000 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0000000 00000 00 00 0 0 0 0 0 0 00 0 0 0 0 00 0 0 0 0 00 00 0 0 0 0 00 0 0 0 0 00 0 0 0 0 00000000 0 0 0 0 00 0 0 0 0 00 0 0 0 0 00000000000000@00000000000000000000000000000000000000000000000000000000 00 00 000 0 0 0t0 0 0 00 0 0 00 0 0 00 0 0 00 0 0 00 0 0 00 0 0 00 0 0 00 0 0 00 0 0 00 0 0 00 0 0 00 0 0 00 0 0 00 0 0 00 0 0 000000000000000000000000000000000000000000000000 000000@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@000@0@0@0@0@000@0@0@0@0 00@0@0@0@0! 0000000000000 %0 %0 %0 00 %0 %0 %0 00 0 0 0 00 0 0 0 00 0 0 0 00 0 0 0 00 0 0 0 00 0 0 0 00 0 0 0 00 0 0 0 000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000#0#00000000%0%0000%0%0000%0%000 0 %0 %0 00 0 %0 %0 00 0 %0 %0 00 0 %0 %0 00 0 %0 %0 00 0 %0 %0 00 0 %0 %0 00 0 %0%0 %0%0 00 0 %0%0 %0%0 00 0 %0 %0 00 0 %0%0 %0%0 00 0 %0 %0 00 0 %0 %0 00 0 %0 %0 0%0 00 0 %0 %0 00 0 %0 %0 00 0 %0 %0 00 0 %0 %0 00 0 %0 %0 0000 %0 %0 %0 00 0 0 0 00 0 0 0 00 0 0 0 00 0 0 0 00 0 0 0 00 0 0 0 00 0 0 0 00 0 0 0 00 0 0 0 00 0 0 0 00 0 0 0 00 0 0 0 00 0 0 0 00 0 0 0 00 0 0 0 00 0 0 0 00 0 0 0 00 0 0 0 00 0 0 0 00 0 0 0 00 0 0 0 00 0 0 0 00 0 0 0 00 0 0 0 00 0 0 0 00 0 0 0 00 0 0 0 00 0 0 0 00 0 0 0 00 0 0 0 00 0 0 0 00 0 0 0 00 0 0 0 00 0 0 0 00 0 0 0 00 0 0 0 00 0 0 0 00 0 0 0 00 0 0 0 00 0 0 0 00 0 0 0 00 0 0 0 00 0 0 0 00 0 0 0 00 0 0 0 00 0 0 0 00 0 0 0 00 0 0 0 00 0 0 0 00 0 0 0 00 0 0 0 00 0 0 0 00 0 0 0 00 0 0 0 00 0 0 0 00 0 0 0 00 0 0 0 0%0 0 0 0 0%0 0 0 0 00 0 0 0 000000000000 0 00 0 00 0 00 0 00 0 00 0 00 0 00 00 00 0 00 0 00 0 00 0 00 0 00 0 000000000000000000000000000000000 0 00 0 00 0 00 0 00 0 00 0 00 0 00 0 00 0 00 0 00 0 00 0 00 0 00 0 00 0 000000000000000000000000 0 00 0 00 0 00 0 000 0 00 0 000 0 00 0 00000000000 00 000 0 00 000 000 00 0 0 0 0 0 0 00 0 0 0 0 0 0 00 0 0 0 0 0 0 00 0 0 0 0 0 0 000 0 0 0 0 0 00 0 0 0 0 0 0 000 0 0 0 0 0 00 0 0 0 0 0 0 000 0 0 0 0 0 00 0 0 0 0 0 0 00 0 0 0 0 0 0 00 0 0 0 0 0 0 00 0 0 0 0 0 0 00 0 0 0 0 0 0 00 0 0 0 0 0 0 00 0 0 0 0 0 0 00 0 0 0 0 0 0 00 0 0 0 0 0 0 00000 00 000 0 00 000 000 00 0 0 0 0 0 0 00 0 0 0 0 0 0 00 0 0 0 0 0 0 00 0 0 0 0 0 0 00 0 0 0 0 0 0 00 0 0 0 0 0 0 00 0 0 0 0 0 0 00 0 0 0 0 0 0 00 0 0 0 0 0 0 00 0 0 0 0 0 0 00 0 0 0 0 0 0 00 0 0 0 0 0 0 00 0 0 0 0 0 0 00 0 0 0 0 0 0 00 0 0 0 0 0 0 00 0 0 0 0 0 0 00 0 0 0 0 0 0 00 0 0 0 0 0 0 0000000000000 0 00 0 0 00 00 0 0 0 0 0 00 0 0 0 0 0 00 0 0 0 0 0 00 0 0 0 0 0 00 0 0 0 0 0 00 0 0 0 0 0 00 0 0 0 0 0 00 0 0 0 0 0 00 0 0 0 0 0 00 0 0 0 0 0 00 0 0 0 0 0 00 0 0 0 0 0 00 0 0 0 0 0 00000 0 00 0 0 00 00 0 0 0 0 0 00 0 0 0 0 0 00 0 0 0 0 0 00 0 0 0 0 0 00 0 0 0 0 0 00 0 0 0 0 0 00 0 0 0 0 0 00 0 0 0 0 0 00 0 0 0 0 0 00 0 0 0 0 0 00 0 0 0 0 0 00 0 0 0 0 0 00 0 0 0 0 0 00 0 0 0 0 0 0000 00 0z00000000 0 00 0 0 00 00 0 0 0 0 0 00 0 0 0 0 0 00 0 0 0 0 0 00 0 0 0 0 0 00 0 0 0 0 0 00 0 0 0 0 0 00 0 0 0 0 0 00 0 0 0 0 0 00 0 0 0 0 0 00@00000000000000000000000000000000000000000000000000@0K08L0K08K08K00 @0000000 0 00 0 0 00 00 0 0 0 0 0 00 0 0 0 0 0 00 0 0 0 0 0 00 0 0 0 0 0 00 0 0 0 0 0 00 0 0 0 0 0 00 0 0 0 0 0 0@0 K08g7K08fK08eK08d@00 0 0 0 0 0 0000000000000000000000000000000000000000000000000000@0K0-9&. >K0-9%K0-9$K0-9#@00000000000 %0 00 %0 %0 00 %0 %0 00 0 0 00 0 0 00 0 0 00 0 0 00 0 0 00 0 0 00 0 0 00 0 0 000000000 %0 %0 00 %0 %0 00 0 0 00 '0 '0 00 '0 '0 00 0 0 0 0 0 0 00 0 0 00 0 0 00 0 0 00 0 0 00 0 0 00 0 0 00000 %0 %0 00 %0 %0 00 0 0 00 '0 '0 00 0 0 00 0 0 00 0 0 00 0 0 00 0 0 00 0 0 00 0 0 00 #0 #0 0%0 0 0 0000000000000 %0 %0 00 %0 %0 00 0 0 00 #0 #0 00 #0 #0 00 #0 #0 00 #0 #0 00 #0 #0 00 #0 #0 00 #0 #0 00 #0 #0 00 #0 #0 00 #0 #0 00 #0 #0 00 #0 #0 00 #0 #0 0 0 #0 #0 0 0 #0 #0 00 #0 #0 00 #0 #0 00 #0 #0 00 0 0 00 #0#0 #0#0 00 #0 #0 00000 %0 %0 00 %0 %0 00 0 0 00 '0 '0 00 '0 '0 000 000 000 0000000000000 0 0 00 0 0 00 #0 #0 00 #0 #0 00 #0 #0 00 #0 #0 0%0 0 0 0%0 0 0 0%0 0 0 00 #0 #0 0%0 0 0 0%0 0 0 0%0 0 0 0%0 0 0 0000000 0 0 00 0 0 00 #0 #0 00 #0 #0 00 #0 #0 00 #0 #0 00 #0 #0 00 #0 #0 0%0 0 0 0000000 0 0 00 0 0 00 #0 #0 00 #0 #0 00 #0 #0 00 #0 #0 00 #0 #0 00 #0 #0 0%0 0 0 0000000 0 0 00 0 0 00 #0 #0 00#0#000#0#000#0#000#0#000#0#000 0 0 00000 0 0 00 0 0 00 #0 #0 00 #0 #0 00 #0 #0 00 #0 #0 00 #0 #0 00 0 0 0000000 0 0 00 0 0 00 #0 #0 00 #0 #0 00 #0 #0 00 #0 #0 00 #0 #0 00 #0 #0 0%0 0 0 0%0 #0 #0 0%0 0 0 0%0 0 0 000000000 0 0 00 0 0 00 0 0 00 #0 #0 00 #0 #0 00 #0 #0 00 #0 #0 00 #0 #0 00 #0 #0 00 #0 #0 00 #0 #0 00 #0 #0 00 #0 #0 00 #0 #0 00 #0#0 #0#0 00 #0 #0 00 #0 #0 00 #0 #0 00 #0 #0 00 #0 #0 00 #0 #0 00 #0 #0 00 #0#0 #0#0 0@0 @#0 @#0 @00 #0 #0#0 00 #0 #0 0000 00 00 0K00)0nK00)0n0 %%%(  97z|dw |! "T$%^(I)*- 037;nA6FJPASdWA\^aceff;hijkgmr`tv&wہtF.oąTo@yscVaHۥ<P׹V' I)j;i9Ol׀~ !,6@GNV_al'27CKQR^iqx".=?BR"k0| x%sQ+F~;nd.^+5J[iefcggghDh^h{hhhhi.iKiiiiijlItvv&wwwQxxx@yyydzzR{{{S|| }w}}~(adVzɄ΄?D`e҅ͅ',Y^Նچ/Uv{߇ DWdinI؉0_{Ȋ -Da@pƌKƍ/`ezĎ.KPchΏӏ )QV+B]bsx;ĕ(p_H+aݤHإR̰NgGIOX^pڹܹ "(9_agƺԺ$8EGMO(.@m24:Xd|Ľ  "06PsyGJOt4U[{'*/TW\ZdOb%(-)JPk~Pd.e(@\26L%Tfjz7jn~OSbfx]9=a*Idhtx MlS)tx'+^ ,d"&C{Ox/3Jpo ?CUIMfYSFq    "#$%&'()*+-./012345789:;<=>?ABCDEFHIJKLMOPQRSTUWXYZ[\]^`bcdefghijkmnopqrstuvwxyz{|}~     !"#$%&()*+,-./01345689:;<=>?@ABDEFGHIJLMNOPSTUVWXYZ[\]_`abcdefghjklmnoprstuvwyz{|}~     !#$%&'()*+,-/0123456789:;<>AC !(!!l,b$l?xK-}*1@(  f  c 6A!SHANDONB S  ?s`8t OLE_LINK4 OLE_LINK7 OLE_LINK6 OLE_LINK8 OLE_LINK9 OLE_LINK13 OLE_LINK14 OLE_LINK33 OLE_LINK100 OLE_LINK101 OLE_LINK12 OLE_LINK15_Hlk252804176 OLE_LINK2 OLE_LINK30 OLE_LINK28 OLE_LINK29_Hlk252956248 OLE_LINK1yy<DD%   yy@KK+Cd{;e{TZFf{\sg{h{Di{dj{k{l{wm{n{l$o{p{$q{r{?s{<t{!u{v{ܻ!w{\#x{QFy{?@AB_$8888888V;<<<@-G2G2G]]__ggkyy}}#.e3>q|eiP[_jz&&    !"#$%&'()*+,-./0123456789:;<=>?@AB8/*urn:schemas-microsoft-com:office:smarttagsCity=?*urn:schemas-microsoft-com:office:smarttags PlaceName=>*urn:schemas-microsoft-com:office:smarttags PlaceTypeBB*urn:schemas-microsoft-com:office:smarttagscountry-region9C*urn:schemas-microsoft-com:office:smarttagsplace;)*urn:schemas-microsoft-com:office:smarttagschsdate<A*urn:schemas-microsoft-com:office:smarttagschmetcnv  01122008200925030000 3073128303150000000aDayFFalseHasSpacein IsLunarDate IsROCDateMonthNegative NumberType SourceValueTCSCTrueUnitNameYearCBA  A ?>C>??>A C?>CC?>C/C/C/C)   )   )   )   )   )   A A CB)   )   CCB)   )   )   )   )   )   )   )   A   A  )   )   )   )   )   )   )   )   )   )   C/C//CvR\h$n$$$m'u'3334A>E>F>L>y>>@@HDPD$G-G~ڟL=R<4-I:H VG VD WD8^`. TTVDXWD8^T`. VDWD8^`.   VDWD8^ `. VD WD8^`OJQJo(l TTVDXWD8^T`OJQJo(l VDWD8^`OJQJo(l   VDWD8^ `OJQJo(lhhWD8^h`. hhWD8^h`OJQJo(l\^`\PJo(.  ^` hH0  ^` hH.  ^` hH. `  ` ^` ` hH0 @  @ ^@ ` hH.    ^ ` hH.  ^` hH0  ^` hH.--^-`o(()  ^` hH0 e e^e` hH. E  E ^E ` hH. %  % ^% ` hH0  ^` hH.  ^` hH.  ^` hH0  ^` hH.^`PJo(() \^`\hH)  \^ `\hH. 0 \^0 `\hH. \^`\hH) x\^x`\hH. \^`\hH. \^`\hH) d\^d`\hH.i\^i`\OJPJQJo(hH$ \^`\OJQJo(hHn\^`\OJQJo(hHuU \^U `\OJQJo(hHl \^ `\OJQJo(hHn \^ `\OJQJo(hHuA\^A`\OJQJo(hHl\^`\OJQJo(hHn\^`\OJQJo(hHu0^`0o(. H\H^H`\hH) \^`\hH. \^`\hH. 4\4^4`\hH)  \ ^ `\hH. | \| ^| `\hH.  \ ^ `\hH) \^`\hH. 0^`0PJo(.  ^` hH0  ^` hH.  ^` hH. `  ` ^` ` hH0 @  @ ^@ ` hH.    ^ ` hH.  ^` hH0  ^` hH.hh^h`PJo(0 H\H^H`\hH) \^`\hH. \^`\hH. 4\4^4`\hH)  \ ^ `\hH. | \| ^| `\hH.  \ ^ `\hH) \^`\hH.,^`OJPJQJ^Jo(-j\^j`\OJQJo(hHn\^`\OJQJo(hHu\^`\OJQJo(hHlV\^V`\OJQJo(hHn \^ `\OJQJo(hHu \^ `\OJQJo(hHlB\^B`\OJQJo(hHn\^`\OJQJo(hHu^`PJo(hH. \^`\hH) \^`\hH. $ \^$ `\hH.  \^ `\hH) l \^l `\hH. \^`\hH. \^`\hH) X\^X`\hH. ^` o(hH.  ^` hH0  ^` hH.  ^` hH. `  ` ^` ` hH0 @  @ ^@ ` hH.    ^ ` hH.  ^` hH0  ^` hH. ^` CJOJQJaJo(hHl ^` OJQJo(hHn ^` OJQJo(hHuf  f ^f ` OJQJo(hHlF  F ^F ` OJQJo(hHn& &^&` OJQJo(hHu ^` OJQJo(hHl ^` OJQJo(hHn ^` OJQJo(hHu ^` OJPJQJo(hH$  ^` OJQJo(hHnp p^p` OJQJo(hHuP  P ^P ` OJQJo(hHl0  0 ^0 ` OJQJo(hHn ^` OJQJo(hHu ^` OJQJo(hHl ^` OJQJo(hHn ^` OJQJo(hHu^`o(. r  r ^r ` hH0 R  R ^R ` hH. 2 2^2` hH.  ^` hH0  ^` hH.  ^` hH.  ^` hH0  ^` hH.ZkZ^Z`ko(() \^`\hH) \^`\hH. U \U ^U `\hH.  \ ^ `\hH)  \ ^ `\hH. A\A^A`\hH. \^`\hH) \^`\hH. ^` CJOJQJaJo(hHl ^` OJQJo(hHn ^` OJQJo(hHuf  f ^f ` OJQJo(hHlF  F ^F ` OJQJo(hHn& &^&` OJQJo(hHu ^` OJQJo(hHl ^` OJQJo(hHn ^` OJQJo(hHuhh^h`PJo(. H\H^H`\hH) \^`\hH. \^`\hH. 4\4^4`\hH)  \ ^ `\hH. | \| ^| `\hH.  \ ^ `\hH) \^`\hH.--^-`o(() ^` 0e e^e` .E  E ^E ` .%  % ^% ` 0 ^` . ^` . ^` 0 ^` .^`PJo(() \^`\hH) @\@^@`\hH. \^`\hH.  \ ^ `\hH) , \, ^, `\hH.  \ ^ `\hH. t\t^t`\hH) \^`\hH.,^,`o(.  \^ `\hH) \^`\hH. T \^T `\hH.  \^ `\hH)  \^ `\hH. @\^@`\hH. \^`\hH) \^`\hH.D^D`OJPJQJ^Jo(-$\^$`\OJQJo(hHn\^`\OJQJo(hHul\^l`\OJQJo(hHl \^ `\OJQJo(hHn \^ `\OJQJo(hHuX \^X `\OJQJo(hHl\^`\OJQJo(hHn\^`\OJQJo(hHu^`5B*o(ph. N N^N` hH0 . .^.` hH.    ^ ` hH.    ^ ` hH0    ^ ` hH.  ^` hH.  ^` hH0 n n^n` hH.hh^h`o(. ^` 0 ^` . ^` .`  ` ^` ` 0@  @ ^@ ` .   ^ ` . ^` 0 ^` .^`OJPJQJo(hH$  ^` OJQJo(hHn ^` OJQJo(hHu ^` OJQJo(hHl`  ` ^` ` OJQJo(hHn@  @ ^@ ` OJQJo(hHu   ^ ` OJQJo(hHl ^` OJQJo(hHn ^` OJQJo(hHu ^` OJPJQJo(hH$  ^` OJQJo(hHn ^` OJQJo(hHu`  ` ^` ` OJQJo(hHl@  @ ^@ ` OJQJo(hHn   ^ ` OJQJo(hHu ^` OJQJo(hHl ^` OJQJo(hHn ^` OJQJo(hHu^`PJo(. \^`\hH) \^`\hH. $ \^$ `\hH.  \^ `\hH) l \^l `\hH. \^`\hH. \^`\hH) X\^X`\hH. 0^`05B*o(ph.  ^` hH0 p p^p` hH. P  P ^P ` hH. 0  0 ^0 ` hH0  ^` hH.  ^` hH.  ^` hH0  ^` hH. ^` CJOJQJaJo(hHl ^` OJQJo(hHn ^` OJQJo(hHuf  f ^f ` OJQJo(hHlF  F ^F ` OJQJo(hHn& &^&` OJQJo(hHu ^` OJQJo(hHl ^` OJQJo(hHn ^` OJQJo(hHu0^`05B*PJo(ph.  ^` hH0  ^` hH.  ^` hH. `  ` ^` ` hH0 @  @ ^@ ` hH.    ^ ` hH.  ^` hH0  ^` hH.! ^` CJOJPJQJaJo(hH$  ^` OJQJo(hHn ^` OJQJo(hHuf  f ^f ` OJQJo(hHlF  F ^F ` OJQJo(hHn& &^&` OJQJo(hHu ^` OJQJo(hHl ^` OJQJo(hHn ^` OJQJo(hHu'e;7S&iU`[c"V A5vV %O8 [2j-0Hz%~}| Gcnz, Kn`                h62                "d        5                 H->HxWHzK9LfmLwN*OqR,;S`OSmSRT*Wj}X1YCZ/$[oY\n=_}a4Ec1YdR'e/eHe]4fAfgzg#h=NhMi4iati0jmz naoDrqrKSt%y.3yeu{8|-}jy}E~(d~vbHzm}Rvo9qg_hk CU:ml!uG3Jhdh;[R`{X&. zc-0g:*oh0bs'`dFs[? #Bx8$u}hLi#~X!I MVBf[ (9~]'lT"0 Ord(pL/2U=]=^#?u8Iu]$:',-%qkYZg(oEu7O)B\ ahTkKUkv>vW}kK:b{K *78@KVaby LT\de ()<ENWX / 8 9 : ; < = M \ ] n     T c q y  ! . / W f u }  " 3 D E | 9>CINST}{| '8IJrGVcsNTZixyB\XZ[\B]G]U]c]d]]]]]^^^ ^=^D^M^N^w^}^^^^^^^^^^^^^^^____6_:_<_=___a_e_f_v_w_x_y_____________`"`*`+`P`T`V`W`````mmm$m%m&m+m0m5m:m;mTmfmxmmmmmmmmnnn-n?nQncndnnnnnnnnnoooo7oGoVoeotouooooooooppp+p,pHpVpdppp~ppppppppqq$q2q@qAqqqqqqqqqq rrr8rFrUrcrrrsrrrrrrrss s/s=s>sXshswsssssssssstt&t5tDtEtttttttt uu1uHuIu_uaucueuguhuuuuuuuuuuuuuuvv$v5v6vTvdvuvvvvv ww4wKwLwwwwwwwxmyyyyyyyyyyyyyyzzzzzzzzzzz z!z)z+z5z?z@zAzBzCzDzEzSzTz`zlzmznzozpzqzrzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzz{{{ { { { {.{/{9{C{D{E{F{G{H{I{a{b{l{v{w{x{y{z{{{|{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{|||| |!|"|#|$|%|8|:|C|K|L|M|N|O|P|Q|e|g|o|v|w|x|y|z|{||||||||||||||||||||||||||}}}}}} } } } }}}5}7}@}U}V}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}~ ~ ~ ~ ~~~~+~,~-~.~/~]~^~c~i~j~~~~~~ MNVabcdefg$%&'()*+,4>?nou΀πӀ׀؀!"*12\]emnցׁ߁ $%&'()*9:;<=IJRZ[wy‚ !126<=ST[bcz{̃̓ԃփ׃؃كڃۃ܃݃ރ '*2:;VW[abnouyz„ÄĄńƄDŽȄɄфلڄۄ܄݄ބ߄ /0:DEFGHIJ_`abcqrzDžȅɅʅ˅̅ͅ#$+2345678EFPZ[\]^_`vwxyzɆʆцӆԆՆֆ׆؆نچۆˉ̉'78Q9:NƋ܋݋ OPč͌pqՒ./A]^qטؘ56Jyzޙߙ();RS\stҚNO&pq«ëīūӫ#$%&'Ez{|}~ڬ۬ܬݬެ1@]t®îĮŮƮήϮЮѮҮӮԮծ'-5=DNPQRSTUVWXY`jrzƯ̯ͯկ֯ׯدٯگۯܯݯޯ !"#,-<=>?@AJKYZ[\]^gh°ðİŰ-DS[\]emu}ȱϱױٱ !"#$%&'()0:BIQ[efghijklmnβϲвѲҲӲڲ۲,-./01:;Z[\]^_fghijklmno3A^t{|}ƶζֶ޶ !56789CDEFGHIJK_gov}·÷ķŷ޷߷%BX_`aiqyʸ˸̸͸θϸиѸҸ&'()*+,-.BJQW^fghijklmn¹ʹ˹̹͹ιϹйѹҹ$qrsɽнѽҽڽ)18@DLMkryž˾;о׾ؾ %*.45]adfjno34JYv *3;?ENObjrz$AW^_`hpx KQWY\bc '/01234567OU\bdkl|u $/019ABCDEFJT^_fnvwq%,-cgijklmnov}~'()4?@AIQRSTUVpqrs ; MNOZefgr}~<BHIlpvwxyz{MSYZ[\]^%)/0oxZ[\][\ !DEFQ\]^fnopqrs18?@ySTU`klmu}~ #%)*+,-./7?@+-nop{ $()?AEFGHIJPV\]UVW\abckstuvwx$%&'()5;BC )/568'(SY_` FLRSdhlm#$@GOP`dhi}4:ABVY\]^_`ayz{|02:;<=>?v!"[\] Uca2%. y0y0O0GC$y0[7Uz^-g3]g@Lvvvtvuv@@@ @@@~@@@@Unknown Lenovo User MC SYSTEMUserGz Times New Roman5Symbol3& z ArialC .PMingLiUe0}fԚU.{ @CalibriCentury Gothic;[SOSimSun3z Times] Times-BoldTimes New Roman]SimSunLucida Sans Unicode[ (DFPFangSongW4-B5PMingLiU;ўSOSimHei?5 z Courier New;" Helvetica5& zaTahoma;Wingdings9E .DFKai-SB FKC䆳,$2{,$2{!xxd2qHX?8|2 2006 ANNUAL RESULTS ANNOUNCEMENTWonderful Sky_o(u7b'                           ! " # $ % & Oh+'0(< P\ |  $2006 ANNUAL RESULTS ANNOUNCEMENTWonderful Sky$generated by an Adobe application Normal.dot ΢û179Microsoft Office Word@@@ @Tb@ ,$2՜.+,0 `h Wonderful Skyx{   !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~     !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~     !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~     !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXY[\]^_`abcdefghijklmnopqrstuvwxyz{|}~     !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~     !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~    &Root Entry FqV(Data ZzA1Table WordDocumentSummaryInformation(DocumentSummaryInformation8CompObjm  FMicrosoft Office Word ĵ MSWordDocWord.Document.89q